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It has become increasingly evident that gene expression processes in 
eukaryotes involve communication and coordination between many complex, 
independent macromolecular machines. To query these processes and to 
explore the potential relationships between them in the budding yeast 
Saccharomyces cerevisiae, we designed a versatile reporter employing 
multicolor high-throughput flow cytometry. Due to its design, this single reporter 
exhibits a distinctive signature for many defects in gene expression including 
transcription, histone modification, pre-mRNA splicing, mRNA export, nonsense-
mediated decay, and mRNA degradation. Analysis of the reporter in 4967 non-
essential yeast genes not only revealed striking phenotypic overlaps between 
similar functions, but also provided us a dataset in which to compare additional 
genetic or chemical perturbations. Utilizing a binning and clustering algorithm we 
developed we are able to compare reporter expression data from thousands of 
 vii 
mutants in a semi-automated fashion, essentially grouping mutants or conditions 
based on the levels of reporter signal.  
I further utilized our reporter to screen a vast library of in vivo produced 
cyclic peptides using fluorescence-activated cell sorting (FACS), identifying a 
cyclic peptide that resulted in mild gene-specific pre-mRNA splicing inhibition. 
Additionally, I adapted our reporter assay to perform a high-throughput small 
molecule screen to identify inhibitors or modulators of specific gene expression 
processes. Our efforts led to the identification of a small molecule that inhibits 
pre-mRNA splicing in a dose-dependent manner. Moreover, I utilized our reporter 
system to quickly identify loss-of-function mutants in the poorly characterized 
gene SWM2. The three mutants of interest have reduced interaction with Tgs1p, 
the conserved trimethylguanosine synthase, which we believe leads to 
decreased hypermethylation of the 5’ caps of spliceosomal snRNAs. Altogether 
this work describes the development, validation and utility of the versatile gene 
expression reporter system we developed, providing our lab and others a 
valuable tool to interrogate a wide-range of gene expression processes in yeast. 
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Chapter 1: Introduction 
1.1 EUKARYOTIC GENE EXPRESSION 
Within the information-rich genomes of all living organisms lie the 
instructions for each cell to function correctly, as well as the template for 
generating future generations. In eukaryotic organisms, the double-stranded 
DNA (deoxyribonucleic acid) that constitutes the genome is tightly packed by 
proteins within the nucleus, forming a structure called chromatin (Wolffe 1998). 
Although the length of DNA is condensed by orders of magnitude, the genetic 
material is spatially constrained and gene expression is temporally controlled, 
resulting in a highly functional nuclear architecture that allows for regulatory 
mechanisms (Cremer and Cremer 2001; Misteli 2005; Herrmann 2013).  
The process by which genetic information is decoded and used by the cell 
to generate a functional product is often referred to as gene expression. The flow 
of genetic information, which is commonly referred to as the central dogma of 
molecular biology (Crick 1958, 1970), is typically thought to start with DNA, to 
RNA (ribonucleic acid), and end with protein by the way of transcription and 
translation respectively. In the years subsequent to Francis Crick’s seminal work, 
it has been demonstrated that genetic information can flow in reverse and 
horizontal directions (reverse transcription and RNA replication respectively). 
Gene expression also involves the post-transcriptional and post-translational 
regulation of gene products with processes such as RNA interference and 
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ubiquitination among many others. Additionally, the functional product of gene 
expression is not limited to proteins, as many RNAs are functional, such as 
ribosomal RNA (rRNA), transfer RNA (tRNA) and small nuclear RNA (snRNA). 
Since the work I present here was completed in the budding yeast 
Saccharomyces cerevisiae, most of the information provided will relate to this 
organism, with exceptions being noted. 
1.2 TRANSCRIPTION AND MRNA PROCESSING 
The first step in gene expression is the generation of the messenger RNA 
(mRNA) from template DNA in a processed called transcription, which is 
catalyzed by the enzyme RNA polymerase II (RNA Pol II) in the nucleus. As the 
pre-mRNA is being produced by RNA Pol II, additional machineries are recruited 
to the nascent mRNA mainly by virtue of the C-terminal domain (CTD) of RNA 
Pol II, which can act as a landing pad for mRNA processing factors, such as 
capping enzyme that co-transcriptionally attaches a 7-methylguanosine to the 5’ 
end of the mRNA (Ghosh and Lima 2010). Not only does the cap function in 
stabilizing the mRNA, it also is important for downstream processing and gene 
expression events such as pre-mRNA splicing, mRNA export and translation. In 
addition to 5’ capping and pre-mRNA splicing, almost all pre-mRNAs are cleaved 
and polyadenylated prior export from the nucleus. The cleavage of the nascent 
transcript and subsequent addition of a poly(A) tail are coordinated by cis-acting 
RNA elements (Chan et al. 2011; Tian and Graber 2012). In yeast, mutation of 
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3’-end processing factors result in nuclear poly(A) RNA accumulation and mRNA 
export mutations result in hyper-polyadenlyation of mRNAs (Brodsky and Silver 
2000; Hilleren and Parker 2001; Hammell et al. 2002; Dower and Rosbash 2002; 
Dower et al. 2004). These findings highlight the importance and connection of 
both 3’-end processing and mRNA export for a proper gene expression program. 
1.2.1 Pre-mRNA splicing 
A common feature of eukaryotic pre-mRNAs is the presence of noncoding 
internal sequences called introns that are removed in a process called pre-mRNA 
splicing, which results in ligated coding sequences (exons). Intron removal is 
catalyzed by the spliceosome which is a multi-megadalton macromolecular 
machine comprised of five small nuclear ribonucleoprotein (snRNP) complexes, 
as well as many transacting factors (Will and Lührmann 2011). The five snRNPs 
include a small nuclear RNA (U1, U2, U4, U5 or U6) and its associated proteins. 
The aforementioned 5’ cap has long been known to stimulate pre-mRNA splicing 
(Krainer et al. 1984; Konarska et al. 1984; Edery and Sonenberg 1985; Fresco 
and Buratowski 1996; Schwer and Shuman 1996), highlighting the functional 
connections between mRNA processing events. In terms of conservation of the 
splicing machinery, proteomic analysis has revealed that 85% of yeast proteins 
are conserved in humans, providing strong evidence that the yeast spliceosome 
that we study in our laboratory embodies an important and evolutionarily 
conserved splicing machinery (Fabrizio et al. 2009).  
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1.2.1.1 Pre-mRNA splicing mechanism 
The first reaction in the splicing mechanism involves the 2’ hydroxyl of the 
conserved branchpoint adenosine nucleophilically attacking the phosphodiester 
bond of the 5’ splice site. The second reaction involves the newly formed 3’ 
hydroxyl of the 5’ exon attacking the phosphate immediately upstream of the 3’ 
exon at the 3’ splice site. A simplified version of the step-wise splicing model is 
shown in Illustration 1.1. This model begins with the U1 snRNP base pairing with 
the 5’ splice site (Legrain et al. 1988; Séraphin et al. 1988). At the branchpoint 
the U2 snRNP replaces Msl5p and Mud2p in an ATP-dependent step. After 
rearrangements within the U2 snRNP, the preassembled U4/U6!U5 tri-snRNP 
associates with the pre-mRNA substrate. By the way of protein and RNA 
rearrangements within and among the snRNPs and other transacting splicing 
factors, the spliceosome is then activated. Key characteristics of the activated 
spliceosome is the release of U1 by the ATP-dependent helicase Prp28p (Staley 
and Guthrie 1999), and the separation of U4 from U6 (Raghunathan and Guthrie 
1998), permitting U6 to bind at the 5’ splice site, replacing U1 (Lesser and 
Guthrie 1993). Additionally, the U5 snRNP binds to the 5’ and 3’ exons.  
When the activated spliceosome is in the precise structural conformation, 
the RNA helicase Prp2p initiates the first transesterification reaction by gross 
rearrangement of the branchpoint-binding U2 snRNP (REA’S PAPER), yielding 
the free 5’ (upstream) exon and the intron lariat intermediate. Through ATP-
independent and ATP-dependent rearrangements, the 3’ splice site and 3’ 
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hydroxyl of the 5’ exon are positioned in the active site (Schwer and Guthrie 
1991; James et al. 2002; Schwer and Gross 1998). The second 
transesterification then can occur, yielding the products of pre-mRNA splicing, 
the spliced exons and the intron lariat. As with higher eukaryotes, the majority of 
yeast introns are removed cotranscriptionally and pre-mRNA splicing is sensitive 
to chromatin marks and transcriptional rates (Oesterreich et al. 2011), once again 
highlighting the interconnectivity of gene expression processes. 
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Illustration 1.1: Canonical pre-mRNA splicing model 
The canonical model for a prototypical two exon (blue boxed) and one intron 
(black line in-between with the “A”) pre-mRNA. The pre-mRNA is first addressed 
by the U1 snRNP at the 5’ splice site followed by U2 at the branchpoint. After tri-
snRNP (U4, U5 and U6) joins and rearrangements are made, U6 is bound at the 
5’ splice site with U5 interacting with Exon 1. The first transesterification then 
occurs with the branchpoint adenosine (A) nucleophilically attacking the 5’s 
splice site (orange arrow). U5 bridges Exon 1 with the lariat intermediate and the 
second transesterification ensues with the 3’ hydroxyl of the Exon 1 attacking the 
last intron nucleotide, resulting in ligated exons and the intron lariat. Please see 
section 1.2.1 for more details. 
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1.2.1.3 Function and importance of introns 
The yeast Saccharomyces cerevisiae contains relatively few and short 
introns, with only 5% of its 6000 or so genes containing a single intron (Spingola 
et al. 1999; Juneau et al. 2007; Parenteau et al. 2008). This being said, the 
majority of Pol II transcripts in yeast arise from intron containing genes, which 
mostly consist of highly expressed genes such as those encoding ribosomal 
proteins (Ares et al. 1999; Warner 1999). Additionally, the presence of introns 
most often results in increased levels of transcripts (Juneau et al. 2006). In 
contrast, 94% of human genes contain an intron, with an overall average of 
seven introns per gene (Lander et al. 2001; Venter et al. 2001; Sakharkar et al. 
2004). In genes containing more than two exons, alternative splicing can occur, 
providing increased transcript and proteome diversity. As human introns range 
from 20 to 490,000 bp (Sakharkar et al. 2004), it may not be surprising that they 
contain other non-coding yet functional information and elements such as 
microRNAs, snoRNAs and Alu elements (Rearick et al. 2011; Hadjiargyrou and 
Delihas 2013). 
1.3 MRNA EXPORT AND TRANSLATION 
While mRNA biogenesis occurs within the nucleus, the resulting transcript 
must be exported to the cytoplasm to be translated. In higher eukaryotes the 
exon junction complex (EJC) and THO/TREX complex are deposited onto the 
mRNA through the processes of splicing (Bono and Gehring 2011; Luna et al. 
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2012). Moreover, polyadenlyation stimulates the nucleocytoplasmic transport of 
mRNAs (Huang and Carmichael 1996). In yeast, splicing is not believed to 
encourage mRNA export. The only known link between splicing and export in 
yeast is the SR protein Npl3p, which is a Mex67 adaptor, also enables 
cotranscriptional recruitment of U1 and U2 (Kress et al. 2008). Moreover Npl3p 
functions in histone H2B ubiquitination, providing a common link between mRNA 
transcription, splicing and export (Moehle et al. 2012). 
Mex67p and the metazoan counterpart TAP/NXF1 are the transporters for 
nucleocytoplasmic transport and function to link poly(A) RNA to the nuclear pore 
FG-nucleoporins (Segref et al. 1997; Gruter et al. 1998; Kang and Cullen 1999; 
Herold et al. 2000; Zenklusen and Stutz 2001). Mex67p is loaded onto mRNAs 
cotranscriptionally and also facilitates anchoring of genes at nuclear pore 
complexes (Gwizdek et al. 2006; Dieppois et al. 2006). The main RNA adaptors 
for Mex67p/TAP are Yra1p in yeast or Aly/REF in higher eukaryotes (Strasser 
and Hurt 2000; Stutz et al. 2000; Zenklusen et al. 2001). Additionally the poly(A)-
biding protein Nab2p (Iglesias et al. 2010), the THO/TREX complex which Yra1p 
associates with (Chávez et al. 2000; Libri et al. 2002; Strasser et al. 2002), the 
TREX-2 complex (Fischer et al. 2002; Rodriguez-Navarro et al. 2004; Wilmes et 
al. 2008; Jani et al. 2009; Ellisdon et al. 2010), and the previously mentioned 
Npl3p can all function in coupling mRNA biogenesis with export. 
For mRNAs, as opposed to noncoding RNAs, translation is required for 
the functional product of the gene to be synthesized. As with the spliceosome, 
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the ribosome is a large dynamic machine comprised of both RNA and protein. 
The abovementioned 5’ cap on mRNAs also functions to recruit translation 
machinery to the mRNA (Sonenberg 1993). Additionally, the 3’ poly(A) tail 
binding protein Pab1p can functionally, but not covalently, circularize the mRNA 
by associating with the cap binding eIF4E and the translation initiation factor 
eIF4G, resulting in enhancement of translation (Gallie 1991; Tarun and Sachs 
1995; Wells et al. 1998; Gross et al. 2003; Sonenberg and Hinnebusch 2009). 
Although the biosynthesis of proteins is of utmost importance to generate 
functional molecules, their function and stability can be regulated via 
posttranslational mechanisms, which is beyond the scope of this work. 
1.4 MRNA DEGRADATION 
As important as mRNA biogenesis and translation are in gene expression, 
the stability and degradation of mRNAs are crucial for controlling and regulating 
the overall result. When transcripts are being translated, they are relatively 
protected from the degradation machinery by virtue of the ribosome and the cap 
and poly(A) binding factors. Cytoplasmic mRNA degradation commonly occurs in 
structures known as P-bodies (Parker and Sheth 2007). The major degradation 
pathways most often begin with deadenylation of the 3’ poly(A) tail by the 
Ccr4/Not complex (Tucker et al. 2002). Most often the decapping enzyme 
Dcp1p/Dcp2p then removes the 5’ cap (LaGrandeur and Parker 1998; Dunckley 
and Parker 1999), followed by 5’ to 3’ degradation by Xrn1p (Larimer and 
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Stevens 1990; Larimer et al. 1992). It was recently demonstrated that defects in 
the cytoplasmic 5’ to 3’ decay machinery lead to transcription downregulation 
(Haimovich et al. 2013). Additionally, they show that these same components 
shuttle into the nucleus and associate with chromatin near transcription start sites 
and stimulate transcription initiation and elongation. This once again highlights 
the interconnectedness of gene expression process. Transcripts in the cytoplasm 
can also be degraded in a 3’ to 5’ direction by the exonuclease Dis3p within the 
exosome once the poly(A) tail is removed (Dziembowski et al. 2007).  
Eukaryotic cells have also evolved machinery and mechanisms to purge 
the cell of potentially deleterious transcripts, such as one with a premature 
termination codon (PTC). The nonsense-mediated decay (NMD) pathway 
depends on detection of PTCs by the ribosome (González et al. 2001). NMD-
targeted transcripts are most often decapped and shunted into the 5’ to 3’ decay 
pathway (Muhlrad et al. 1994; Hagan et al. 1995; Beelman et al. 1996), in 
contrast with the deadenylation/3’ to 5’ pathway of non-NMD targets. In addition 
to PTCs, extended 3’ untranslated regions can also serve as a signal for NMD 
(Muhlrad and Parker 1999b, 1999a; Das et al. 2000). In addition to NMD, there 
are also no-go and non-stop decay pathways that handle transcripts with stalled 
translation elongation or without a termination codon respectively (Harigaya and 
Parker 2010; Vasudevan et al. 2002). 
The last mRNA degradation pathway of note is the nuclear exosome and 
TRAMP (Trf4p/Air2p/Mtr4p Polyadenlyation) complex (Raijmakers et al. 2004; 
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LaCava et al. 2005; Houseley et al. 2006; Schmidt and Butler 2013). Within the 
nucleus the exonucleases Dis3p and Rrp6p function as a surveillance system 
that regulates levels of coding and noncoding RNAs, including intron-containing 
pre-mRNAs (Lemieux et al. 2011). It is interesting to note that the TRAMP 
complex and Rrp6p are cotranscriptionally recruited to intron-containing genes 
(Kong et al. 2014) and that Rrp6p escorts spliced and unspliced transcripts 
throughput their nuclear lifecycle, releasing them in the vicinity of the nuclear 
pore (Hessle et al. 2012). These connections between biogenesis and quality 
control once again highlight the interconnectedness of gene expression 
processes. There are of course additional means of mRNA degradation and 
regulation such as small interfering RNAs, microRNAs, localization and 
riboswitches; but these are beyond the scope of this work and will not be 
discussed. 
1.5 DISSERTATION OBJECTIVES 
 Since joining the Stevens Laboratory, my efforts have been focused 
around developing and validating a novel reporter technology in order to study 
yeast gene expression in an efficient and meaningful way. The second chapter 
describes much of the design and validation of our reporter system, whereas the 
third and fourth chapters explore two different ways I utilized the reporter in my 
studies. The final chapter describes the overall significance of my work and the 
future directions that our reporter and key findings can be taken. 
 12 
Chapter 2: Gene expression reporter design and validation 
2.1 BACKGROUND 
Eukaryotic gene expression is orchestrated by a complex, dynamic, and 
regulated network of protein-protein and protein-nucleic acid interactions. These 
interactions require several multi-protein/ribonucleoprotein complexes working in 
concert to achieve and maintain proper levels of transcribed mRNA and 
translated protein (Komili and Silver 2008), and to avoid a disease state. From 
the organization of chromatin to the degradation of mRNAs, the ability to study 
the individual processes within gene expression, as well as the connections 
between them, has been aided by technological advances including the use of 
reporter genes that are sensitive to defects in a specific gene expression 
process. Many of these techniques and reporters have been developed for the 
model eukaryotic organism Saccharomyces cerevisiae. 
2.1.1 Existing pre-mRNA splicing reporters 
To query the pre-mRNA splicing pathway in yeast, initial efforts involved 
the fusion of intron-containing fragments to various reporter genes such as lacZ 
(Larson et al. 1983; Teem and Rosbash 1983; Jacquier et al. 1985; Rain and 
Legrain 1997), HIS4 (Parker and Guthrie 1985), and a thymidine kinase (Fouser 
and Friesen 1986). These relied on the spliceosome to excise the intron from 
reporter gene pre-mRNA to produce a translation-competent mRNA, ultimately 
generating the measured signal. These reporters often had limitations of low 
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signal and a narrow dynamic range. A complementary reporter with splicing-
dependent signals was also created in which a synthetic intron was cloned into 
the lacZ gene such that β-galactosidase activity resulted from translation of the 
unspliced pre-mRNA (Legrain and Rosbash 1989), resulting in increased signal 
under suboptimal pre-mRNA splicing conditions. This was unique because the 
construct reports levels of pre-mRNA splicing substrate and not product. 
Although this reporter improved upon some limitations, and has additional utility 
as an mRNA export assay, it still required extract preparation and biochemical 
analysis originating from one or more heterogeneous populations of cells. 
Further progress was made with the development of the ACT1-CUP1 
reporter which was designed so that the degree of copper resistance positively 
correlated with pre-mRNA splicing efficiency (Lesser and Guthrie 1993). 
Although this reporter has proved to be instrumental in examining cis-pre-mRNA 
splicing elements and transacting factors, it does have limitations. Most notably 
the endogenous nonessential CUP1 gene is often present in two or more copies 
in most laboratory strains (Karin et al. 1984; Tohoyama et al. 1996), requiring 
that all genomic copies of this gene be removed in order to specifically query pre-
mRNA splicing efficiency. Additionally, after the high copy reporter is introduced 
into cells, the data derive from growth on solid media containing an ensemble 
population of cells. More recently a series of lacZ splicing reporters with 
competing splice sites was developed in yeast which enables the identification of 
factors that have a propensity to regulate alternative splicing (Dreumont and 
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Séraphin 2013). There are also many alternative splicing reporters for use in 
higher eukaryotes that utilize a combination of reporter genes, but as alternative 
splicing is far less prevalent in budding yeast, these are beyond the scope of this 
work. 
2.1.2 Existing reporters for other gene expression processes 
Reporters that query other gene expression events in yeast, such as 
transcription have also been developed. One such system employs the synthetic 
genetic array methodology (Tong et al. 2001, 2004) as well as a dual fluorescent 
reporter system as a genome-wide approach to discover regulators of a promoter 
of interest (Fillingham et al. 2009; Kainth et al. 2009; Kainth and Andrews 2010). 
This system greatly improved upon early hybrid yeast promoter reporters that 
utilized lacZ (Guarente and Ptashne 1981; Guarente et al. 1982) or genes for 
nutritional requirements (Titz et al. 2006). It is important to note that the product 
of some reporter genes can be very stable, confounding gene induction studies 
and requiring approaches such as exploiting a destabilized GFP as a 
transcription reporter (Li et al. 1998). Another challenge with reporters, especially 
in high-throughput studies when using β-galactosidase activity, is the need for 
cell lysis. This can be alleviated using reporter genes/signals that do not require 
lysis, or other approaches such as a secreted luciferase (Tochigi et al. 2010). 
In surveying gene expression, one also needs to consider the role of pre-
mRNA and mRNA degradation, not just their biogenesis, processing, and export. 
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For example, two groups developed plasmid-based nonsense-mediated decay 
(NMD) reporters that use lacZ gene fusions with premature termination codons 
(Leeds et al. 1991; Wang et al. 2001). In these systems, there is an increase in 
β-galactosidase activity in the absence of functional NMD. A similar approach 
was used with a lacZ construct that was used to assay the effects of cis-elements 
on transcript stability (Muhlrad et al. 1995). There are also NMD reporters that 
use GFP (Paillusson et al. 2005) and chemiluminescence (Boelz et al. 2006) in 
mammalian cells, one for Giardia lamblia that uses chemiluminescence (Chen et 
al. 2008), and one utilizing GFP and/or DsRed in Drosophila melanogaster 
(Metzstein and Krasnow 2006). 
2.1.3 Significance and importance of single-cell analysis and flow 
cytometry 
Although a clonal population of cells may be genetically identical, there 
are often high-levels of cell-to-cell variation across several parameters. Analysis 
or observations based on the population as a whole can mask differences in 
subpopulations or a small minority of cells, which can often be biologically 
significant (Johnston 2012). One main source of cell heterogeneity or variation is 
the stochastic or noisy nature of gene expression. The sources and importance 
of this gene expression variability have been recently reviewed (Sanchez and 
Golding 2013; Frank 2013). Single-cell analyses, such as flow cytometry are 
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used to tease apart and identify these potentially interesting phenotypic 
differences.  
Although flow cytometry has been the workhorse for single-cell analyses 
for decades, the ever-increasing repertoire of fluorophores, coupled with 
advances in optics, fluidics, and software have resulted in large high-content flow 
cytometry datasets. For example, the HyperCyt Autosampler (IntelliCyt) boasts 
an analysis rate of under 2 seconds per sample (Edwards et al. 2001, 2007; 
Black et al. 2011), facilitating the generation of ever-larger datasets. Although 
there are some built-in analysis tools within high-throughput flow cytometry 
(HTFC) platforms, they commonly analyze bulk statistics of the entire population 
of events and do not take into account the cell-to-cell variability within and among 
multiple parameters, limiting the power of HTFC.  
2.1.4 High-throughput flow cytometry analysis 
Available analysis platforms did not meet our needs of comparing 2D flow 
cytometry plots which resulted from our specific reporter assay (Sorenson and 
Stevens 2014). For instance SiZer can identify statistically significant features 
within single parameter histograms then compares them using hierarchical 
clustering (Pratt et al. 2009). However, this analysis tool lacks the ability to 
compare more than one parameter at a time. Another tool automatically identifies 
subpopulations of interest within multiparameter data (Kalina et al. 2009), but 
does not allow for comparison between heterogeneous samples. With a similar 
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constraint, FLAME (FLow Analysis with automated Multivariate Estimation), as 
well as Hyperlog and FCOM (Petrausch et al. 2006), define and characterize 
discrete populations in high-dimensional flow cytometry data (Pyne et al. 2009). 
One of the most advanced algorithms for comparing multiparameter/high-
dimensional data is SPADE (Spanning-tree Progression Analysis of Density-
normalized Events) (Qiu et al. 2011). SPADE specializes in analyzing datasets 
that represent lineage progression and/or include rare cell types while comparing 
numerous functional markers simultaneously.  
Although these analysis tools work well for the specific tasks for which 
they were designed, we required a tool that compared the shapes of 2D flow 
cytometry plots across a large number of samples allowing for variable 
parameter input. 
2.2 MATERIALS AND METHODS 
2.2.1 Construction of yeast strains 
Standard yeast methods were used (Sherman 1991). Isogenic wild-type 
yeast strains BY4741 or BY4742 were used as wild-type comparisons except 
where noted. For the mCherry-Ufd2p-GFP strain (SS4065), a PCR product 
containing the TDH3 promoter and the mCherry ORF was used to genomically 
N-terminally tag UFD2-GFP (SS4066) by homologous recombination (Huh et al. 
2003) using the standard lithium acetate transformation method (Gietz and 
Woods 2002). For directed deletion mutant screen and the deletion collection 
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screen, the Yeast MATalpha Collection was used (Thermo/Open Biosystems; 
Cat# YSC1054). For mex67-5 experiments the mex67-5 strain SS4142 (Segref 
et al. 1997) was transformed with empty (SS4145) or MEX67 plasmids (SS4146) 
and a CUP1-Reporter, selecting only for the introduced plasmids not the “native” 
mex67-5 plasmid. Refer to Table 2.1 for a complete table of yeast strains used in 
this chapter, as well as Table 2.2 and Table 2.3 for plasmids and DNA 
oligonucleotides, respectively, used to make these strains. 
Table 2.1 Yeast strains used in Chapter 2 
Strain 
(SS) 
Mating 
type 
Genotype 
 
4004 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 (BY4741) 
4011 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 + pRS426 TDH3-mCherry (MS122) (mCherry only control) 
4022 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 +pRS316 TDH3-GFP (MS125) (GFP only control) 
4030 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 + pRS316 TDH3-BPS mutation Reporter (MS#135) 
4031 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 + pRS316 TDH3-3’SS mutation Reporter (MS#136) 
4034 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 + pRS416 (MS103) (Nonfluorescent control) 
4050 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 (BY4742) 
4052 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 + pRS316 TDH3-Reporter  
4065 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 UFD2-GFP-His3MX 
4066 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 URA3::GPD-mCherry-UFD2-GFP-His3MX (GFP-mCherry dimer control) 
4142 a ade2,his3,leu2,trp1,ura3,mex67:HIS3 + pUN100 LEU2 mex67-5 (AJY1231/PSY1687) 
4145 a 
ade2,his3,leu2,trp1,ura3,mex67:HIS3 + pUN100 LEU2 
mex67-5 + pRS426 (MS107)+ pRS414 CUP1-Reporter 
(MS388) 
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(Table 2.1 continued) 
 
4146 a 
ade2,his3,leu2,trp1,ura3,mex67:HIS3 + pUN100 LEU2 
mex67-5 + pRS426 MEX67 (MS382)+ pRS414 CUP1-
Reporter (MS388) 
Table 2.2 Plasmids used in Chapter 2 
MS # 
 
Common Name 
 
Purpose Source 
101 pRS414 Yeast Expression 
Vector 
(Sikorski and 
Hieter 1989) 
103 pRS416 Yeast Expression 
Vector 
(Sikorski and 
Hieter 1989) 
107 pRS426 Yeast Expression 
Vector 
(Sikorski and 
Hieter 1989) 
120 pRS316 RPL25-GFP Yeast expression 
vector with eGFP 
(Gadal et al. 
2001) 
122 pRS426 TDH3-mCherry mCherry over 
expression control. 
Also used as 
template for dimer 
control 
This work 
124 Synthesized reporter 
fragment 
Exon 1 through exon 
2 
Mr. Gene. 
125 pRS316 TDH3-GFP eGFP over 
expression control. 
Also used to clone 
reporter 
This work.  
Plasmids MS 
120 and 130 
127 pRS316 TDH3-Reporter TDH3 driven reporter  This work. 
Plasmids MS 
124 and 125 
130 pGEM TDH3 Cloning vector with 
TDH3 promoter 
This work 
135 pRS316 TDH3-BPS mut. 
Reporter  
BPS mutant reporter This work. 
Plasmid MS 127 
and oligos MS 
109-110 
136 pRS316 TDH3-3’SS mut. 
Reporter 
3’SS mutant reporter This work. 
Plasmid MS 127 
and oligos MS 
111-112 
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(Table 2.2 continued) 
 
162 TA CUP1 Promoter Cloning vector with 
CUP1 promoter 
This work. 
163 pRS316-CUP1-Reporter CEN URA3 inducible 
reporter 
This work. 
Plasmids 162 
and 127. 
251 pRS313 Reporter qPCR1-2-3 qPCR Control 
Template 
This work. 
283 pGAL1-RRP6 RRP6 
overexpression clone 
from Yeast ORF 
Collection 
Thermo 
Scientific 
382 pRS426 MEX67 Wild-type MEX67 
expression (pAJ282) 
(Hung et al. 
2008) 
388 pRS414 CUP1-Reporter CEN HIS3 inducible 
Reporter 
This work. 
Plasmids 101 
and 163. 
 
Table 2.3 DNA oligonucleotides used in Chapter 2 
MS# 
 
Sequence  
(5’ to 3’) 
Purpose 
 
109 CGATAAAATGTCCAGTTGAAA
ACCTGTTTTACTAGCGATTTA
AAAATTGTATTTCAT 
Site-directed PCR Mutagenesis – 
Reporter BPS A to G mutation FWD 
110 ATGAAATACAATTTTTAAATC
GCTAGTAAAACAGGTTTTCAA
CTGGACATTTTATCG 
Site-directed PCR Mutagenesis – 
Reporter BPS A to G mutation REV 
111 TTTCATTACAATATTTTTTTTG
TACTGCCGGTTAAGGTCGTA
TCTCT 
Site-directed PCR Mutagenesis – 
Reporter 3’SS A to T mutation FWD 
112 AGAGATACGACCTTAACCGG
CAGTACAAAAAAAATATTGTA
ATGAAA 
Site-directed PCR Mutagenesis – 
Reporter 3’SS A to T mutation REV 
146 GTGGGCGGCCGCTCCCATTA
CCGACATTTGGGCGCTA 
PCR – CUP1 Promoter FWD 
147 GTGGGGATCCTGATTGATTG
ATTGATTGTACAGTTTG 
PCR – CUP1 Promoter REV 
257 TCACGTCTCAGGCCGGTTAA
GGTC 
qPCR – Reporter mRNA FWD 
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(Table 2.3 continued) 
 
258 GCAGCTTGCCGGTGGTGCAG
ATG 
qPCR – Reporter mRNA REV 
303 TAATAGAGGTGTACGCCGCA
ATCATTGTTAATCATTAAGTA
ATTGCCATTAGAGTGCACCAT
ACCACAGC 
PCR – mCherry-UFD2-GFP dimer 
FWD 
304 GTATCGGAAGGATCGGTGGT
GATTTGTAAAATATCTTCTAT
GGCGGTCATCTTGTACAGCT
CGTCCATGC 
PCR – mCherry-UFD2-GFP dimer 
REV 
309 CGTTAAGCACCCAGCTGACA qPCR – Reporter pre-mRNA FWD 
310 TGCATAACTGGACCGTCAGA
TG 
qPCR – Reporter pre-mRNA REV 
2.2.2 Site-directed PCR mutagenesis 
Primers were designed to both incorporate the desired mutation and to 
amplify the template plasmid. Reaction conditions were as described previously 
(Barnes 1994). PCR cycling was performed at 95°C 1 minute followed by 17 
cycles of [95°C 50 seconds, 45°C - 65°C 50 seconds, 70°C (1.25 min/Kb of 
template)] followed by incubation at 70°C for one elongation-length step. 
Reactions were treated with the restriction enzyme DpnI to destroy the template 
plasmid and were transformed into competent E. coli. Mutant plasmids were 
screened by diagnostic restriction enzyme digest and sequencing. 
2.2.3 Robotic high-throughput 96-well yeast transformation 
We adapted the standard lithium acetate (Gietz and Woods 2002) and 
microplate methods (Gietz and Schiestl 2007) to utilize robotic techniques and 
increase transformation efficiency and speed. Except where noted, liquid 
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handling was performed using a BioMek FX laboratory automation workstation 
(Beckman Coulter). 96-well plates containing cryogenically preserved yeast 
strains were thawed and small volumes transferred to a 96-well plate containing 
150 µL/well fresh YPD medium supplemented with 200 µg/ml G418 (effective 
concentration; Gibco) using sterile pin replicators. Strains were grown for 16-20 
hours at 31°C and breathable sealing film (Axygen) was used to minimize cross 
contamination. Cells were pelleted and washed twice with 100 mM lithium 
acetate, then mixed with a pin replicator in pre-warmed transformation master 
mix (33.3% PEG 8000, 100 mM lithium acetate, 2 mg/mL salmon sperm DNA 
and 500 ng plasmid/reaction at 42°C). Plates were incubated at 42°C for 45 
minutes, washed twice with ddH2O and resuspended in 50 µL ddH2O. To select 
for transformants, 20% of the cell suspension was spotted onto solid minimal 
selecting for the plasmid (SD-uracil + 200 µg/mL G418). The remaining 80% of 
cell suspension was cryogenically preserved by adding an equal volume of 50% 
glycerol and stored at -80°C. If transformants were not obtained in the initial 20% 
spot plating, the remaining transformation mixture was thawed and spread onto 
selective media. 
2.2.4 Flow cytometry analysis 
For standard flow cytometry, log-phase yeast were fixed in 10% 
formaldehyde, washed and resuspended in 1X PBS. For high-throughput flow 
cytometry, 96-well plates containing stocks of the deletion strains harboring the 
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reporter were replicated into 150 µL selective media. When the average well in a 
plate reached mid-log phase, cells were harvested, washed and resuspended in 
100 µL 1X PBS and analyzed immediately with a Becton Dickinson LSRFortessa 
equipped with a high-throughput sampler unit. For excitation of eGFP and 
mCherry, 488 nm and 561 nm lasers were used respectively. For detection a 505 
LP and 530/30 BP were used for eGFP and a 600 LP and 610/20 BP for 
mCherry. For each sample 21,000 events were collected and 10,000 events are 
shown in the phenographs. FlowJo (version 9.6.4, Tree Star Inc., Ashland OR) 
was used to analyze data and to prepare phenographs, plotting cells based on 
their fluorescent intensity (GFP on x-axis and mCherry on y-axis), which is in 
arbitrary units based on predetermined cytometer settings. 
Data in Figure 2.12 were obtained from the dataset “T cell stimulation 
(human)-titration and timecourse” from the public Cytobank repository and 
submitted by A. Landrigan. These data represent precursors to the work 
presented in their subsequent publication (Landrigan et al. 2011). The same 
gating hierarchy (FSC-A/SSC-A (FSC/SSC), FSC-A/FSC-H, CD45RA/CD45RO) 
was used to identify live, single, naïve CD45RA+ cells respectively for further 
analysis. Briefly, human CD4+ T cells were purified and stimulated with anti-CD3 
(OKT3 or UCHT; 0.3 or 0.8 µg/mL) with or without at 10 µg/mL anti-CD28 for 3, 
6, or 10 minutes. Upregulation of pSLP76/S6 and pCD247 was assessed. 
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2.2.5 Binning and clustering analysis of flow cytometry data (CHUBACA) 
FlowJo (version 9.6.4, Tree Star Inc., Ashland OR) was used to create all 
flow cytometry plots and to process flow cytometry data. For further analysis, 
scale values for two parameters were exported as text files, one file for each 
sample. The text files were processed using SAS software (Version 9.2, SAS 
Institute Inc.). First, the user sets the range of x- and y-axis values, the number of 
bins for each axis, as well as the total number of events to be analyzed. When 
the analysis begins, a log transformation is applied to the scale values and 
individual events are assigned a bin based on those two scale values and the 
other applied settings. Binning begins at the origin (lowest value for each axis) 
then proceeds up the y-axis. It then returns to the x-axis, shifting to the right one 
bin then proceeding up, continuing until the last bin in the top right of the plot 
(highest values for each axis). Sample/data files that do not meet the standards 
set by the user-defined settings are not incorporated into the final analysis and 
this exception is reported. After binning all of the events for each sample, the 
results are exported into a text file that reports the number of events in each bin 
(columns) for each sample (rows). Data are then hierarchically clustered with 
Cluster (Eisen et al. 1998) and a dendrogram is prepared using Java TreeView 
(Saldanha 2004). I refer to our analysis pipeline as “CHUBACA” (Comparative 
Hierarchy Using Binning And Clustering Analysis). 
When using CHUBACA I recommend naming samples in a simple and 
systematic format and then renaming the samples after the binning analysis 
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using a VLOOKUP function in Microsoft Excel. Per SAS limitations, sample/file 
names for TXT files should not contain any spaces or punctuation, except 
underscores. The character limit for samples is 12. It is recommended that TXT 
files be processed in smaller groups if working with a large dataset. For example, 
we broke up our analysis of the 5000 yeast deletion mutants into groups of eight 
96-well plates (768 samples). The SAS source code is available upon request. 
2.2.6 Total yeast RNA isolation 
Two OD units of log phase cells were harvested by centrifugation in a 
microfuge tube and total RNA was extracted with 266 µL acid phenol and 266 µL 
AES Buffer (50 mM sodium acetate pH 5.3, 10 mM EDTA and 1% SDS). 
Samples were vortexed well and incubated for 6 minutes at 65°C, vortexing 
every minute (Wise 1991). Samples were placed in ice water for 5 minutes, then 
transferred to a Phase Lock Gel Heavy 2 mL tube (5 PRIME). Tubes were 
centrifuged for 5 minutes at 2500 rpm. Acid phenol (266 µL) was added; tubes 
were gently inverted five times and then centrifuged. Chloroform (266 µL) was 
added; tubes were inverted to mix and then centrifuged. The aqueous phase 
above the gel matrix was transferred to a new microfuge tube. 3 M sodium 
acetate (1:10 volumes, pH 5.3) was added, followed isopropanol (1.1 volumes). 
Tubes were incubated at -20°C overnight to precipitate the RNA. RNA was 
harvested and washed twice with 1 mL 70% cold ethanol and resuspended in 30-
50 µL DEPC-treated water. 
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2.2.7 RT-qPCR analysis 
Total RNA (5 µg) was DNase treated (5 U RQ1 DNase, Promega) for 20 
minutes at 37°C. RNA Clean and Concentrator kit (Zymo) was used to purify the 
RNA per the manufacturer’s protocol (6.5 µL DEPC water was used to elute, 
resulting in an final volume of 5 µl). To the DNase-treated RNA, the following was 
added: 1 µL 10X RT Buffer (0.5 M Tris-HCl pH 8.5), 1 µL random nonamer 
primers (25 µM; Integrated DNA Technologies; MS299-302) and 2 µL DEPC 
H2O. The RNA/primer mix was incubated at 60°C for 5 minutes and immediately 
transferred to ice for 5 minutes. 11 µL of an RT master mix (1X RT Buffer, 3 mM 
MgCl2, 10 mM DTT, 0.5 mM dNTPs and 5 U/µL MultiScribe RT enzyme) was 
added. The RT reaction was incubated overnight at 42°C and the resulting cDNA 
was diluted with four volumes DEPC H2O. Each qPCR reaction contained 5 µL 
cDNA, 7.5 µL Power SYBR Green PCR Master Mix (ABI) and 2.5 µL primers (1.5 
µM each). Standard thermocycling, fluorescence detection and analysis 
(standard curve) were completed using the ViiA 7 Real-Time PCR System (Life 
Technologies). 
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2.3 RESULTS 
2.3.1 Design, cloning, and validation of the eukaryotic gene expression 
reporter 
We designed a reporter that is amenable to high-throughput single-cell 
analysis and simultaneously generates signals reflecting pre-mRNA and mRNA 
levels. To accomplish our goal, we chose to drive transcription of our reporter 
with the strong and constitutive TDH3 (GPD) promoter. The exons (EX1 and EX2 
in Figure 2.1A) and intron were based on the relatively inefficiently spliced yeast 
RPL28/CYH2 gene (Swida et al. 1986) to increase the chances that the 
unspliced transcript levels were detectable. 
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Figure 2.1: Gene expression reporter design and validation. 
Design (A) of the gene expression reporter construct is shown. Expression of the 
synthetic reporter was driven by the strong constitutive TDH3 promoter. Exon 1 
(EX1), the intron and exon 2 (EX2) were designed using features of the 
inefficiently spliced CYH2 gene. Dashed lines indicate the region comprising the 
intron. The mCherry ORF was placed in frame with EX1 and the eGFP ORF was 
cloned in frame with EX2. Exported intron-containing pre-mRNAs and mature 
mRNAs are translated resulting in proteins which fluoresce red and green 
respectively. The construct was cloned into pRS316 (see Materials and Methods 
for more detail). Control samples (B) for flow cytometry are shown. Phenographs 
for wild-type yeast harboring an empty vector (non-fluorescent), or vectors 
expressing GFP-only or mCherry-only are shown (left panel). In the right panel, a 
phenograph of the expression of the mCherry-Ufd2p-GFP dimer results in a 1:1 
mCherry:GFP signal. The pseudo color represents cell density within the 
phenograph. Reporter expression in wild-type yeast (C) is displayed and referred 
to as a phenograph. Phenographs for branch point (A to G) and 3’ splice site 
(CAG to CuG) mutant reporters (D) in wild-type yeast are shown (top and bottom 
panels respectively). The y- and x-axis depict mCherry and GFP fluorescence 
respectively. 
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An annotated version of the reporter sequence can be found in Appendix 
I. All nucleotide positions and descriptors below refer to Appendix I. To generate 
the reporter, the region from EX1 through EX2 (640-1598) was commercially 
synthesized (Mr. Gene; Regensburg Germany) and cloned into the BamHI site of 
pRS316-TDH3-eGFP (derived from pRS316-RPL25-GFP) by replacing the 
RPL25 promoter and ORF with the TDH3 promoter (31-639) using BamHI and 
NotI restriction enzymes. In the design, we removed an inhibitory sequence 
(Swida et al. 1988) within the CYH2 intron and positioned a yeast codon 
optimized mCherry ORF (nucleotides 763-1470 in the sequence below) upstream 
of the branch point sequence (1526-1532) which removed 32 bp from the intron. 
The mCherry ORF was placed in frame with EX1 and a stop codon was placed 
immediately at the end of the mCherry ORF. The resulting plasmid contains a 
small portion of the CYH2 EX2 fused in frame with the eGFP ORF (1600-2322). 
This construct was cloned into a suite of pRS vectors (Sikorski and Hieter 1989) 
using BamHI/SalI, maximizing utility. In Appendix I, underlined bases are those 
that were mutated for the branch point mutant and 3’ splice site mutant and the 5’ 
GT and 3’ AG intron boundaries are in lower-case text. 
In this system, levels of exported pre-mRNA (intron containing) are 
reflected by red fluorescence via a codon-optimized open reading frame (ORF) 
for mCherry (Shaner et al. 2004) that was placed between the 5’ splice site and 
branch point sequence, in frame with the first exon and a portion of the intron 
(Figure 2.1A left side). After nuclear export, translation of this pre-mRNA 
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terminates at a stop codon located at the end of the mCherry ORF. To measure 
the level of exported spliced message, the enhanced GFP (eGFP) ORF (Heim et 
al. 1995) was cloned in frame with the second exon (Figure 2.1A right side). 
When the pre-mRNA is unspliced, the second exon was designed to be out of 
frame with the first exon and a stop codon is present after the mCherry ORF, 
ensuring that GFP translation and fluorescence results only from the spliced 
message. The final construct was built into a series of low-copy centromeric 
plasmids with different auxotrophic and dominant selection markers to maximize 
flexibility.  
To rapidly measure the levels of reporter fluorescence in individual yeast 
cells we utilize flow cytometry. In Figure 2.1B, we show flow cytometry data for 
an empty vector control (non-fluorescent) and cells over-expressing either GFP 
or mCherry alone (Figure 2.1B, left panel). As an additional control to determine 
the behavior of mCherry and GFP when present at high levels and at a defined 
1:1 ratio, we designed a strain in which the yeast gene UFD2 was tagged at the 
C-terminus with GFP (Huh et al. 2003) and was modified to contain the TDH3 
promoter followed by an N-terminal mCherry tag. This non-essential yeast gene 
was chosen as a linker between the fluorescence proteins as the X-ray crystal 
structure of this protein shows that the N- and C-termini are ≈146 Å apart (Tu et 
al. 2007), eliminating potential fluorescence resonance energy transfer between 
GFP and mCherry (Albertazzi et al. 2009), while keeping their mRNA and protein 
levels equal. Expression of the dimer resulted in equivalent amounts of 
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fluorescence in the flow cytometer, demonstrating that fluorescence operates as 
a suitable proxy for in vivo reporter transcript levels (Figure 2.1B, right panel).  
In wild-type yeast cells, our reporter exhibited 2.5-fold greater red 
fluorescence than green fluorescence, indicating that while translating pools of 
pre-mRNA and mRNA are not 1:1, as in the dimer control, our reporter produces 
both translated pre-mRNA and mRNA at adequate levels for detection and with 
sufficient dynamic range available to measure changes (Figure 2.1C). We refer 
to the flow cytometry data presented in this work as a phenograph, as it 
graphically represents the reporter expression phenotype in a given yeast strain. 
To ensure that no GFP signal results from the pre-mRNA transcript, we mutated 
the intron branch point nucleotide from A to G or the 3’ splice site from AG to UG. 
As predicted, both of these mutations abolished green fluorescence, 
demonstrating that intron removal is required for the production of GFP from this 
reporter (Figure 2.1D).  
We note that the elongated shape of the phenograph is due to 
heterogeneity of cell volume as we observed a strong correlation between 
fluorescence intensity and cell volume (Figure 2.2A). Additionally, the fact that 
the cells fall near the middle of the phenographs allows for detection of an 
increase or decrease of at least two orders of magnitude with either signal. 
Reassuringly, the levels of fluorescent protein correlate with transcript levels by 
RT-qPCR (Figure 2.2B).  
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Figure 2.2: The reporter phenograph is a reproducible product of cell volume and 
reporter transcript levels. 
Reporter expressing cells were gated (A) into four equally populated groups 
based on their position within the phenograph, moving out from origin (essentially 
grouping cells based on their fluorescence intensity). The inset compares the 
average total fluorescence with the average cell volume (forward scatter) for the 
four groups. An exponential regression line is applied (R² = 0.98). The flow 
cytometry mCherry/GFP ratio is plotted for several deletion strains versus the 
ratio of unspliced and spliced reporter transcripts (B), which was determined by 
RT-qPCR analysis. Flow cytometry and RT-qPCR ratios are relative to wild-type 
(WT) and an exponential trend line is shown (R² = 0.91). The inset cartoon 
depicts the primer location for the unspliced (top) and spliced transcripts. 
Phenographs from wild-type yeast analyzed on different days (C) are visually 
indistinguishable when overlaid. 
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As with any technology or assay, reproducibility is of critical importance, 
especially if one wishes to compare data from experiments performed on 
different days. To demonstrate this quality of our reporter, I compared data from 
wild-type cells containing our constitutive reporter from four separate 
experiments on different days. When these data are overlaid, they are virtually 
indistinguishable (Figure 2.2C), demonstrating great day-to-day reproducibility. 
2.3.2 Deletion of genes within specific gene expression processes exhibit 
similar phenograph patterns 
To assess the behavior of the reporter I generated phenographs from a 
small collection of yeast strains, each lacking a single gene functioning in some 
aspect of gene expression. It was expected that defects in the splicing machinery 
would decrease the efficiency of intron removal (Vijayraghavan et al. 1989), 
resulting in populations of cells that are red-shifted, due to a decrease in green 
fluorescent signal which would result from decreased levels of spliced reporter 
transcript. In the first set of splicing mutants (mud2∆, swm2∆, and swt21∆) we 
detected a relatively minor red shift, whereas in the bud13∆, ist3∆, and lea1∆ 
strains we detect a more severe red-shift (cf. Figures 2.3A and 2.3B 
respectively). This shift in the ratio of the translation products of the pre-mRNA to 
mRNA is also reflected in the corresponding RNA levels as determined by RT-
qPCR (Figure 2.2B). 
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Figure 2.3: Mutations within specific gene expression pathways result in red-
shifted phenographs. 
The gene expression reporter described in Figure 2.1A and 2.1C was 
transformed into the indicated strains. Each phenograph overlay contains data 
from the indicated deletion strain in pseudo color and an isogenic wild-type strain 
(SS4050/BY4742) in the grayscale for comparison. Each gene expression 
process (A-F) is indicated above the phenographs and the out-group (G) 
represents three unrelated, randomly chosen deletion mutants to serve as 
negative controls. The y- and x-axis depict mCherry and GFP fluorescence 
respectively. 
 
  
C. Nonsense-Mediated Decay 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
nam7Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
nmd2Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
upf3Δ 
D. mRNA Transcription 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
rtr1Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
rtf1Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
srb5Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
mud2Δ 
Pre-mRNA Splicing 1 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
swt21Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
swm2Δ 
A. Chromatin Remodeling 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
htz1Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
arp6Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
vps72Δ 
E. 
Out-group 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y-
A
atg11Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
pig2Δ 
G. 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
cue3Δ 
Histone Modification 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
set2Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
rpd3Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
hos3Δ 
F. 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
bud13Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
ist3Δ 
0 10
2
10
3
10
4
10
5
GFP-A
0
10
2
10
3
10
4
10
5
m
C
h
e
rr
y
-A
lea1Δ 
Pre-mRNA Splicing 2 B. 
 35 
Next, we considered whether our reporter was sensitive to and behaved 
differently in strains containing mutations in other gene expression pathways. 
The most striking were the nonsense-mediated decay (NMD) mutants nam7∆, 
nmd2∆ and upf3∆ (Figure 2.3C; He et al. 1997). This is not surprising because 
the long 3’ UTR of the reporter pre-mRNA, which extends from the 3’ end of the 
mCherry ORF through the GFP coding region, is predicted to be an ideal 
substrate for NMD in wild-type yeast (Muhlrad and Parker 1999). Without a 
functional NMD pathway, we would expect increased mCherry signal due to 
increased stability and translation of the reporter pre-mRNA. As predicted we 
detected a severe red-shift which was a result of over a 10-fold increase in red 
fluorescence with very little change in green fluorescence intensity, supporting 
the suggestion that disruptions in the NMD pathway result in accumulated levels 
of translatable reporter pre-mRNA transcripts (He et al. 1993). RT-qPCR analysis 
further corroborates this, revealing a large increase in the pre-mRNA/mRNA ratio 
in NMD mutants compared to wild-type cells (Figure 2.2B). NMD has also been 
shown to mask intron accumulation of poorly spliced transcripts by degrading the 
pre-mRNA transcripts in yeast (Sayani et al. 2008), which is also consistent with 
the red-shifted phenographs and RT-qPCR results. Our results indicate that the 
reporter pre-mRNA is inefficiently spliced and that this is masked by NMD in wild-
type cells, similar to the suboptimally spliced natural introns highlighted by 
Sayani et al. I also analyzed forward scatter values in these mutants to see if cell 
volume increased compared to wild-type. There was no difference seen in these 
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mutants, supporting the conclusion that increased translation of the stabilized 
pre-mRNA resulted in the red-shift and not an accumulation of fluorescent 
proteins in a larger cell (data not shown). 
Defects within early steps of gene expression also altered reporter 
expression. I analyzed the phenographs of several mutants lacking factors 
involved in mRNA transcription (rtf1∆, srb5∆ and rtr1∆; Figure 2.3D), chromatin 
remodeling (htz1∆, arp6∆ and vps72∆; Figure 2.3E) and histone modification 
(hos3∆, rpd3∆ and set2∆; Figure 2.3F). The phenographs from these mutants 
were primarily red-shifted, but to a lesser degree than in NMD mutants and more 
closely resembling some pre-mRNA splicing mutants (Figure 2.3A). The 
observed red-shift in these mutants, which is a result of a decrease in green 
fluorescence (spliced signal), is not surprising due to the large number of reports 
describing the interconnected nature of chromatin remodeling, histone 
modification, transcription and pre-mRNA splicing. We also note that the 
phenographs for mutants with no direct function in gene expression do not 
significantly change compared to wild-type (atg11∆, cue3∆ and pig2∆; Figure 
2.3G).   
Interestingly, a subset of gene expression factor deletions produced an 
overall green-shifted phenograph rather than red-shifted phenographs, indicating 
a relative increase in the spliced reporter signal and/or a decrease in pre-mRNA 
signal. This was most striking in yeast strains lacking factors of the TREX-2 
complex (sac3∆, thp1∆, sus1∆, and sem1∆; Figure 2.4A), which couples mRNA 
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transcription and mRNA export (Fischer et al. 2002; Rodriguez-Navarro et al. 
2004). The loss of TREX-2 core components Sac3p or Thp1p results in 
indistinguishable phenographs, which would be expected. Sus1p has been 
proposed to serve as a link between the SAGA complex and TREX-2 complex 
(Ellisdon et al. 2010), which results in a similar but not identical phenograph 
when removed from yeast. Analysis of different classes of mRNA export related 
mutants, such as the THO complex and components of the nuclear pore (Stewart 
2010), demonstrate a similar green-shift (Figures 2.4B-C). Possible explanations 
for this effect are changes in mRNA stability, a preferential export of specific 
transcripts, or as our RT-qPCR data suggests, the defect in mRNA export likely 
leads to a lengthened nuclear residency and might increase the likelihood of 
splicing, increasing the green to red ratio (Figure 2.2B). It is also important to 
note that others have used translationally competent reporter pre-mRNAs as 
mRNA export reporters, providing further support for the green-shifted effect we 
observed (Galy et al. 2004; Dufu et al. 2010; Teplova et al. 2011; Caporilli et al. 
2013). 
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Figure 2.4: Mutations within specific gene expression pathways result in green-
shifted phenographs. 
The gene expression reporter described in Figure 2.1A was transformed into the 
indicated deletion strains. Each phenograph overlay contains data from the 
indicated deletion strain in pseudo color and an isogenic wild-type strain 
(SS4050/BY4742) in the grayscale for comparison. Each gene expression 
process or complex (A-H) is indicated above the phenograph. Asterisk indicates 
a deletion that overlaps the verified ORF THO2. The y- and x-axis depict 
mCherry and GFP fluorescence respectively. 
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One interesting green-shifted phenograph was that of the mlp1∆ mutant 
(Figure 2.4D), a result of a nearly 80% decrease in mCherry signal, with a minor 
change in GFP. This is in contrast to the green-shifts observed in the previously 
described mutants (Figures 2.4A-C, which primarily result from an increase in 
GFP). Mlp1p has been shown to mediate retention of unspliced reporter mRNAs, 
resulting in increased pre-mRNA reporter translation in its absence (Galy et al. 
2004; Hackmann et al. 2014), which is in contrast with the result shown here. 
Although both reporters are weakly spliced due to suboptimal intron architecture, 
our reporter contains the extended 3’UTR that is efficiently degraded in the 
cytoplasm via NMD (Figure 3C). This feature, along with the role of Mlp1p as a 
checkpoint for export competent messenger ribonucleoparticles (mRNPs; Green 
et al. 2003; Palancade et al. 2005), leads us to believe that exported unspliced 
reporter mRNPs in mlp1∆ cells could be improperly packaged, leading to a 
decreased signal by virtue of NMD and/or other degradation pathways. Further 
studies are needed to confirm this. Of note, I also observed a similar effect in 
cells lacking the SR-like protein Gbp2p (Figure 2.4E), which was recently shown 
to be involved with Mlp1p in a potential mRNP quality control mechanism 
coupled with export (Hackmann et al. 2014). 
We also note that the deletion of factors involved the turnover of mRNA 
transcripts, which stabilizes mRNA messages, also results in green-shifted cells 
(dhh1∆ and ccr4∆; Figures 2.4F-G; Goldstrohm and Wickens 2008). Although the 
rrp6∆ mutant results in an overall green-shift like dhh1∆ and ccr4∆ (Figure 2.4H), 
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it is important to note that the rrp6∆ mutant is the only deletion mutant that results 
in significant increases of both GFP and mCherry fluorescence. Rrp6p is a 
nuclear exosome component with 3’-5’ exonuclease activity, and is thought to 
degrade aberrant transcripts, among other functions (Chlebowski et al. 2013). 
Loss of this enzyme could stabilize the pre-mRNA and in turn increase the 
probability of it being spliced within the nucleus. This may lead to increased 
signals of both reporter messages. On the other hand, the dhh1∆ and ccr4∆ 
mutants only increase in the green fluorescence spliced signal, which is most 
likely due to their function in decreasing the stability of mature cytoplasmic 
transcripts in a wild-type strain. 
I also looked into the effects on total fluorescence of many of these 
mutants by plotting the mean mCherry and GFP values for the 21,000 cells that 
were analyzed by flow cytometry (Figure 2.5). As expected, we observed a 
decrease in the overall fluorescence in mRNA transcription mutants, as well as 
specific patterns for other mutant groups, such as NMD and mRNA export. The 
directed screen of gene expression mutants demonstrates that our reporter is 
uniquely sensitive to many gene expression events, increasing its utility by 
permitting numerous biological pathways to be queried at single-cell resolution. 
The similarity between phenographs resulting from mutants within a given gene 
expression process (cf. each panel in Figures 2.3 and 2.4) suggests that our 
reporter can be used to test the relatedness within and between pre-mRNA 
processing events. It is interesting that numerous nonessential translation 
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mutants were analyzed, no appreciable effect on reporter expression was 
detected, suggesting no translation bias between the spliced and unspliced 
reporter RNAs (Figure 2.6). It is important to note that the red- and green-shifts 
can be a result of changes in one or both signals, as shown in Figure 2.5 
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Figure 2.5: Comparison of total fluorescence readings from representative 
deletion mutants. 
To describe the trend of the changes in both GFP and mCherry 
fluorescent signals, we plotted a number of mutants from Figures 2.3 and 2.4 
based on the mean mCherry and GFP value in arbitrary fluorescence units for 
the 21,000 cells analyzed by flow cytometry. Note the scale of the inset graph is 
different that the scale for the larger graph, with the breaks in axes noted with a 
tilde. The arrows describe a vector for the average fluorescence change in the 
corresponding mutant group, with the arrowhead representing the actual average 
value for the mutant group. 
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Figure 2.6: Nonessential translation-related deletion mutants have a minimal 
effect on reporter expression. 
As in Figures 2.3 and 2.4, flow cytometry data from the indicated nonessential 
mutants were individually plotted and overlaid onto a grayscale dataset from wild-
type cells. GFP and mCherry fluorescence are shown on the x- and y-axis 
respectively. 
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2.3.3 Optimization and utilization of a copper-inducible reporter 
We also explored using our reporter with conditional alleles of essential 
genes involved in gene expression. Since most temperature- or cold-sensitive 
conditional alleles exhibit rapid response to changed temperature, the existing 
pools of extremely long-lived fluorescent proteins (Kitsera et al. 2007) would 
mask changes resulting from the mutation due to the relatively short time spent 
at the non-permissive temperature. To circumvent this, and to measure de novo 
signal after temperature shift, I placed the reporter described in Figure 2.1A 
under the control of the CUP1 promoter, which is rapidly and highly activated 
upon addition of copper (Peña et al. 1998). Induction with 1 mM CuSO4 resulted 
in significant fluorescence within one hour, reaching peak levels within 3-4 hours 
(Figure 2.7A). For completeness I followed the time course into stationary phase 
(6+ hours) and did not see any appreciable differences in reporter expression, as 
compared to the 4-hour time point. During optimization efforts I found that 
induction efficiency was highly dependent on growth phase, with the highest and 
most consistent levels produced when cells were induced between OD 0.1-0.2 
(A600, data not shown). Additionally, I have demonstrated that data from cells 
grown in standard culture tubes, 96-well, and 384-well plates are comparable 
using the CUP1-Reporter (Figure 2.8), simplifying the nature of high-
throughput/high content experiments. 
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Figure 2.7: Exploring conditional alleles and drug treatment with a copper-
inducible reporter. 
A time course (A) of CUP1-Reporter induction is shown. Wild-type cells harboring 
a CUP1-Reporter were grown to early logarithmic phase and induced with 1 mM 
CuSO4. Samples were taken at the indicated time points. Yeast with wild-type 
MEX67 or mex67-5 and the CUP1-Reporter were grown at permissive (31°C) 
temperature, then shifted to permissive or nonpermissive (34°C or 37°C) 
temperature with 1 mM CuSO4 (to induce reporter) for 4 hours before analysis. 
Data for cells at permissive temperature are shown in the background in red, with 
data from cells at nonpermissive temperature in the foreground in blue (B). 
Pseudo color phenographs insets are shown for the corresponding 
nonpermissive conditions. Wild-type cells with CUP1-Reporter and an empty 
vector or RRP6 overexpression plasmid were grown in minimal media with 
galactose. Cells were treated with DMSO (vehicle only control) or 100 µM 
fluorouracil (5-FU), induced with 1mM CuSO4 and grown for 4 hours before 
analysis (C). The rightmost panel of each set is an overlay of the DMSO and 5-
FU datasets for comparison. 
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Figure 2.8: CUP1-Reporter expression in different culture conditions. 
Wild-type cells harboring the CUP1-Reporter described in Figure 2.7 were 
induced with 1 mM CuSO4, distributed into different growth vessels, and induced 
for 4 hours. Cells were then analyzed via flow cytometry (A). We also compared 
reporter expression in 96- and 384-well plates when grown without shaking (B). 
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Since we observed many mutants in the mRNA export pathway resulting 
in strong green-shifts, I analyzed the prototypical mex67-5 allele of the essential 
Mex67p, homolog of the human TAP mRNA export factor (Segref et al. 1997). 
Yeast with the temperature sensitive mex67-5 allele fail to export bulk mRNA at 
elevated temperature. I cultured MEX67 (wild-type) or mex67-5 yeast at 
permissive temperature (31°C) to early log phase, and then shifted to 
nonpermissive temperature (34˚C or 37°C) while adding 1 mM CuSO4 to induce 
the CUP1-driven reporter. Yeast with wild-type MEX67 displayed very little 
difference between permissive and nonpermissive temperature, while cells with 
mex67-5 were green-shifted at nonpermissive temperature (Figure 2.7B). The 
green-shifted phenotype is consistent with the previously analyzed nonessential 
gene deletions in this process (Figure 2.4A-C), yet I observed more cell-to-cell 
variability with the conditional allele, which is perhaps not surprising since one 
would expect a more uniform phenotype with a complete gene deletion. I 
attempted to analyze the strong temperature sensitive splicing allele prp2-1 but 
we found that the cells were not able to express sufficient levels of the reporter at 
nonpermissive temperature during the experiment, most likely due to the rapid 
growth defects conferred by the prp2-1 allele (Hartwell 1967). 
We were also interested in determining the utility of the inducible reporter 
with chemical insults that impair a specific gene expression process. Drug 
treatment of cells is similar to the use of conditional alleles in that existing pools 
of mCherry and GFP would not significantly change during the relatively short 
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treatment, thus the inducible reporter would add great utility to these 
experiments. The nucleoside analog fluorouracil (5-FU), a widely used 
chemotherapeutic (Longley et al. 2003), has been shown to inhibit the 3’-5’ 
exonuclease Rrp6p of the nuclear exosome (Fang et al. 2004; Kammler et al. 
2008), although the exact mechanism of inhibition is unknown. As expected, 
treatment with 100 µM 5-FU while inducing the CUP1-Reporter resulted in a 
green-shift, compared to a DMSO only control (Figure 2.7C), and mimicked the 
deletion of RRP6 (Figure 2.4H). Additionally, I show that overexpression of RRP6 
is able to reverse the effect of 5-FU on reporter expression (Figure 2.7C). 
Together, the mex67-5 and 5-FU data demonstrate the usefulness of the 
inducible CUP1-Reporter in analyzing essential genes and chemical 
perturbations.  
2.3.4 Description of our analysis pipeline 
The nature of our reporter also allows for rapid high-throughput flow 
cytometry analysis, permitting one to acquire data from hundreds of unique 
strains or conditions within a matter of hours, while collecting tens of thousands 
of data points (events or cells) for each sample. With the significant amount of 
data our reporter system generates, we sought out ways to compare reporter 
expression in many different samples in an unbiased manner. Since this type of 
analysis platform was lacking for flow cytometry data, we developed a statistical 
workflow that vectorizes the data, describing the phenograph shape by reporting 
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the distribution of fluorescent events in the two-dimensional phenographs. These 
vectorized data are then compared to each other using a standard hierarchal 
clustering algorithm.  We named our analysis pipeline “CHUBACA” (Comparative 
Hierarchy Using Binning And Clustering Analysis).  
A graphical representation of CHUBACA is shown in Figure 2.9. To begin, 
we used FlowJo to process FCS files. Scale values for GFP and mCherry 
fluorescence for all events were exported into a text file, resulting in an individual 
file for each sample containing a column for each value and a row for each event. 
These files were then processed within SAS using our script to bin the events 
based on their position within the 2D plot (demonstration of binning order and 
pattern is shown in Figure 2.10). To adjust the scale of each axis, the minimum 
and maximum values can be independently adjusted according to the needs of 
the user. Additionally, the resolution of each axis can be tuned by adjusting the 
number of evenly spaced bins. We found that empirical determination with 
technical and/or biological replicates is essential for determining the appropriate 
resolution (bin number). The binning results for all samples were exported as a 
single, tab-delimited text file. The first row and column of the resulting file 
contained the bin number and sample names respectively. Each row contains the 
number of events contained within each of the bins. The data were then 
clustered hierarchically (using Cluster) to create the CDT and GTR files from 
which Java TreeView generates the dendrogram files.  
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Figure 2.9: Graphical representation of the CHUBACA analysis pipeline. 
Briefly, standard FCS files are processed in FlowJo and scale values for two 
parameters are exported into a text file (TXT). Individual files for each sample are 
imported into SAS, binned, and a single TXT file is created describing the 
number of evens in each bin for all samples. These data are then hierarchically 
clustered and analyzed/viewed using Cluster and Java TreeView. Further details 
are described in the Materials and Methods and Section 2.2.5. 
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Figure 2.10: Description of binning and clustering process. 
Flow cytometry data (A) is exported from FlowJo and imported into SAS. An 
algorithm then sorts the individual cells within the phenograph into n x n bins (B) 
and reports the number of cells in each bins. The bins are ordered starting from 
the origin (see arrows) and up the y-axis. It shifts rightward to the next column, 
goes up again etc., ending with the top right bin. These data are then exported as 
a TXT file, imported into Cluster for hierarchical clustering. The occupancy 
patterns are shown for our fluorescence controls (C) to demonstrate the binning 
pattern. 
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2.3.5 Demonstration of bin density importance in CHUBACA 
As stated earlier, CHUBACA allows for fine-tuning of axis (parameter) 
settings to allow for a wide range of values as well as an adjustment of 
resolution. To demonstrate the utility of optimizing the number of bins in the 
analysis, I used data from dozens of deletion mutants containing our gene 
expression reporter. This dataset contained 68 samples, including a number of 
biological replicates and controls. 20,000 events were binned for each sample 
and the results were hierarchically clustered. In Figure 2.11A, I demonstrate the 
effect of iteratively increasing the number of bins applied to the 2D plot, resulting 
in 100, 400, 1600, or 6400 bins (10, 20, 40 or 80 bins per axis). When observing 
the clustering pattern, one can appreciate the influence of bin number on the 
resulting analysis by first comparing the clustering behavior of the fluorescence 
controls. For instance when I binned with a 10x10 grid, the mCherry-only controls 
cluster in a clade separate from nonfluorescent cells and wild-type samples with 
the reporter (Figure 2.11A, 1st panel). When I increased the bins to 20x20 (Figure 
2.11A, 2nd panel), the mCherry samples join the nonfluorescent and wild-type 
samples and then cluster separately when further increased to 40x40 and 80x80 
bins (Figures 2.11A, 3rd and 4th panels, respectively). With increasing bin number 
I also observed deeper and more distinctive clades. This may be expected as 
when the same data are separated into an increasing number of bins, the 
resulting data become more distinct between samples, essentially increasing the 
resolution of the analysis. Consistent with this trend is the decreasing correlation 
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coefficient within a specific clade. For example the correlation between the 6 
nonfluorescent controls is 0.877 with 100 bins, decreasing to 0.719 with 6400 
bins.  
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Figure 2.11: Fine-tuning and optimization of the binning algorithm. 
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(Figure 2.11 continued) 
 
Dendrograms for the analysis of 68 yeast samples are shown (A). A legend for 
annotated controls is shown at the top and nodes/branches for the 
aforementioned groups are colored respectively. Below each dendrogram are the 
vectorized data indicating the degree of bin occupancy (yellow, occupied; blue, 
unoccupied). Bin number densities are indicated below each dendrogram and bin 
occupancy map. (B) Expanded, full annotation of the optimal 40x40 bin density 
dendrogram. The same colors used in (A) are used to highlight control samples. 
Bolded sample names are represented in (C). (C) Representative flow cytometry 
data from the indicated samples are shown in pseudocolor. 8K events are 
shown. 
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It is critical to note the importance of incorporating out-groups and 
biological replicates to empirically determine the optimal settings when binning 
data from a given dataset or experimental system. When identifying the axis 
range, I limited the range as much as possible within the data being generated 
from our system to provide the analysis adequate separation between events. In 
terms of bin number I monitored the clustering behavior of biological replicates 
and genetic or chemical perturbations that result in similar effects. For instance, I 
find that using 40 bins on each axis (Figure 2.11B) is ideal for our reporter assay 
since the non-wild-type sample sap30Δ clustered with wild-type samples when 
we increase the bin number beyond this point (Figure 2.11A, 4th panel). Another 
example is that of the biological replicates of lea1Δ which clustered together in 
Figure 2.11B and are separated and include related but not identical mutants 
when the resolution is increased beyond 1600 bins. A number of representative 
2D phenographs from the minimized dataset are shown in Figure 2.11C. 
2.3.6 Multi-parametric analysis in a comparison of T cell activation 
Experiments utilizing flow cytometry often examine multiple parameters 
simultaneously. To demonstrate that our analysis pipeline is amenable to typical 
flow cytometry samples such as those derived from human blood cells, I 
analyzed a publically available dataset (see Materials and Methods Section 
2.2.4). The 36 samples analyzed involve the titration and optimization of ligands 
leading to human T-cell activation. Over a 10-minute time course, the 
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researchers queried two different anti-CD3 antibodies (clone OKT3 or UCHT1) at 
high or low concentration in the presence or absence of anti-CD28 antibodies 
(see Materials and Methods Section 2.2.4 for further detail Landrigan et al. 
2011). Within this time course, a transient peak in both phosphorylated 
SLP76/S6 (pSLP76) and phosphorylated CD247/TCRζ (pCD247) is evident at 
the 3-minute time point. After this time point levels decrease, reaching near 
baseline levels by 10 or 20 minutes, agreeing with previous studies showing 
similar SLP76 phosphorylation kinetics in Jurkat cells (Houtman et al. 2005). In 
my analysis, I binned the data for multiple 2D comparisons beyond the primary 
parameters of interest (which were phosphorylated SLP76/S6 (pSLP76) and 
phosphorylated CD247/TCRζ (pCD247)). In addition to the pSLP76/pCD247 
comparison, I also binned the naïve CD45+ T cells by FSC/SSC and 
CD45RA/CD45RO, which were used to gate living and naïve cells respectively. 
Since there was inevitably less variability among the parameters that were used 
in gating, I expected much less distinction between samples when looking at 
these comparisons.  
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Figure 2.12: Multiparameter binning and clustering analysis of a T cell 
stimulation dataset. 
Binned, six-parameter flow cytometry data from 36 samples of naïve T cells 
(gated by FSC-A/SSC-A, FSC-A/FSC-H, and CD45RA/CD45RO for live, single, 
naïve cells respectively) (nodes/rows) were combined and clustered 
hierarchically (A). The three blue/yellow bin arrays were offset for easier 
visualization and depict occupied (yellow) and unoccupied (blue) bins within the 
2D plots labeled above (bins which were empty in all samples were removed 
from the analysis). Samples are labeled to the right with the type of CD3 antibody 
(U, UCHT1; O, OKT3); absence (-) or presence (+) of 10 µg/mL CD28 antibody; 
low (0.3 µg/mL, L) or high (0.8 µg/mL, H) concentration of CD3 antibody; 
stimulation duration in minutes; and a reference number if visualized in panel B. 
Samples labeled in grey are unstimulated vehicle-only controls. Eight thousand 
events from samples labeled with a number in the “Visual.” column of panel A are 
shown in pseudocolor (B), reflecting phosphorylation levels of SLP76 and CD247 
on the x- and y-axis respectively. Internal labels correlate with the visualized 
sample number and treatment conditions. 
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Operationally, each of the three binning analyses was performed in series 
and individual results were combined prior to clustering, ensuring that all 6 
parameters were utilized in the comparison. In Figure 2.12 I illustrate the results 
of the six-dimensional binning and clustering analysis of naïve T-cells using 1600 
bins per analysis. Samples are labeled to the right of the dendrogram and 10 
specific samples are labeled arbitrary (Samples 1-10) in the far right column to 
aid in discussion. The 36 samples separated into two main groups, the top group 
possessing higher levels of pSLP76 and pCD247 and the lower group 
possessing lower levels. When examining the binning patterns, it is clear that 
there is much more variation within the pSLP76/pCD247 plot (right) compared to 
FSC/SSC and CD45RA/CD45RO (left and middle), agreeing with our earlier 
prediction. Twelve unstimulated controls cluster very tightly together near the 
bottom of the panel. In agreement with their time-course data (Landrigan et al. 
2011), we observe many of the shorter (3 minutes) stimulation time points, at 
which time pSLP76 and pCD247 levels peak, cluster together at the top of the 
dendrogram.  
To illustrate how the flow cytometry data appear, I display pSLP76 and 
pCD247 levels for 10 of the 36 samples in Figure 2.12B. When looking at 
samples with high pSLP76 and pCD247 levels, I noticed the shorter time points 
resulted in more significant shifts from the unstimulated state (top of Figure 
2.12B). This is not only seen in the pSLP76/pCD247 plots, but also in the binning 
pattern shown in Figure 2.12A. More bin occupancy is seen towards the right, 
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relating to the top-right section of the plots, compared to the other samples. 
Additionally, the presence of anti-CD28 does not significantly affect the levels of 
pSLP76 and pCD247, which also agrees with the published analysis (Landrigan 
et al. 2011). I also observed that the higher concentration of anti-CD3 typically 
resulted in slightly higher levels of pSLP76 and pCD247, which is likely why the 
authors chose to use a higher concentration in their subsequent work. 
2.3.7 Reporter is amenable to high-throughput analysis 
The flow cytometry datasets analyzed thus far did not take full advantage 
of the scalability of our analysis pipeline, CHUBACA. To demonstrate the high-
throughput nature and reproducibility of our reporter and analysis pipeline, as 
well as to query all nonessential yeast genes for their role(s) in gene expression, 
I completed a high-throughput screen of 5103 viable strains in the yeast haploid 
deletion collection (Winzeler et al. 1999). Individual transformants were obtained 
for 5020 strains (98%), and were individually analyzed by high-throughput flow 
cytometry. Data conforming to our criteria were obtained for 4967 mutants (97% 
of viable strains, 99% of transformed strains). To first assay the reproducibility of 
our assay across the multiple days this experiment took place, we observed the 
clustering behavior of data from biological replicates assayed on different days. 
In Figure 2.13A I show the clustering behavior of the deletion collection data with 
the biological replicates added. Figures 2.13B and 2.13C enlarge areas of 
interest and reveal the tight clustering of fluorescent controls, as well as 
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previously described gene expression mutants such as sac3∆, lea1∆, and 
bud13∆. The replicates clustered very tightly together and near genes of similar 
function within this large dataset, further demonstrating the reproducibility and 
robustness of our assay. 
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Figure 2.13: Robustness and reproducibility of the reporter assay demonstrated 
with the deletion collection screen data. 
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(Figure 2.13 continued) 
 
Phenograph data for fluorescent controls and replicates of telltale deletion 
mutants were incorporated into the deletion collection dataset and clustered (A). 
The control data were taken from random days of large-scale analysis and serve 
as day-to-day controls to monitor experimental reproducibility. Phenograph data 
for the deletion mutants and control samples were binned and clustered using 
complete linkage and an uncentered correlation similarity metric and the 
complete dendrogram is shown. Clusters of interest were enlarged and the 
binning pattern for several mutants is shown (B). The bottom panel (mCherry and 
GFP) clearly demonstrates the relationship between phenograph and binning 
pattern. Bins are ordered from the origin to the top right, increasing in y value till 
the top, then shifting to the next x bin, etc. (explained visual in Figure 2.10). Dash 
numbers represent biological duplicates of controls sampled on different days 
and are shown in the enlargements (C). Nodes without a dash are the yeast 
strains that were analyzed within the original screen. Nodes are color-coded by 
function or sample indicated in the legend. 
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2.3.8 Clustering behavior of the haploid deletion collection 
Since most of the strains in the deletion collection are not related to gene 
expression, it was reasonable to expect that the vast majority of strains would be 
highly similar to wild-type (Figures 2.1C and 2.3G). I observed that 87% of the 
deletion mutants clustered within a very large clade (Figure 2.14A bottom). The 
limited variation observed between the mutants in this group likely describes 
biological noise or mild indirect effects on gene expression.  
Within a small clade near the top of the dendrogram (Figure 2.14A), a 
group of yeast strains (n=16) was detected that was enriched with mutants 
lacking mRNA export factors (n=9; Figure 2.14B). Note the tight clustering of 
sac3∆ and thp1∆ (Figure 2.14B), which was expected due to their nearly 
indistinguishable phenographs (Figure 2.4A) and their roles in the TREX-2 
complex. Moreover, there were other export factors such as additional TREX-2 
components (sus1∆ and sem1∆), THO complex (thp2∆), nuclear pore 
components (mlp1∆ and nup120∆) and the poly(A) RNA binding factor gbp2∆. 
Also within this clade were mutants lacking genes that influence mRNA decay or 
stability including dhh1∆ (decapping), ccr4∆ (deadenylation) and rrp6∆ (nuclear 
exosome). 
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Figure 2.14: An unbiased comparison of phenographs from the deletion 
collection strains reveals clustering of related genes. 
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(Figure 2.14 continued) 
 
Clustered, vectorized phenograph data for the 4967 deletion collection strains as 
calculated by Cluster (using complete linkage/uncentered correlation) and 
visualized by Java TreeView (A). The 1600 bins (columns) are ordered from the 
origin of the phenograph to the top right of the phenograph and correspond to the 
same bin across all strains analyzed (rows). Yellow shading indicates the level of 
occupancy in the given bin. A number of green-shifted deletion mutations 
represent mRNA export and RNA decay mutants and cluster strongly (B). The 
gene deleted is indicated and functional classes of genes are color-coded 
according to the scale at the bottom. A representative phenograph for a green-
shifted mutant overlaid on a grayscale wild-type is shown. Asterisks indicate 
strains with phenographs in Figure 2.4. Genes in parentheses are partially 
overlapped by the deleted dubious or unverified ORF. A midlevel view (C) of the 
clustering behavior of a large red-shifted clade containing a number of pre-mRNA 
splicing mutants in shown. Clusters of specific red-shifted gene expression 
deletion mutants (D-H) are shown. Branch lengths are kept to scale in elements 
to demonstrate levels of similarity within and between clades. For reference, 
asterisks indicate strains with phenographs in Figures 2.3 and 2.4. 
 
  
 67 
Next, I investigated the clustering behavior of pre-mRNA splicing mutants 
and other red-shifted mutants within the larger red-shifted clade (n=85; Figure 
2.14C). The smaller groups within this clade are each enriched with factors within 
certain gene expression processes such as pre-mRNA splicing, transcription, 
chromatin remodeling, histone modification and NMD (Figures 2.14D-H). The 
pre-mRNA splicing mutants clustered into two slightly offset clades within this 
group (Figures 2.14D and 2.14G). This suggests that our reporter is differentially 
sensitive to pre-mRNA splicing mutations and quantitatively illustrates the 
difference in the phenographs we reported in Figures 2.3A and 2.3B. 
Within this red-shifted group, there was enrichment of chromatin 
remodeling and mRNA transcription mutants (Figures 2.14B, 2.14E, 2.14F). 
Adding to the confidence that the clustering of the reporter data correlates with 
functionally related genes, the chromatin remodeling mutants in this clade 
contain components of the SWR1 complex (swc3∆ and arp6∆) and also the 
H2AZ histone variant (HTZ1) on which it operates (Mizuguchi et al. 2004). 
Similarly, the mRNA transcription clade contained deletions of constituents of the 
mediator complex (cse2∆, srb5∆, soh1∆ and srb2∆; (Guglielmi et al. 2004)). The 
most tightly clustering group within this red-shifted clade contained the NMD 
mutants (Figure 2.14H), which was expected due to their distinct phenograph 
shape (Figures 2.3C). The remarkable degree to which the transcription, histone 
modification, and chromatin remodeling mutants cluster among pre-mRNA 
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splicing mutants (Figure 2.14C) is not surprising, given that most introns are 
believe to be removed cotranscriptionally (Brugiolo et al. 2013).  
2.4 DISCUSSION  
When compared to existing yeast pre-mRNA splicing reporters for budding 
yeast, the reporter described here expresses well from a low-copy vector, is able 
to simultaneously measure both pre-mRNA and mRNA levels, and is amenable 
to rapid, sensitive gene expression analysis in single cells via flow cytometry 
without the need to prepare extracts from cells. It is important to note that the 
red- and green-shifts are not only due to changes in splicing efficiency, per se, 
but can also be a result of the localization and relative stability of either the pre-
mRNA or mRNA, as exemplified by mRNA export mutants (Figures 2.4A-C and 
2.7C) and mRNA degradation and stability mutants (Figures 2.3C and 2.4F-H). 
Please refer to Illustration 2.1 for visual representation of the gene expression 
processes that influence our reporter’s behavior and their effects. The use of flow 
cytometry to analyze reporter expression also permits simultaneous observation 
of cell volume and complexity using the forward and side scatter measurements, 
respectively. These features enable us to assay the noise in eukaryotic gene 
expression among a population of cells in a unique way (Tang et al. 2011; Waks 
and Silver 2010), as well as simultaneously examining effects on yeast 
morphology with forward and side scatter values. 
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Illustration 2.1: Demonstration of gene expression reporter using a yeast “mood 
ring” model 
The gene expression processes that our gene expression reporter is sensitive to 
are labeled within the cartoon yeast cell. The processes are then labeled on the 
colored “mood ring” to demonstrate the resulting color on a red-to-green 
spectrum. Wild-type cells would be in the yellow area. This visualization was 
made possible thanks to the creativity and skill of Mariana Grenadier, Computer 
Illustrator at the College of Natural Sciences. 
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In the design of our reporter, one goal was to maximize its utility compared 
to previously described gene expression reporter. Since our readout was single-
cell in nature, we also desired to use a stable low-copy centromeric plasmid to 
potentially limit the amount of cell-to-cell variability due to copy number variation, 
as well as to express our reporter at more natural levels. The single-cell aspect of 
our reporter also permits the investigator to use our reporter and fluorescence 
activated cell sorting to identify clones of interest in a rapid and unbiased manner 
when used in conjunction with conventional genetic screens. This assay should 
be feasible and cost effective for researchers at research institutions that have 
access to core facilities with flow cytometry capabilities. Additionally, with the 
advent of many small-footprint tabletop flow cytometers, it is also within reach for 
many investigators to complete the flow cytometry analysis within their own 
laboratory. Also, by avoiding the use of endogenous reporter genes, and by 
cloning the reporter into plasmids with various auxotrophic and dominant 
selection markers, we have virtually eliminated genotypic restrictions. Moreover, I 
expanded the application of our reporter by developing the copper-inducible 
CUP1-reporter, and demonstrated its usefulness with conditional mutants of 
essential genes (mex67-5), as well as with treatment of 5-FU. During 
development of the CUP1-reporter, we also examined reporter expression in the 
same mutants as in Figures 2.3 and 2.4 and compared expression to the TDH3-
driven reporter saw patterns and shifts of similar magnitude (data not shown). 
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In our survey of nearly 5000 knockout strains, our novel gene expression 
reporter proved to be highly sensitive and specific for numerous gene 
expression-related processes. This dataset, as well as binned data for the 
biological replicates and controls in Figure 2.13, are available with our published 
work (Sorenson and Stevens 2014). This will allow the community to perform 
similar analyses in additional strains or under difference conditions and directly 
compare their data to learn more about their genes or alleles of interest. 
Additionally, researchers can reanalyze these data and look for their gene of 
interest to identify knockout mutants with similar effects on reporter expression, 
as well as refer to a list of red- and green-shifted mutants (Appendix II). Our 
ability to directly compare the expression of the reporter between strains by 
means of the vectorized phenograph, and the fact that genes participating in 
related functions behave similarly by these analyses makes this a useful tool for 
future studies. Within our clustering analyses of the deletion collection, we 
noticed that mutations predicted to lead to a completely defective, non-essential 
pathway (e.g. NMD) cluster tightly with each other. This is in contrast to 
mutations of components of essential machineries (e.g. pre-mRNA splicing), 
which cluster less-tightly and result in decreased efficiency, but not a complete 
loss. Lastly, we observed that mutants containing deletions of dubious or 
unverified ORFs regularly clustered near deletions of verified ORFs with which 
they overlapped, such as ynl140c∆ and tho2∆, ydl094c∆ and pmt5∆, and 
ydr290w∆ and rtt103∆ respectively.  
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I also demonstrated that our reporter assay was robust and reproducible. 
When I included reporter data from biological replicates of wild-type cells into the 
deletion collection data, we observe that they cluster with deletion mutants 
unrelated to gene expression (cf. Figures 2.2C and 2.3G) that have wild-type-like 
phenographs. The reproducible behavior of mutants with a more distinct 
phenograph (Figure 2.13) demonstrates the robustness of our assay and 
analysis pipeline.  
A very powerful aspect of our reporter is that it is sensitive, yet uniquely 
specific, to defects in many different gene expression events, including the 
processes involved in both biogenesis of mRNAs as well as their degradation. 
This allows for a researcher to simultaneously assay the effects of a wide variety 
of stimuli on many processes. We have found that our analysis pipeline using our 
binning and clustering technique, as well as our telltale phenograph patterns 
(Figures 2.3 and 2.4), quickly identifies potential pathways to explore further with 
orthogonal assays, such as the RT-qPCR we present in Figure 2.2B. 
Additionally, multiplexing of reporters can also be a way to screen for effects on 
multiple reporters simultaneously (Chen et al. 2012; Kulak and Lum 2013), as 
long as their signals do not overlap or disturb each other. But as with all other 
reporter technologies, it is still critical to ascertain the effect on the original or 
endogenous targets. 
Compared to traditional microscopy, which is prone to subjective biases, 
flow cytometry is relatively automated and can provide quantitative, 
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multiparameter output for thousands to millions of cells per sample. Thus flow 
cytometry has become a trusted platform in biomedical research and in clinical 
settings. There is an increasing need for analyses that can identify specific cell 
populations within a complex sample and identify differences and similarities 
between samples across multiple parameters. Although there are many robust 
and sensitive platforms that identify specific populations of interest within a 
sample, our platform, CHUBACA, compares overall populations across any 
number of parameters by comparing the shape of one or more 2D plots. We 
demonstrated that CHUBACA not only works for our two-color yeast reporter 
system (Sorenson and Stevens 2014), but that it is appropriate for conventional 
flow cytometry data of primary samples.  
We have found that in the wide range of analyses performed, the binning 
settings work well between experiments once empirically determined for a 
specific experimental system. Additionally, if flow cytometry settings are carefully 
calibrated between experiments, the data from separate experiments can be 
meaningfully compared. As discussed above when describing the effect of 
changing the binning parameters (Figure 2.11), we noted that the correlation 
coefficient of specific sample groups decreases as the number of bins is 
increased. Although this might seem counterintuitive, when considering the 
signal-to-noise ratio between samples, variability becomes amplified as the 
number of bins increases.   
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When compared to the CHUBACA pipeline, clustering the T cell dataset 
presented in Figure 2.12 using the mean value of each of the 6 parameters the 
results are subtly, but meaningfully different. In particular, Sample 4 in Figure 
2.12, which previously clustered with similarly treated samples, clustered by itself 
when the mean was used instead of the vectorized flow data (Figure 2.15). We 
believe this is due to the increased cell-to-cell heterogeneity within that sample; 
information of this sort is lost when considering only the mean values. 
Additionally, samples which had returned to baseline levels (bottom three 
samples in Figure 2.12A) clustered less coherently and was interspersed with 
other samples but not with the unstimulated controls as expected (cf. blue 
samples in Figure 2.15A vs. 2.15B). We believe this change is due to the small 
increase in the mean pSLP76 levels when compared to the unstimulated 
controls. As described earlier, when mean or median values on whole 
populations of cells are used to compare samples (Irish et al. 2004), much of the 
valuable information on individual cells generated by flow cytometry is lost. By 
considering and utilizing the granularity inherent to the single-cell resolution of 
flow cytometry data, CHUBACA captures and retains these data for multiple 
populations and takes cell heterogeneity into account. This is in contrast to mean 
and median analyses in which the granularity is lost. As with any experiment, it is 
very important to identify the specific question to be answered when choosing an 
analysis method to ensure the end result reflects an unbiased analysis of the 
experimental system and goal. 
 75 
 
Figure 2.15: Clustering T cell data based on binning versus mean values. 
(A) Clustering of binned data from Figure 2.12 (to be used as a reference). The 
only difference is that additional color-coding was used for specific samples for 
comparison with panel B (as discussed in main text). See Figure 2.12 legend for 
a description of the columns. (B) Dendrogram reflecting the relatedness of the 36 
T cell samples using the mean values of each of the 6 parameters compared in 
panel A. Mean values were calculated using FlowJo and represent the same 
events that were binned in panel A. The red colored sample, Sample 4 (O + H 
10), and the blue colored samples have different clustering behavior depending 
on the methods used for comparison.  
O - L 3 
O + L 3 1 
O - H 3 
O + H 3 
O - L 6 2 
O + L 6 
O - H 6 
O + H 6 
U - H 3 
U + H 3 3 
O - L 10 
O - H 10 
O + H 10 4 
U + H 6 
U - L 3 
U + L 3 5 
O + L 10 
U - H 6 
U + L 6 
U + H 10 6 
U + L 10 
O - L 3 
O - H 3 7 
O - L 6 
O - H 6 
O - L 10 
O - H 10 8 
U - L 3 
U - H 3 
U - L 6 
U - H 6 9 
U - L 10 
U - H 10 
U - L 6 
U - L 10 
U - H 10 10 
O - L 10 
O - H 10 8 
U - L 3 
U - H 3 
O - L 3 
O - H 3 7 
U - L 6 
U - H 6 9 
O - L 6 
O - H 6 
U - L 10 
U - H 10 
O + H 10 4 
O - L 3 
O + L 3 1 
O - H 3 
O + H 3 
O + H 6 
O - L 6 2 
O + L 6 
U - H 3 
O - H 6 
U + H 3 3 
O + L 10 
O - H 10 
U + L 3 5 
U - H 10 10 
U + H 10 6 
O - L 10 
U - L 3 
U - H 6 
U - L 6 
U - L 10 
U + H 6 
U + L 6 
U + L 10 
Clustering of Binning 
Results 
Clustering of Mean 
Values 
B. A. 
 76 
One limitation we have encountered is working with an odd number of 
parameters, since the binning step requires two variables. We have overcome 
this by simply binning the variable of interest (on the y-axis) with any other 
parameter (on the x-axis), then collapsing the rows by determining the sum within 
the respective row (Illustration 2.2). This retains important elements of the single-
cell nature of the data and the resulting data can be added to binning results of 
other parameters, as in Figure 2.12. Another limitation we foresee is comparing 
data from different cytometers. If systems are calibrated well, direct comparisons 
can be made if the proper controls cluster with each other from both platforms. If 
not, a transform can be applied to the scale values to resolve differences 
between flow cytometers.  
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Illustration 2.2: Binning and processing of an additional (odd) parameter 
A cartoon two-dimensional plot is shown on the left. A parameter of interest 
(which will be queried) is plotted on the y-axis and an additional parameter is 
plotted on the x-axis, in order to employ the binning algorithm. Events are binned 
as described in the Materials and Methods Section 2.2.5. The middle panel 
shows the binning results of the panel on the left. To eliminate the “other 
parameter” and only query the parameter of interest, the total number of events 
in each row is determined by taking the sum of all bins within a row. The resulting 
data can then be added to the binning results of the other two-dimensional plots. 
This process can be automated using a simple script. 
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Moreover, we can imagine our analysis pipeline being adapted and used 
to compare other experiments or data that result from multi-variable input, adding 
to the inherent utility of our system. We trust that CHUBACA will serve as a new 
analytical tool to explore high content and/or high-throughput flow cytometry data 
by establishing the relationship of samples based on the similarity of multiple 
parameters. In contrast to manual analysis of multiple flow cytometry plots, 
typically performed using 2D-overlays, CHUBACA is semi-automated, 
decreasing both subject bias and time spent. The visual nature of the analysis 
and resulting dendrograms are intuitive, quantitative and can be applied to a wide 
range of experiments. Our analysis pipeline has been used to survey thousands 
of genetic and chemical perturbations in diverse datasets and has the capability 
to generate exciting new discoveries with existing and new flow cytometry data.  
Although researchers have scoured the yeast genome for decades, it is 
often with the advent of new technologies and techniques that new 
breakthroughs occur. Here, I have described the design, validation, and broad 
utility of our novel gene expression reporter (Sorenson and Stevens 2014). The 
reporter not only improves upon previous pre-mRNA splicing reporters in terms 
of speed, sensitivity, and genetic limitations, but it also is sensitive and specific to 
many other gene expression events. Our analysis pipeline, CHUBACA, coupled 
with high-throughput flow cytometry allows for rapid, unbiased evaluation of 
thousands of mutations or conditions. Using our gene expression reporter with 
standard genetic screening approaches, in series with fluorescence activated cell 
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sorting allows researchers to explore gene expression processes, and 
connections within and between them, with increased speed and sensitivity. The 
broad utility and uniqueness of our reporter make the budding yeast genome, 
which is often described as barren due to deep cultivation for years, ripe again 
for identifying novel factors and interactions involved in gene expression. 
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Chapter 3: Discovery of small molecule modulators of gene 
expression  
3.1 BACKGROUND 
3.1.1 Introduction to drug discovery 
Humans have continually been searching for compounds or substances 
that have the ability to eliminate or alleviate medical symptoms resulting from 
trauma or an underlying illness (Drews 2000; Sundberg 2000; Pina et al. 2009; 
Jones 2011). Centuries ago those involved in these searches relied on traditional 
remedies using natural products that displayed efficacy. Moving forward, early 
scientific researchers sought to identify the active ingredients of these traditional 
remedies using crude biochemical techniques. Once an active compound was 
identified, a common approach is to employ synthetic chemistry to develop 
derivatives of the compound to optimize the efficacy of the drug. Decades of 
identifying and generating natural and synthetic small molecules and related 
derivatives have led to vast chemical databases and libraries, serving as an ideal 
starting point for most drug discovery efforts. Screening these libraries in a high-
throughput manner has been a staple of biomedical and pharmaceutical research 
(Macarron et al. 2011). 
Since the sequencing of the human genome (Lander et al. 2001) and the 
advent of modern cloning and biochemical techniques, the common approach to 
drug discovery at the laboratory bench has been reverse pharmacology. This 
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process involves the high-throughput screening of large libraries of compounds 
against a purified protein in an in vitro reaction to identify inhibitors or modulators 
of the target protein. It is important to note that compounds that can do so by 
means other than enzymatic inhibition, such as inhibiting the interaction of a 
molecule with another, or modulating the localization or stability of that protein. 
The aforementioned protein-based assays typically utilize colorimetric, 
fluorometric, chemiluminescent, light scattering, or any other number or 
combination of methodologies that result in a measurable signal. 
Although the standard drug discovery pipeline is a tried and true process, 
it is very expensive and often takes 10 or more years from initial screens to FDA 
approval, and can cost as much as $5 billion dollars (DiMasi et al. 2003; Morgan 
et al. 2011). Large pharmaceutical companies are often abandoning drug 
screening efforts and either outsourcing the work to academic or research 
facilities or acquiring promising drug candidates through licensing or acquisitions. 
These trends, along with heavy competition and intellectual property issues have 
partially led to a trend of increasing development of orphan drugs (Sharma et al. 
2010), which treat rare medical conditions. There are also specific sources of 
federal and private funding as well that help fuel advancement in this area. 
3.1.2 Cell-based drug discovery assays 
In comparison with the relatively simple approach using specific purified 
protein(s) in a biochemical assay, one can also use a cell-based approach to 
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identify candidate drugs with high-throughput screening. Although this can 
drastically complicate the screening process in terms of cell growth, 
contamination, etc., it is most often considered to be advantageous because the 
assay is completed in the context of a cell, in which a drug would most likely 
need to be stable, active, and nontoxic. An advantage of cell-based assays is the 
target is much more likely to be in its native form, conformation, or complex; in 
contrast to a purified system in which the target might adopt a non-natural shape 
or conformation. Although cell-based assays have their benefits, as discussed, 
there is still a high rate of candidate drug failure downstream in the pipeline. The 
balance of advantages and challenges of such systems in drug discovery are 
beyond the scope of this work and have been reviewed by others (Astashkina et 
al. 2012).  
Instead of being restrained to the previously mentioned signals of a 
biochemical assay, researchers can gauge cell viability or any type of 
measurable cellular response when screening compounds. For example, a 
common approach in early chemotherapeutic discovery is screening chemical 
libraries against diseased and normal cells, looking for specific effects or toxicity 
in the diseased cells. A wide range of human cell lines have been commonly 
used, with embryonic and induced pluripotent stem cells becoming more routine 
for certain disease models with increasing feasibility (Sartipy et al. 2007; Crook 
and Kobayashi 2008; Jensen et al. 2009; Phillips and Crook 2010; Inoue et al. 
2014; Engle and Vincent 2014). Cell types can be specifically chosen depending 
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on the potential target or disease studied. Additionally, panels of different types 
of human cells are often used to gauge toxicity and specificity in subsequent 
screening. One specific challenge to cell-based assays is target identification, 
which is of critical importance since the measured phenotype or response is 
assayed in the context of biological system (Schenone et al. 2013). There are 
many methods for identifying drug targets, from standard affinity/biochemical 
techniques to next generation RNA sequencing (Ong et al. 2009; Rix and 
Superti-Furga 2009; Ong et al. 2012; Wacker et al. 2012). 
3.1.3 Cyclic peptides as therapeutic compounds 
A separate class of bioactive small molecules is cyclic peptides. Cyclic 
peptides are natural-product-like in structure, offering a very attractive chemical 
space for discovering small molecules that interact with intracellular and 
extracellular biological targets (Driggers et al. 2008; Thorstholm and Craik 2012; 
Joo 2012; Bockus et al. 2013). Many natural cyclic peptides are not synthesized 
ribosomally and rely on large multienzyme complexes that function as an 
assembly line (Sieber and Marahiel 2003). In terms of biological production of 
cyclic peptides in the laboratory, there are many different biochemical 
approaches available (Aboye and Camarero 2012). Examples include using 
proteases (Marx et al. 2003; Thongyoo et al. 2008), inteins (Tavassoli and 
Benkovic 2007), thioester-based ligation using modified inteins (Kimura et al. 
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2006; Austin et al. 2009, 2010) or genetic program recoding (Kawakami et al. 
2009).  
One specific system used to generate head-to-tail cyclic peptides in vivo is 
SICLOPPS, which stands for Split-Intein-mediated Circular Ligation Of Proteins 
and PeptideS (Scott et al. 1999; Horswill et al. 2004; Horswill and Benkovic 2005; 
Kritzer et al. 2009). The genetic construct that generates these peptides uses a 
split intein approach that allows a variable linker region to be spliced out as a 
cyclic peptide. The variable linker region can code for a desired stretch of amino 
acids with a length of anything greater than 4 amino acids. The power of this 
specialized chemical genetics system first comes from the ability to generate a 
library of plasmids (and in turn cyclic peptides) by randomizing the linker region, 
creating libraries that can be screened to identify cyclic peptides of interest 
(Horswill and Benkovic 2005). Once a clone is identified and verified, structure-
activity relationships can be queried by simply employing site-directed 
mutagenesis to change the structure of the peptide. Moreover, a candidate cyclic 
peptide can then be synthesized in vitro and used in affinity chromatography to 
identify binding targets. 
Although the SICLOPPS system was originally developed in bacteria, it 
has been successfully adapted to multiple eukaryotic systems. The first scheme 
involved human B cells in which inhibitors of interleukin-4 signaling were 
identified from a relatively small library of 270,000 cyclic peptides (Kinsella et al. 
2002). SICLOPPS was also adapted for use in budding yeast to screen a library 
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of 5 million members to rapidly identify two cyclic peptides that specifically 
reduced the toxicity in a Parkinson’s model (Kritzer et al. 2009). Additionally, 
these two peptides also prevented dopaminergic neuron loss in a Caenorhabditis 
elegans Parkinson’s model. A visual description of the SICLOPPS construct and 
the protein splicing chemistry are shown in Illustration 3.1. 
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Illustration 3.1: Description of the SICLOPPS construct and splicing mechanism 
(A) The SICLOPPS (Split-Intein-mediated Circular Ligation Of Proteins and 
PeptideS) construct is shown. The dnaE self-splicing intein is split into two, and 
the C-terminal half is placed upstream of the cyclic peptide linker which is 
followed by the N-terminal protein of dnaE and a chitin-binding-domain (CBD) tag 
for monitoring expression and processing. The strong and constitutive PGK1 
promoter drives expression of the construct. (B) The primary structure of the 
resulting cyclic peptide precursor is shown, which contains a cysteine followed by 
7 random amino acids (X) for the cyclic peptide linker. (C) The circular ligation 
mechanism chemistry is illustrated. The split-intein first forms a ligase active site 
and catalyzes an N-to-S acyl shift to produce the thioester. Via a 
transesterification, the highlighted sulfur acts as a nucleophile, forming the lariat. 
From there, cyclization with the IC asparagine side-chain frees the cyclic peptide 
as a thiolactone and produces the intein byproduct. Finally, an S-to-N acyl shift 
generates the stable lactam cyclic peptide product. The precursor and intein 
byproduct can be distinguished by western blot via the CBD. Gray side-chains 
are part of intein while and black side-chains makeup part of the cyclic peptide. 
This illustration was adapted from Scott et al. 1999 and aided by personal 
communication with Joshua Kritzer (Tufts).  
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Cyclic peptides have been long used as drugs. In 1909 Sir Henry H. Dale 
discovered and named an unknown substance that contracted the uterus of a 
pregnant cat. It was not till 1953 that the structure of the hormone oxytocin was 
discovered (Du Vigneaud et al. 1953), which is used to induce labor. The fungal 
derived cyclosporine has been used as a immunosuppressant (Kahan 1985). 
Bacitracin, a mixture of cyclic peptides from Bacillus subtilis is used as a 
antibiotic effective against gram positive and gram negative bacteria (Johnson et 
al. 1945). Furthermore Actinomycin D (Waksman and Woodruff 1940), which was 
the first antibiotic that was shown to have anti-cancer activity (Hollstein 1974), 
inhibits transcription by binding DNA. Although these cyclic peptides can be large 
and bulky, they are extremely stable in the digestive tract, making them very 
attractive to designers of protein-based drugs. 
3.1.4 Yeast as a tool for drug discovery 
The budding yeast Saccharomyces cerevisiae has been hailed as a 
powerful tool for drug discovery (Buschini et al. 2003; Simon and Bedalov 2004; 
Auerbach et al. 2005; Barberis et al. 2005; Pereira et al. 2012; St Onge et al. 
2012; Bilsland et al. 2013; Bancos et al. 2013). There is a high degree of 
conservation in terms of genes, cellular machinery, and processes between 
mammalian cells and yeast. Moreover, a large number of human genes have 
orthologs in lower eukaryotes (Venter et al. 2001). Yeast has many properties 
that make it a very attractive tool for drug screening. These features include but 
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are not limited to its short doubling time, inexpensive and simple media 
requirements, and the ease by which it is genetically modifiable and tractable.  
One feature of yeast that can limit its potential in driving the discovery of 
therapeutics or biological tools is that yeast can be relatively insensitive to 
compounds that negatively affect other types of eukaryotic cells. The current 
belief is that this phenomenon is due to the large number of transporters and 
efflux pumps present in yeast (Paul and Moye-Rowley 2014). The most common 
approach has been to delete genes that code for transcription factors, such as 
PDR1 and PDR3 (Delaveau et al. 1994; Mamnun et al. 2002), that serve to drive 
expression of many ABC transporters (Oldham et al. 2008; Locher 2009). 
Membrane permeability can also be increased by deleting the sterol biogenesis 
gene ERG6 (Gaber et al. 1989), rendering yeast sensitive to a wide range of 
compounds when combined with pdr1Δ and pdr3Δ (Simon and Bedalov 2004). A 
curious finding is that Pdr1p and Pdr3p also regulate the expression of hexose 
transporters, which also can affect pleiotropic drug resistance (Nourani et al. 
1997). One group took a brute force approach and deleted 6 ABC transporters in 
a strain lacking PDR3, resulting in a hypersensitive yeast strain referred to as 
AD12345678 (Decottignies et al. 1998). This idea was taken to another level by 
Fredrick Roth’s lab when they used a creative method of sexual assortment and 
fluorescence selection termed Green Monster (Suzuki et al. 2011). With this 
technology they deleted all 16 ABC transporters, generating an even more 
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sensitive yeast strain (ABC-16) with broad drug-sensitivity, even when compared 
to AD12345678.  
Many approaches have also exploited the expression of human proteins in 
yeast. Of note, 12 of 38 human cDNAs, which are considered potential 
chemotherapeutic targets, inhibited growth when expressed in yeast 
(Tugendreich et al. 2001), providing a means of selection for inhibitors. One 
interesting tool that was developed is a yeast strain expressing the active form of 
platelet-derived growth factor receptor β (PDGFRβ), which results in decreased 
growth rate (Barberis et al. 2005). When these slow growing cells are treated 
with Gleevec (PDGFRβ inhibitor and chemotherapeutic), growth is restored, 
creating a situation in which a positive growth selection can be used in screening. 
Yeast have been successfully used to identify novel human PARP1 inhibitors 
(Perkins et al. 2001), which were shown to improve the efficacy of DNA-
damaging agents used in chemotherapy (Tentori et al. 2003). A multiplexed 
yeast screen utilizing high-throughput flow cytometry identified a novel inhibitor of 
yeast TORC1 (Chen et al. 2012). Combinatorial effects of common drugs can 
also be studied in yeast (Torres et al. 2013). A specific study discovered a 
suppressive interaction between the antilipemic gemfibrozil and the 
antidepressant fluoxetine when looking at effects on cell cycle (Hoose et al. 
2012).  
Yeast has not only been used to identify compounds, but also to identify 
unknown targets of small molecules, the most famous example being mTOR and 
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rapamycin (Heitman et al. 1991). Moreover, in taking advantage of the arsenal of 
genetic tools available for yeast, a field of yeast chemical genomics has 
emerged. Essentially, the yeast deletion collections and/or overexpression 
strains are screened in the presence of compounds to identify positive or 
negative interactions (Giaever et al. 2004; Lum et al. 2004; Parsons et al. 2004; 
Fortney et al. 2013), helping to deconvolute the mechanism(s) of action for the 
given compound. Other tools in yeast that have been used for target identification 
are yeast three-hybrid methods (Griffith et al. 2000; Henthorn et al. 2002), as well 
as microarray techniques in fission yeast (Arita et al. 2011). 
3.1.5 Gene expression machinery as drug targets 
Many processes within gene expression are attractive drug targets for 
diseases such as cancer. Early in gene expression, even before genes are 
transcribed, nucleosome/chromatin remodeling and histone modification have 
been shown to be implicated in metastasis and tumorigenesis (Li et al. 2012a; 
Chernikova et al. 2012). Transcription inhibitors, such as fludarabine and 5-
fluorouracil, are used to treat a wide range of cancers (Mandel 1981; Huang et al. 
2000). Of particular interest is the increasing number of connections between 
pre-mRNA and cancer, which has been extensively reviewed (Faustino and 
Cooper 2003; Srebrow and Kornblihtt 2006; Wang and Cooper 2007; Grosso et 
al. 2008; Cooper et al. 2009; Oltean and Bates 2013). Of note were separate 
groups identifying mutations in SF3B1 in myelodysplasia and leukemia (Yoshida 
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et al. 2011; Papaemmanuil et al. 2011; Rossi et al. 2011; Wang et al. 2011; 
Malcovati et al. 2011). SF3B1 functions in the catalytic core of the spliceosome, 
highlighting its importance in gene expression and avoiding a diseased state. 
More recently, in cases without SF3B1 mutations, PRPF8 (Prp8p in S. 
cerevisiae) mutations conveyed poor patient prognosis and result in a second-
step splicing defect (Kurtovic-Kozaric et al. 2014). Moreover, the RNA-binding 
protein/splicing factor hnRNPA2 is overexpressed in prostate cancer (Stockley et 
al. 2014) and has also been shown to be involved in liver cancer development 
(Shilo et al. 2014). 
Beyond pre-mRNA splicing, other mRNA processing and transport 
processes are also involved in avoiding disease. For example, the 
immunosuppressive drug mizoribine monophosphate blocks the proliferation of B 
and T lymphocytes, apparently by inhibiting the human RNA capping enzyme 
(Picard-Jean et al. 2013). The 5’ cap structure of mRNAs is important for not only 
stability and translation of mRNAs, but also their splicing and export. In terms of 
export, the germinal center-associated protein (GANP), which is an integral part 
of the mammalian mRNA export pathway (Wickramasinghe et al. 2010), is 
associated with transformation of melanocytes (Kageshita et al. 2006) and is 
present in elevated levels in lymphomas (Fujimura et al. 2005). Interestingly, 
researchers have also found that knockdown of GANP can induce selective 
death of p53-deficient cancer cells (Phimsen et al. 2012). Additionally, other 
mRNA export factors, such as CRM1, nucleoporin 88, REF/Aly, and THO are 
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dysregulated in samples from tumors; which have recently been reviewed (Hurt 
and Silver 2008; Siddiqui and Borden 2011).  
The biogenesis of mRNAs is not the only aspect of gene expression that is 
important in disease, as posttranscriptional regulation, mRNA stability, and 
translation are also important to control. One exciting area in cancer research is 
that of microRNAs, which are most often dysregulated in cancer (Iorio and Croce 
2012). Not only are there potential therapeutic targets within this pathway, but 
also there is also great promise in terms of diagnostics. An essential component 
to cellular proliferation is translation. 
3.1.6 Experimental approach and rationale 
We sought to further take advantage of the utility of our gene expression 
reporter, which is sensitive to defects in many gene expression pathways, by 
performing complementary screens to identify small molecules that modulate 
gene expression. Instead of the traditional yeast drug screening approach of 
looking for growth or absence of growth, our assay is much more diverse and 
versatile in terms of the potential phenotypes that can be used to identify small 
molecules of interest. Not only can our approach identify biologically interesting 
modulators of gene expression, but also it can potentially identify novel targets 
for future small molecule therapy approaches.  
This chapter describes the efforts taken to discover novel small molecules 
that inhibit or modulate specific gene expression pathways. The first 
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experimental approach I took was to use the yeast optimized SICLOPPS system 
in conjunction with our reporter (Kritzer et al. 2009). By using fluorescence-
activated cell sorting, I sorted clones that shifted our reporter towards the 
mCherry or GFP axis separately and identified two clones of interest. Alanine 
scans were performed to determine structure-activity relationship. Our red-shifted 
clone, R6_E04, reproducibly shifted reporter expression towards the mCherry 
axis and mimicked a pre-mRNA splicing defect. RT-qPCR analysis identified 
minor gene specific pre-mRNA splicing defects of endogenous introns. Affinity 
chromatography techniques were unsuccessful in determining in vivo binding 
targets, leaving the specific biological activity of this cyclic peptide largely 
unknown. 
The second approach we took was to use our reporter to identify small 
molecules that modulate gene expression. Our copper-inducible reporter was 
used in conjunction with a drug-sensitive yeast strain (Suzuki et al. 2011) to 
perform a pilot screen of a diverse set of small molecules. Out of 3467 initial 
compounds we tested 354 for dose dependency in a secondary screen and 
identified 16 compounds of interest. Most of the 16 compounds were green-
shifted while only two were significantly red-shifted. I discovered that one of the 
red-shifted small molecules, TI3D_0104_B19, gives rise to a reproducible and 
dose dependent pre-mRNA splicing defect. Further experimentation will be 
needed to determine its mechanism of action. This pilot screen validates our 
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high-throughput screening approach and lays the foundation for a more broad 
and extensive screening effort. 
3.2 MATERIALS AND METHODS 
3.2.1 Cyclic peptide plasmid libraries 
The SICLOPPS plasmid libraries were kindly provided by Joshua Kritzer 
(Kritzer et al. 2009). The four libraries that were obtained were based on high 
copy URA3 plasmids (pRS426) with the PGK1 promoter. The libraries differ in 
the size of the linker/cyclic peptide; including 5, 6, 7, or 8 random amino acids 
following a cysteine (named CX5-CX8 and stored as plasmids MS307-310 
respectively). A control cyclic peptide, HPQ (MS306), was also provided which is 
expressed and processed yet has no known phenotypes. The libraries are 
reported to contain between 30 and 50 million unique clones. Libraries and 
plasmids discussed can be found in Table 3.1 
 
Table 3.1 Plasmids used in Chapter 3 
MS # 
 
Common Name 
 
Purpose Source 
169 pRS415 TDH3-Reporter TDH3 driven reporter  This work. 
Plasmids MS 
124 and 125 
163 pRS316-CUP1-Reporter CEN URA3 inducible 
reporter 
This work. 
Plasmids MS 
162 and 127. 
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165 pRS413 CUP1-Reporter CEN HIS3 inducible 
reporter 
This work. 
Plasmids MS 
101 and 163. 
306 pRS426 PGK-HPQ CFTNVHPQFANA 
cyclic peptide, used 
as negative control 
Kritzer lab 
307 pRS426 PGK-CX5 Library Cyclic peptide library 
with 5 random amino 
acids 
Kritzer lab 
308 pRS426 PGK-CX6 Library Cyclic peptide library 
with 6 random amino 
acids 
Kritzer lab 
309 pRS426 PGK-CX7 Library Cyclic peptide library 
with 7 random amino 
acids 
Kritzer lab 
310 pRS426 PGK-CX8 Library Cyclic peptide library 
with 8 random amino 
acids 
Kritzer lab 
302 CX7 G5_C07  Green-shifted clone 
from CX7 screen; 
CWLCFGCA 
Hit from screen, 
this work 
303 CX7 R6_E04 Red-shifted clone 
from CX7 screen; 
CSEVGAGL 
Hit from screen, 
this work 
304 CX7 G5_C07 ii Intein inactivated 
mutant of G5_C07 
This work 
305 CX7 R6_E04 ii Intein inactivated 
mutant of R6_E04 
This work 
100 pRS413 Yeast expression 
plasmid 
(Sikorski and 
Hieter 1989) 
330 CX7 R6_E04 C1A Mut. with MS499/500 
ASEVGAGL 
This work 
331 CX7 R6_E04 C1S Mut. with MS501/502 
SSEVGAGL 
This work 
332 CX7 R6_E04 S2A Mut. with MS503/504 
CAEVGAGL 
This work 
333 CX7 R6_E04 E3A Mut. with MS505/506 
CSAVGAGL 
This work 
334 CX7 R6_E04 V4A Mut. with MS507/508 
CSEAGAGL 
This work 
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335 CX7 R6_E04 G5A Mut. with MS509/510 
CSEVAAGL 
This work 
336 CX7 R6_E04 A6G Mut. with MS511/512 
CSEVGGGL 
This work 
337 CX7 R6_E04 G7A Mut. with MS513/514 
CSEVGAAL 
This work 
338 CX7 R6_E04 L8A Mut. with MS515/516 
CSEVGAGA 
This work 
339 CX7 R6_E04 V4K Mut. with MS523/524 
CSEKGAGL 
This work 
340 CX7 R6_E04 V4K ctrl 1 Mut. with MS527/528 
CSAKGAGL 
This work 
341 CX7 R6_E04 V4K ctrl 3 Mut. with MS529/530 
CSEKGAGA 
This work 
342 CX7 R6_E04 V4K ctrl 2 Mut. with MS539/540 
CSAKGAGA 
This work 
343 CX7 G5_C07 C1A Mut. with MS481/482 
CWLCFGCA 
This work 
344 CX7 G5_C07 C1S Mut. with MS482/483 
SWLCFGCA 
This work 
345 CX7 G5_C07 W2A Mut. with MS484/485 
CALCFGCA 
This work 
346 CX7 G5_C07 L3A Mut. with MS486/487 
CWACFGCA 
This work 
347 CX7 G5_C07 C4A Mut. with MS488/489 
CWLAFGCA 
This work 
348 CX7 G5_C07 F5A Mut. with MS490/491 
CWLCAGCA 
This work 
349 CX7 G5_C07 G6A Mut. with MS492/493 
CWLCFACA 
This work 
350 CX7 G5_C07 C7A Mut. with MS494/495 
CWLCFGAA 
This work 
351 CX7 G5_C07 A8G Mut. with MS496/497 
CWLCFGCG 
This work 
352 CX7 G5_C07 L3K Mut. with MS531/532 
CWKCFGCG 
This work 
353 CX7 G5_C07 C7K Mut. with MS533/534 
CWLCFGKG 
This work 
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3.2.2 Development of yeast cyclic peptide library for reporter screen 
Standard yeast methods were used (Sherman 1991). For cyclic peptide 
screening and analysis, yeast strain BY4742 (SS4050) was transformed with 
pRS415 TDH3-Reporter (MS169). This strain was subsequently transformed with 
the pRS426 PGK1-CX7 SICLOPPS library (MS309), which was kindly provided 
by Joshua Kritzer at Tufts University (Kritzer et al. 2009), and plated on synthetic 
dropout medium lacking leucine and uracil. The construct pRS426 PGK1-HPQ 
(MS317) was also provided and transformed into the same strain to use as a 
negative control and for sorting purposes. The resulting transformants were 
pooled by washing cells off of plates with water. Cells that were not immediately 
analyzed were cryopreserved in 25% glycerol at -80°C. Strains used in Chapter 3 
can be found in Table 3.2 
Table 3.2 Yeast strains used in Chapter 3 
Strain 
(SS) 
Mating 
type 
Genotype 
 
4050 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 (BY4742) 
4127 α 
(adp1∆, aus1∆, bpt1∆, nft1∆, pdr5∆, pdr10∆, pdr11∆, pdr12∆, 
pdr15∆, snq2∆, vmr1∆, ybt1∆, ycf1∆, ynr070w∆, yol075c∆, 
yor1∆); at each loci, tetO2-GFP::URA3 to replace KanMX) 
can1∆::GMToolkit-alpha (CMVpr-rtTA NatMX4 STE3pr-LEU2) 
lyp1∆ his3∆1 leu2∆0 ura3∆0 met15∆0 
4136 α 
(adp1∆, aus1∆, bpt1∆, nft1∆, pdr5∆, pdr10∆, pdr11∆, pdr12∆, 
pdr15∆, snq2∆, vmr1∆, ybt1∆, ycf1∆, ynr070w∆, yol075c∆, 
yor1∆); at each loci, tetO2-GFP::URA3 to replace KanMX) 
can1∆::GMToolkit-alpha (CMVpr-rtTA NatMX4 STE3pr-LEU2) 
lyp1∆ his3∆1 leu2∆0 ura3∆0 met15∆0 + pRS413 CUP1-
Reporter 
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3.2.3 Fluorescence-activated cell sorting for cyclic peptide screen 
To prepare the yeast culture that would generate cells to sort, the pooled 
library was used to inoculate 10 mL of synthetic dropout medium lacking leucine 
and uracil at OD (A600) 0.1. The culture was incubated at 31°C for 7-8 hours. 
Immediately prior to flow cytometry, the cells were harvested by centrifugation 
and resuspended in sterile 1X PBS. For fluorescence-activated cell sorting 
(FACS), the HPQ control (plasmid MS306) was used to determine gating 
boundaries. Two gates were created on the prototypical mCherry versus GFP 
plot (y-axis and x-axis respectively), one to the left of the control population (red-
shifted) and one to the right (green-shifted). Gates were placed in order to sort 
between 0.1 and 0.3% of the total population that was shifted most significantly 
towards the respective axis. 10,000+ cells were sorted from each gate and half 
the cells were plated for single colonies on large format synthetic dropout agar 
plates lacking leucine and uracil, while the other half was cryogenically 
preserved. Individual clones were transferred to flat bottom 96-well plates along 
with the HPQ controls, cultured, and cryogenically preserved.  
3.2.4 Yeast plasmid mini prep 
Plasmids from cyclic peptide clones of interest were isolated using the 
Zymoprep Yeast Plasmid MiniprepII kit (Zymo). Briefly, clones were grown in 
synthetic dropout media lacking uracil to specifically select for the cyclic peptide 
plasmid, not the reporter. The protocol for liquid cultures was followed. The 
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resulting plasmid DNA was transformed into E. coli and miniprepped. After a 
diagnostic digest to make sure the plasmid looked correct, it was sequence 
verified with oligonucleotide MS480 (Table 3.3). 
3.2.5 Western blot analysis 
Protein samples were separated on PAGE gels (Invitrogen) and 
transferred to nitrocellulose. Membranes were blocked with BLOTTO (PBST + 
5% SDS) and then probed with anti-CBP at 1:5000 (NEB, E8034S). Blots were 
then probed with HRP conjugated goat anti-mouse (Rockland, 610-1302). 
Washes were preformed with PBST and visualized using X-ray film using 
chemiluminescence (Perkin Elmer). 
3.2.6 Serial dilutions and spot plating 
Yeast were grown in the appropriate media to log phase. All cultures were 
normalized to OD (A600) 1.0 in sterile ddH2O. In a 96-well plate, five 10-fold 
dilutions were made. 5 µL of the undiluted and 5 dilutions were spotted onto 
appropriate media.  
3.2.7 Site-directed PCR mutagenesis 
For full method refer to Section 2.2.2. Primers for the intein inactivation 
mutant T69A H72A (Ghosh et al. 2001; Kritzer et al. 2009) were MS478 and 
MS479. DNA oligonucleotides used in this Chapter can be found in Table 3.3 
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Table 3.3 DNA oligonucleotides used in Chapter 3 
MS# 
 
Sequence  
(5’ to 3’) 
Purpose 
 
282 CCATTGTCACTCTAGATGTCAAGCC TEF5 total FWD qPCR 
283 GATACCGAAACCAATTGGGATAAAT TEF5 total REV qPCR 
295 TCCAGGAGCGCACCATCTT Reporter total FWD qPCR 
296 TCTGCTTGTCGGCCATGATA Reporter total REV qPCR 
299 NNNNNNNNG NonamerG for RT 
300 NNNNNNNNA NonamerA for RT 
301 NNNNNNNNT NonamerT for RT 
302 NNNNNNNNC NonamerC for RT 
307 ACACCATCGTTGAACAATACGAA Reporter pre-mRNA FWD 
qPCR 
308 TACGACCTTAACCGGCTGTACA Reporter pre-mRNA REV 
qPCR 
313 GATAGCACAGAGCAGAGTATCATTA TEF5intFWDjp qPCR 
314 CTGGAGAATTCTGGGTAAGCAGATT TEF5intREVjp qPCR 
478 GCTCAGTAATCCGAGCTGCCTCTGA
CGCCCGCTTTTTAACC 
T69A H72A intein inactivation 
mutant TOP 
479 GGTTAAAAAGCGGGCGTCAGAGGC
AGCTCGGATTACTGAGC 
T69A H72A intein inactivation 
mutant BTM 
480 GCTGCCACAAGGCAGGAACGTTGG
A 
Sequencing cyclic peptide 
clones 
481 GGGCGATCGCCCACAATGCTTGGC
TGTGCTTC 
CX7_G5_C07 Alanine Scan;  
C0A TOP 
482 GAAGCACAGCCAAGCATTGTGGGC
GATCGCCC 
CX7_G5_C07 Alanine Scan;  
C0A BTM 
483 GGGGCGATCGCCCACAATTCATGG
CTGTGCTT 
CX7_G5_C07 Alanine Scan;  
C0S TOP 
484 AAGCACAGCCATGAATTGTGGGCG
ATCGCCCC 
CX7_G5_C07 Alanine Scan;  
C0S BTM 
485 CGATCGCCCACAATTGTGCTCTGTG
CTTCGGGTGCG 
CX7_G5_C07 Alanine Scan;  
W1A TOP 
486 CGCACCCGAAGCACAGAGCACAAT
TGTGGGCGATCG 
CX7_G5_C07 Alanine Scan;  
W1A BTM 
487 CGCCCACAATTGTTGGGCATGCTTC
GGGTGCGCGT 
CX7_G5_C07 Alanine Scan;  
L2A TOP 
488 ACGCGCACCCGAAGCATGCCCAAC
AATTGTGGGCG 
CX7_G5_C07 Alanine Scan;  
L2A BTM 
489 CCCACAATTGTTGGCTGGCATTCGG
GTGCGCGTGCTT 
CX7_G5_C07 Alanine Scan;  
C3A TOP 
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490 AAGCACGCGCACCCGAATGCCAGC
CAACAATTGTGGG 
CX7_G5_C07 Alanine Scan;  
C3A BTM 
491 CCACAATTGTTGGCTGTGCGCAGG
GTGCGCGTGCTTAAGTT 
CX7_G5_C07 Alanine Scan;  
F4A TOP 
492 AACTTAAGCACGCGCACCCTGCGC
ACAGCCAACAATTGTGG 
CX7_G5_C07 Alanine Scan;  
F4A BTM 
493 AATTGTTGGCTGTGCTTCGCATGCG
CGTGCTTAAGTTTTG 
CX7_G5_C07 Alanine Scan;  
G5A TOP 
494 CAAAACTTAAGCACGCGCATGCGAA
GCACAGCCAACAATT 
CX7_G5_C07 Alanine Scan;  
G5A BTM 
495 GTTGGCTGTGCTTCGGGGCCGCGT
GCTTAAGTTTTG 
CX7_G5_C07 Alanine Scan;  
C6A TOP 
496 CAAAACTTAAGCACGCGGCCCCGA
AGCACAGCCAAC 
CX7_G5_C07 Alanine Scan;  
C6A BTM 
497 GCTGTGCTTCGGGTGCGGTTGCTT
AAGTTTTGGCAC 
CX7_G5_C07 Alanine Scan;  
A7G TOP 
498 GTGCCAAAACTTAAGCAACCGCACC
CGAAGCACAGC 
CX7_G5_C07 Alanine Scan;  
A7G BTM 
499 GGCGACCGCCCACAATGCTTCGGA
GGTCGG 
CX7_R6_E04 Alanine Scan;  
C0A TOP 
500 CCGACCTCCGAAGCATTGTGGGCG
GTCGCC 
CX7_R6_E04 Alanine Scan;  
C0A BTM 
501 GGGCGACCGCCCACAATTCTTCGG
AGGTC 
CX7_R6_E04 Alanine Scan;  
C0S TOP 
502 GACCTCCGAAGAATTGTGGGCGGT
CGCCC 
CX7_R6_E04 Alanine Scan;  
C0S BTM 
503 CGACCGCCCACAATTGTGCTGAGG
TCGGCGCG 
CX7_R6_E04 Alanine Scan;  
S1A TOP 
504 CGCGCCGACCTCAGCACAATTGTG
GGCGGTCG 
CX7_R6_E04 Alanine Scan;  
S1A BTM 
505 CCACAATTGTTCGGCCGTCGGCGC
GGGCC 
CX7_R6_E04 Alanine Scan;  
E2A TOP 
506 GGCCCGCGCCGACGGCCGAACAAT
TGTGG 
CX7_R6_E04 Alanine Scan;  
E2A BTM 
507 TTGTTCGGAGGCCGGCGCGGGCC CX7_R6_E04 Alanine Scan;  
V3A TOP 
508 GGCCCGCGCCGGCCTCCGAACAA CX7_R6_E04 Alanine Scan;  
V3A BTM 
509 TTCGGAGGTCGCCGCGGGCCTGT CX7_R6_E04 Alanine Scan;  
G4A TOP 
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510 ACAGGCCCGCGGCGACCTCCGAA CX7_R6_E04 Alanine Scan;  
G4A BTM 
511 TTCGGAGGTCGGCGGAGGCCTGTG
CTTAAG 
CX7_R6_E04 Alanine Scan;  
A5G TOP 
512 CTTAAGCACAGGCCTCCGCCGACC
TCCGAA 
CX7_R6_E04 Alanine Scan;  
A5G BTM 
513 CGGAGGTCGGCGCGGCTCTGTGCT
TAAGTTTTG 
CX7_R6_E04 Alanine Scan;  
G6A TOP 
514 CAAAACTTAAGCACAGAGCCGCGC
CGACCTCCG 
CX7_R6_E04 Alanine Scan;  
G6A BTM 
515 GGAGGTCGGCGCGGGCGCATGCTT
AAGTTTTGGCA 
CX7_R6_E04 Alanine Scan;  
L7A TOP 
516 TGCCAAAACTTAAGCATGCGCCCG
CGCCGACCTCC 
CX7_R6_E04 Alanine Scan;  
L7A BTM 
523 CCACAATTGTTCGGAGAAAGGCGC
GGGCCTGTGCT 
CX7_R6_E04 V4K mutation 
524 AGCACAGGCCCGCGCCTTTCTCCG
AACAATTGTGG 
CX7_R6_E04 V4K mutation 
527 GCCCACAATTGTTCGGCCAAAGGC
GCGGGCCT 
R6_E04 pull-down control 
mutation 
528 AGGCCCGCGCCTTTGGCCGAACAA
TTGTGGGC 
R6_E04 pull-down control 
mutation 
531 GCCCACAATTGTTGGAAGTGCTTC 
GGGTGCGC 
G5_C07 L3K mutation 
532 GCGCACCCGAAGCACTTCCAACAA
TTGTGGGC 
G5_C07 L3K mutation 
533 ATTGTTGGCTGTGCTTCGGGAAAGC
GTGCTTAAGTTTTGGCA C 
G5_C07 C7K mutation 
534 GTGCCAAAACTTAAGCACGCTTTCC
CGAAGCACAGCCAACAAT 
G5_C07 C7K mutation 
539 GCCCACAATTGTTCGGCCAAAGGC
GCGGGCGC 
R6_E04 pull-down control 
mutation 
540 GCGCCCGCGCCTTTGGCCGAACAA
TTGTGGGC 
R6_E04 pull-down control 
mutation 
541 AATCGTGTGACAACAACAGCC PGK1 sequencing primer 
543 AGAGGTCACGTCTCAGG CYH2 Northern probe 
544 ACAACACCACCAGCAGC CYH2 Northern probe 
584 ACAGAATAACGAACCAAATTACTAA
CAGT  
DBP2intFWDms qPCR 
585 CCTGGCATATCGTAGTTGATAACG DBP2intREVms qPCR 
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586 CTTCACCGAACAAAACAAAGGTT DBP2exonFWDms qPCR 
587 TCGGGAGGAATATTTTGATTAGCT DBP2exonREVms qPCR 
592 TTACAATATTTTTTTTGTACAGCCGG CYH2 pre-mRNA FWD qPCR 
593 CACCGGCCATACCTCTACCA CYH2 pre-mRNA REV qPCR 
594 TTATTTCGGTAAGGTTGGTATGAGA
TAC 
CYH2 total FWD qPCR 
595 TGGGATCAATGTCCACAATTTG CYH2 total REV qPCR 
598 CCAGACATTTTTTCCTCGTCCAAAC
G  
RPL22B pre-mRNA FWD 
599 ACTTTTTGCTTTCTGGAAGTCTGTTA
CAG 
RPL22B pre-mRNA REV 
600 TGTAGTATCCAGTGCCAAATTTTCT
GG 
RPL22B total FWD qPCR 
601 ACGAATCTGATCCAGTCTCTTAGCT
G 
RPL22B total REV qPCR 
602 CGCACCGTGCCCTGTT SCR1 FWD qPCR 
603 AGCTCTGCCCAGGACAAATTT SCR1 REV qPCR 
604 GGTAGAACCGCTTCCGGTAAC TDH3 FWD qPCR 
605 AAGACCTTACCGACAGCCTTAGC TDH3 REV qPCR 
620 AGGCCGAATTAACTCTACGC RPL18B pre-mRNA FWD 
qPCR 
621 CATGGAGGGACGATAAATATGAA RPL18B pre-mRNA REV 
qPCR 
 
3.2.8 Pull-down with biotinylated cyclic peptide 
Wild-type BY4742 (SS4050) yeast cells were cultured and harvested at 
OD 1.0 (A600). Cells were washed with cold water and resuspended in 1 mL/gram 
AGK (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 200 mM KCl, 8% glycerol). Yeast 
were frozen in liquid nitrogen and subsequently lysed cryogenically in a Retch 
ball mill (Mayas et al. 2006). The grindate was thawed and centrifuged in a JA-14 
rotor (12,000 rpm, 30 minutes, 4°C). Supernatant was transferred to 
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ultracentrifuge tubes. Extract was centrifuged in a Ti45 (42,000 rpm, 75 minutes, 
4°C). The supernatant was dialyzed twice in 4 L of Buffer D20 (20% glycerol, 20 
mM HEPES, pH 7.9, 50 mM KCl, 0.5 mM DTT, 1.5 mM MgCl2) for 2 hours at 
4°C. Dialyzed extract was transferred to Oakridge tubes and centrifuged in a 
JA17 rotor (14,000 rpm, 10 minutes, 4°C). 10 mL supernatant was aliquoted to 
50 mL falcon tubes, flash frozen in liquid nitrogen, and stored at -80°C. 
Extract was thawed in ice water. While thawing, 100 µL NeutrAvidin Resin 
streptavidin slurry (Thermo) was prepared in a disposable column by washing 
with IPP150 (10 mM Tris, pH 8.0, 150 mM NaCl, 0.1% NP-40, 1.5 mM MgCl2, 8% 
glycerol, 1 mM DTT). When extract was thawed, 1 volume of IPP150 was added. 
Extracts were adjusted to 0.2% NP-40, 1 µM DTT, 0.4 mM PMSF, 5 µM 
leupeptin, and 3 µM pepstatin. Prepared streptavidin beads were transferred to 
the extract and rotated for 1 hour at 4°C. Extract and beads were filtered through 
the disposable column to clear extract. The extract was then cleared again with 
another 100 µL streptavidin slurry. The twice-cleared extract was collected in a 
fresh tube, 100 µg cyclic peptide (or none for control) was added, then rotated for 
60 minutes at 4°C. Freshly washed streptavidin beads (50 µL slurry) were 
transferred to the extract with cyclic peptide and the mixture was rotated for 1 
hour. Extract was filtered through a disposable column and washed four times 
with 10 mL IPP150. The washed beads resuspended with 500 µL 0.1 M glycine 
HCl pH 2.8 and filtered into a microfuge tube containing 50 µL 1M Tris pH 9.0. 
Proteins were extracted with 1 volume acid-phenol chloroform. The organic 
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phase was precipitated with 800 µL cold acetone, overnight at -20°C. Pellets 
were washed twice with cold acetone, twice with 80% ethanol, and allowed to dry 
at room temperature. Samples were resuspended in 15 µL 2X LDS buffer 
containing 200 mM DTT and electrophoresed through an SDS-PAGE gel. The 
gel was fixed, stained with coomassie blue, destained, and visualized on a light 
box. The other half of the protein samples was saved for MS/MS analysis by the 
ICMB proteomics core facility. 
3.2.9 Generation of random-primed DNA probes 
The protocol here was adapted from the instructions provided (Life 
Technologies). A DECAPrime II Kit was used for a 25 µL reaction. In a microfuge 
tube, 25 ng of DNA template was added to a total volume of 11.5 µL (adjusted 
with ddH2O). For template, gel purified PCR product was used, generated from 
wild-type yeast genomic DNA and primers MS543 and MS544 (for probing 
CYH2; sequences in Table 3.3). 2.5 µL 10X Decamer Solution was added to the 
template, mixed, and heated at 95-100°C for 5 minutes. The mixture was flash 
frozen in liquid nitrogen and placed on ice to thaw (centrifuge to collect). On ice, 
added 5 µL 5X Reaction Buffer (-dATP), 2.5 µL ddH2O, 2.5 µL [α-32P] dATP (20 
mCi/mL), 1 µL Exo-Klenow. Tube was flicked to mix, spun down, and incubated 
at 37°C for 10 minutes. Reaction was stopped by the addition of 1 µL 0.5 M 
EDTA. 25 µL of TE was added. Unincorporated radionucleotides were removed 
 106 
by running the solution through a sephadex column. Probes were stored for up to 
one week at -20°C 
3.2.10 Northern blot analysis  
RNA (15 µg) was dried down using a Speedvac. Dried RNA was then 
denatured and electrophoresed on a 1% agarose, 2.2 M formaldehyde gel 
(Sambrook et al. 1989). rRNA was visualized by ethidium bromide staining. RNA 
was then transferred to a nylon membrane (Whatman) via downward capillary 
transfer (using 0.01 N NaOH and 3 M NaCl). After crosslinking by UV light (254 
nm for 1 minute), the membrane was probed with the random-primed body 
labeled DNA (boiled immediately prior to addition) in Church Buffer (500 mM 
Na2HPO4 pH 7.0, 7% SDS, 1 mM ETDA pH 8.0) overnight. The blot was then 
exposed to a phosphorimaging screen and developed in a phosphorimager.  
3.2.11 Development of drug screening strain 
To develop a compatible reporter for the drug-sensitive strain, the reporter 
sequence from plasmid pRS316 CUP1-Reporter (URA3 marked, MS163) was 
removed with BamHI and SalI and ligated into pRS413 (MS100) to generate 
pRS413 CUP1-Reporter (MS165), a low copy HIS3 marked copper inducible 
reporter. This reporter was transformed using standard lithium acetate method 
(Gietz and Woods 2002) into the drug-sensitive green monster ABC-16 strain 
(ABC-16; SS4127), which was kindly provided by the Roth lab (Suzuki et al. 
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2011). This strain (SS4136) was cultured in low fluorescent synthetic dropout 
media lacking histidine and used for drug screening efforts. 
3.2.12 Preparation of low-fluorescent synthetic dropout media 
The protocol for making this media was adapted from previously published 
work (Sheff and Thorn 2004). A 200X master stock is prepared with the following 
amounts of solid chemicals for 500 mL; 50 mg boric acid, 4 mg CuSO4, 10 mg 
KCl, 20 mg FeCl3, 40 mg MnSO4, 20 mg Na2MoO4, 40 mg ZnSO4, 200 mg 
inositol, 40 mg niacin, 20 mg 4-aminobenzoic acid (PABA), 40 mg pyridoxine 
HCl, 40 mg thiamine, 40 mg calcium pantothenate. These solids were dissolved 
in 500 mL ddH2O, filter sterilized, and stored at 4°C covered with tinfoil. To 
prepare 500 mL of liquid media, 100 µL 5000X biotin (10 mg/L in ddH2O, sterile 
filtered, -20°C) and 2.5 mL of 200X master stock were added to 400 mL dH2O. 
While stirring, 2.5 g NH4SO4, 0.5 g KH2PO4, 0.25 g MgSO4, 50 mg NaCl, and 50 
mg Ca2Cl were added, as was the desired amino acid mixture. Commercial 
nitrogen base and ammonium sulfate are not added. The solution is then brought 
up to 500 mL with dH2O and autoclaved. 
3.2.13 Calculation of z-score for plate-based reporter assay 
In the validation process of our reporter assay, the Z-factor/Z-prime (Z’) 
was calculated to determine the effect size between our negative control (copper 
and DMSO to induce reporter to 100%) and our positive control (no copper and 
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DMSO to inhibit expression of the reporter completely, i.e. 100% inhibition). The 
calculation used is: 
Z’ = 1 – [3(σp + σn) / (|µp - µn|)] 
σp = standard deviation of positive control 
σn = standard deviation of negative control 
µp = mean of positive control 
µn = mean of negative control 
The ideal Z’ is 1. An excellent assay has a Z’ between 0.5 and 1.0 and 
marginal assays have values between 0 and 0.5. Assays with a Z’ of less than 0 
are not useful due to not enough separation between positive and negative 
control or very high levels of deviation between replicates. 
3.2.14 High-throughput drug screening 
The drug-sensitive yeast strain ABC-16 (Suzuki et al. 2011) with pRS413 
CUP1-Reporter (MS165; strain SS4126) was grown overnight in synthetic 
dropout media lacking histidine. This culture was then used to inoculate four 200 
mL cultures with the same media at OD (A600) 0.0005, 0.00075, 0.001, and 
0.0015 in 1 L-baffled culture flasks. These cultures were grown for 16 hours at 
31°C in order to have one culture as close to OD (A600) 1.0 as possible (OD 
(A600) 0.9 to 1.1 is ideal). Immediately before bringing the cells and other 
materials to Ti-3D (Texas Institute for Drug & Diagnostic Development, The 
University of Texas at Austin) for high-throughput screening, the appropriate 
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volume of culture was centrifuged in a 50 mL conical in order to have 50 mL of 
cells at OD (A600) 0.25 and the media was decanted (multiple aliquots of cells 
were typically needed, 25 mL final volume of culture was needed for each 96-well 
plate). 50 mL of low fluorescent dropout media lacking histidine was added to the 
tubes. Cells and other materials were transferred to Ti-3D. Using robotics, 135 µL 
of cell culture was added to each well of a black 96-well plate with a flat clear 
bottom. For screens, 1 or 5 µL of stock compounds in DMSO was added to each 
well, resulting in a final concentration of 10 µM. Cells with compounds were 
incubated at 31°C on a microplate shaker for 30 minutes to allow compounds to 
elicit at affect. After 30 minutes, 10 µL 7.5 mM CuSO4 or 15 µL 5 mM CuSO4 
(depending on volume of compound) was added to induce reporter expression 
with a final concentration of 0.5 mM CuSO4, resulting in a total volume of 150 
µL/well. Plates were incubated at 31°C for 6 hours. Absorbance, as well as GFP 
and mCherry fluorescence was measured with a Biotek Synergy H4 plate reader. 
Secondary screens were preformed as described but with final compound 
concentrations of 10 µM, 1 µM, and 100 nM.  
The first and last column of each plate was not treated with compounds, 
and one was not treated with copper, to serve as controls. The wells without 
copper and compound served as a “100% inhibition” positive control to set the 
baseline fluorescence value. The wells with copper, but without compound were 
considered to be the “negative control” in which maximum fluorescence was 
expected. Fluorescence values for each well were divided by the absorbance 
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readings to normalize to cell density. These normalized fluorescence values were 
compared to the average of the negative controls to determine % inhibition for 
each fluorescence value separately. Alternatively, the mCherry/GFP ratio can be 
used as well. A graphical representation of the screening process is shown in 
Illustration 3.2. 
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Illustration 3.2: Graphical representation of high-throughput screen pipeline 
The general process of our high-throughput small molecule screening efforts is 
shown. Starting in the top left, drug-sensitive yeast harboring a copper-inducible 
reporter were dispensed robotically to 96-well plates and compounds were added 
to a final concentration of 10 µM. After 30 minutes incubation, CuSO4 was added 
to 0.5 mM and reporter was induced for 6 hours. 96-well plates were rapidly 
analyzed by a plate reader to identify primary hits, which were then analyzed in a 
secondary screen in which compounds were tested again at 10 µM, as well as 1 
µM and 100 nM. Plate reader and flow cytometry analysis was used to identify 
candidate gene expression inhibitors or modulators. More specific details can be 
found in Section 3.2.14. 
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3.3 RESULTS 
3.3.1 FACS-guided cyclic peptide screen results in two high-confidence 
hits 
The first cyclic peptide screen that I performed utilized the CX7 library 
(MS307) that generates cyclic peptides with 8 amino acids, a cysteine followed 
by 7 random amino acids. This library chosen to use first based on high quality 
results from our collaborators with this particular library (the Kritzer Laboratory, 
Tufts). By performing multiple standard lithium acetate transformations (Gietz 
and Woods 2002) with 500 ng library plasmid DNA into a wild-type yeast strain 
harboring our constitutive gene expression reporter, I obtained an estimated 2 
million transformants. Over 15 million cells were then analyzed by flow cytometry 
to sort red- and green-shifted cells. To determine the gates by which the cells 
were sorted, a control strain was using that harbored both the gene expression 
reporter and the HPQ control cyclic peptide construct. According to our 
collaborator, this cyclic peptide expresses well and had no identifiable 
phenotypes. The reporter phenograph for HPQ expressing cells and the gating 
boundaries can be seen in Figure 3.1A.  
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Figure 3.1: Initial characterization of two CX7 cyclic peptide hits 
(A) Reporter expression in wild-type yeast with the HPQ control cyclic peptide. 
The red (R) and green (G) gates used to sort the CX7 library are shown. (B) 
Reporter phenograph overlays of the two cyclic peptide hits (pseudo color) are 
shown in comparison to wild-type (grayscale). (C) Western blot analysis, probing 
for the chitin-binding-domain fused to the SICLOPPS intein, is shown for the 
HPQ control and the two hits. The slower migrating band is the cyclic peptide 
precursor and the faster band is the intein byproduct (Illustration 3.1). (D) Serial 
dilutions of wild-type yeast harboring the indicated cyclic peptide plasmid were 
made, plated onto synthetic dropout medium, and incubated at the indicated 
temperature for 3 or 7 days. 
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Utilizing FACS I collected 91,250 red-shifted cells and 50,096 green-
shifted cells. While most of these cells were stored for future analysis, a batch of 
nearly 2000 were plated for single colonies and analyzed by high-throughput flow 
cytometry in 96-well plates to identify clones with reproducible reporter 
phenotypes. By using CHUBACA, our binning and clustering algorithm described 
in Chapter 1, I identified 66 clones that clustered separately from the HPQ 
controls. Since we have observed 96-well analysis artifacts in the past, I grew 
these clones in 5 mL culture tubes and analyzed them in early log phase. Within 
these clones, there were 18 that resulted in reproducible reporter phenotypes. 
The plasmids from these strains were isolated from yeast, transformed into E. 
coli, then retransformed into the wild-type yeast strain containing our reporter. 
Out of the 18 clones that were analyzed, only 2 resulted in a reproducible 
reporter phenotype, which are shown in Figure 3.1B. 
The green-shifted hit, G5_C07 (CWLCFGCA), results in a reporter 
phenograph that is drastically shifted towards the GFP axis as a result of a 
decrease in both florescence levels (Figure 3.1B). This phenotype is unlike any 
other I had seen with the green-shifted deletion mutants (Figure 2.4). The red-
shifted hit, R6_E04 (CSEVGAGL), looked very similar to the reporter phenograph 
from cells with a pre-mRNA splicing defect or those lacking functional NMD 
(Figure 2.3B and 2.3C respectively). To verify that these clones were indeed 
expressing the SICLOPPS construct, I performed a western blot to detect the 
levels of cyclic peptide precursor and processed intein, by virtue of the chitin-
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binding-domain tag (Illustration 3.1). As predicted, both G5_C07 and R6_E04 
were expressed and processed (Figure 3.1C), albeit G5_C07 appeared to be 
processed less efficiently than R6_E04 and the HPQ control. Although these 
clones had obvious reporter phenotypes, they did not have a significant effect on 
growth rate at permissive, high, and low temperatures (Figure 3.1D).  
To determine if processing of the cyclic peptide precursor was required for 
the reporter phenotype, I introduced the T69A H72A intein inactivation mutation 
(ii) into these clones to abolish the generation of cyclic peptide (Ghosh et al. 
2001). This mutation permits expression of the cyclic peptide precursor but 
interferes with the active site, resulting in 100% unprocessed cyclic peptide 
precursor. Western blot analysis verified that the ii mutations completely blocked 
the processing of both cyclic peptides (Figure 3.2A). As anticipated, the ii 
mutation also eliminates the reporter phenotypes for both hits (Figure 3.2B). With 
these data in hand, we were confident that the cyclic peptide elicited the red- and 
green shifts for clones R6_E04 and G5_C07 respectively. The primary structure 
of both cyclic peptides is shown in Illustration 3.3. 
 
  
 116 
 
Illustration 3.3: Primary structure of CX7 cyclic peptide hits 
Ball and stick amino acid structures for G5_C07 and R6_E04 are shown on the 
left and right respectively. The amino acids are labeled based on their primary 
sequence starting with the obligatory cysteine. Ball and stick models were 
constructed using ChemDoodle. 
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Figure 3.2: The reporter phenotypes of G5_C07 and R6_E04 are dependent on 
efficient cyclic peptide processing  
(A) Western blot analysis of soluble protein from wild-type cells expressing HPQ, 
G5_C07, and R6_E04 cyclic peptide. For HPQ two OD (A600) time points were 
taken and the OD is indicated above the respective lane. For G5_C07 and 
R6_E04 both the wild-type (WT) and intein inactivated mutation (ii; T69A H72A) 
are analyzed. (B) Reporter phenograph overlays with the indicated cyclic peptide 
construct (pseudocolor) overlaid on an empty vector control (grayscale). 
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In our western analysis of different HPQ samples (Figure 3.2A), it was 
clear that the processing of the control HPQ cyclic peptide is more efficient at 
higher ODs (A600). To ascertain whether there are differences in reporter 
phenotype at different ODs, I performed a timecourse experiment in which I 
sampled a culture of yeast expressing either G5_C07 or R6_E04 at multiple time 
points spanning 10 hours. As with HPQ, the processing efficiency looks to 
increase at later ODs, which might have to do with decreased de novo 
expression when a culture nears stationary phase (Figure 3.3A). This experiment 
also reinforced our earlier observation that G5_C07 is processed less efficiently 
than R6_E04, even at later time points. When looking at reporter phenographs at 
selected time points, it is difficult to ascertain if there are significant differences, 
although time points around OD (A600) look to have the most significant 
phenotype (Figure 3.3B). To look more closely at the individual reporter signals, 
histograms were compared for selected time points. For G5_C07 the greatest 
fluorescent levels in both channels are observed at OD (A600) 0.83 (Figure 3.3C). 
In terms of R6_E04 we see a similar trend, except that the mCherry level is a log 
higher than G5_C07, with the highest levels of fluorescence at OD (A600) 0.92. 
Together, these data show subtle differences across a growth curve in terms of 
cyclic peptide expression, processing, and reporter phenotype. For subsequent 
experiments I will analyze cells and cell material from cultures between OD (A600) 
0.8 and 1.0.  
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Figure 3.3: Timecourse of cyclic peptide expression, processing, and reporter 
phenotype  
For all panels wild-type yeast harboring the gene expression reporter and either 
G5_C07 or R6_E04 were observed over the indicated ODs (A600). Samples were 
taken at the indicated ODs for protein and flow cytometry. (A) Western blot 
analysis of protein collected from the indicated ODs, probing for the chitin-
binding-domain on the cyclic peptide precursor. (B) Select reporter phenographs 
are shown for indicated time points of the cyclic peptide labeled to the right. (C) 
Histograms of flow cytometry data in order to compare the phenographs in panel 
B. Legend within the mCherry graph apply to GFP for the same cyclic peptide. 
The y-axis units are “% of maximum”. 
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3.3.2 Structure-activity relationship of G5_C07 
In identifying two high-confidence cyclic peptide hits from our FACS 
guided screen, we subsequently desired to determine the role of the 8 amino 
acids within these peptides. Using site-directed PCR mutagenesis an alanine 
scan was performed; all non-alanine amino acids of G5_C07 (CWLCFGCA) were 
individually changed to alanine while the alanine was changed to a glycine. 
Mutation of the first cysteine was expected to eliminate processing due to its role 
in processing (Illustration 3.1C). The C1A mutation indeed abolished processing, 
but C1S was actually processed more efficiently that even WT (Figure 3.4A). In 
talking with our collaborators, this is not at all uncommon, since the serine can 
actually take part in the chemistry required for intein splicing. For the rest of the 
mutations, I noticed reduced levels of processing, except for C4A. Since most of 
these mutants resulted in decreased processing, I predicted that most of them 
would reduce the reporter phenotype. In comparing the phenographs from the 
mutants to both an HPQ control and WT G5_C07, it is quite obvious that C1, W2 
are critical for the processing and activity of the cyclic peptide (Figure 3.4B). It is 
interesting that the C4A mutant is expressed and processed well, yet it eliminates 
the cyclic peptides, indicating that C4 is critical. Mutants F5A and G6A have 
intermediate affects on the activity of G5_C07 while L3A, C7A, and A8G have 
very little effect on the activity of the cyclic peptide. I mutated L3 and C7 to lysine 
to determine if this substitution can be used in linking synthesized peptide to an 
affinity matrix, which could then be used to identify cellular components that have 
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high affinity for the cyclic peptide. Both lysine mutations reduce the effect of the 
cyclic peptide on our reporter and most likely would not be an ideal substitution to 
use for target identification (Figure 3.4C). Although the L3K mutation retained 
some effect, this mutation decreases the overall expression of the cyclic peptide 
precursor to barely detectable levels (Figure 3.4D). A lysine substitution at 
position 8 was considered because the peptide still had a significant effect on 
reporter expression, but due to its close proximity to the critical C1 residue, we 
chose not to explore this route. The nullifying effects observed when mutating 
both C1 and C4 led me to believe that this cyclic peptide might contain a disulfide 
bond, which has been observed by our collaborators (Kritzer laboratory, data not 
published). Due to the low level of processing and the finicky behavior of this 
cyclic peptide, we decided to only further pursue R6_E04. 
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Figure 3.4: Alanine scan of G5_C07 determines most residues are critical to 
function 
The CX7 cyclic peptide clone G5_C07 was altered by site-directed PCR 
mutagenesis. (A) Western blot analysis determining cyclic peptide expression 
and processing of wild-type (WT; CWLCFGCA), intein inactivated mutant (ii; 
T69A H72A), and the indicated cyclic peptides (labeled above lanes). Three 
exposures are shown. (B and C) Reporter phenograph overlays are shown with 
data from HPQ (negative control) cells in black, WT G5_C07 in grayscale, and 
the indicated clone in pseudocolor (except for the WT, in which it is only G5_C07 
overlaid onto HPQ). (D) Western blot as in panel B analyzing mutants in panel C. 
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3.3.3 Structure-activity relationship of R6_E04 
As our efforts with the green-shifted hit G5_C07 were inconclusive, I 
employed the same strategy for the red-shifted hit R6_E04 (CSEVGAGL). In 
contrast with the alanine scan mutations of G5_C07, those of R6_E04 appeared 
to express and process efficiently (Figure 3.5A). The only mutant with lower 
processing efficiency was C1A, which is surprising given that cysteine and serine 
side chains are typically used. It is possible that this mutant cleaves yet is not 
fully spliced. Although our collaborator has also observed this phenomenon, 
further experimentation would need to be done to understand the effects of a 
C1A mutation. In analyzing the effect of these alanine scan mutations on reporter 
expression, I noticed that as with G5_C07, almost all the substitutions resulted in 
decreased reporter shift when compared to the parental R6_E04 (Figure 3.5B). 
Of note, the C1A phenograph, which mimics wild-type conditions (no cyclic 
peptide), is consistent with a non-cyclic peptide-producing situation, as discussed 
above. The only mutants that resulted in significant reporter shifts were E3A and 
V4A, with V4A having a slightly more severe shift than the original cyclic peptide. 
I then substituted valine for lysine at position 4 and analyzed reporter expression 
(Figure 3.5C). To my delight the V4K clone not only retained the red-shift but also 
resulted in an even more severe shift than “wild-type” R6_E04 and was 
expressed and processed at similar levels (Figure 3.5D). These data led us to 
further explore using the fourth position in R6_E04 as a potential residue to use 
in target identification.  
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Figure 3.5: Mutagenesis of R6_E04 identifies critical and replaceable residues 
Cyclic peptide clone R6_E04 was modified by site-directed PCR mutagenesis. 
(A) Western blot analysis determining expression and processing wild-type (WT; 
CSEVGAGL), intein inactivated mutant (ii; T69A H72A), and the indicated 
R6_E04 cyclic peptides (labeled above lanes). (B and C) Reporter phenograph 
overlays are shown with data from HPQ (negative control) cells in black, WT 
G5_C07 in grayscale, and the indicated clone in pseudocolor (except for the WT, 
in which it is only R6_E04 overlaid onto HPQ). (D) Western blot as in panel B 
analyzing mutant from panel C. 
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3.3.4 Development of a R6_E04 control peptide for biochemical target 
identification 
After discovering the potential of using a lysine substitution at the fourth 
position of R6_E04 (CSEKGAGL), we wanted to make a cyclic peptide with the 
lysine in place that did not have any apparent activity. This peptide would then be 
used as a control in pull-down experiments. Our hypothesis was that if we 
eliminate essential residues of the R6_E04 cyclic peptide, they would have 
reduced affinity for the target of interest. In our earlier alanine screen, substitution 
of either the 3rd position glutamic acid (E) or 8th position leucine (L) with alanine 
muted the effect of the R6_E04 cyclic peptide (Figure 3.5B). Using site-directed 
mutagenesis, I replaced E3 (V4K control 1, CSAKGAGL), L8 (V4K control 3, 
CSEKGAGA), or both (V4K control 2, CSAKGAGA) with an alanine. These 
clones were expressed alongside our gene expression reporter and the resulting 
phenographs were analyzed (Figure 3.6A). All three control cyclic peptides 
displayed reduced activity when compared to the parental V4K clone (Figure 
3.6B), resulting in a phenograph that is very similar to the negative control HPQ 
(Figure 3.6C). These findings were encouraging because I was looking to 
generate a R6_E04 V4K cyclic peptide with reduced or eliminated activity. 
Moreover, when I analyzed the expression and processing levels of these 
peptides, they all appeared to be expressed and processed well. Given these 
data, we chose to use R6_E04 V4K control 2 as a negative control for affinity 
chromatography. 
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Figure 3.6: R6_E04 V4K control cyclic peptides mute reporter phenotype 
(A) Reporter phenographs are shown for wild-type cells expressing the indicated 
R6_E04 V4K control (ctrl.) cyclic peptide construct (labeled above lanes). These 
are site-directed mutants of the V4K clone. To aid in comparison, these three 
phenographs are then overlaid onto a phenograph for the parental R6_E04 V4K 
(B) and the negative control cyclic peptide HPQ (C). The three V4K control cyclic 
peptides are in the foreground (blue) and the V4K or HPQ cyclic peptide data are 
in the background (red). (D) Western blot analysis determining expression and 
processing of the indicated R6_E04 cyclic peptides (labeled above lanes). 
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3.3.5 Pull-down attempts with biotinylated synthetic cyclic peptides 
 
After determining that control 2 (CSAKGAGA) would be an attractive 
negative control for R6_E04 V4K (CSEKGAGL), we proceeded with a pull-down 
approach in an attempt to identify potential cellular targets. Our collaborators 
synthesized the aforementioned cyclic peptides with a biotin moiety linked to the 
lysine (Kritzer Laboratory, Tufts University). Cleared wild-type yeast extract was 
incubated with no cyclic peptide, cyclo-CSEKGAGL (experimental), cyclo-
CSAKGAGA (control). Protein samples were analyzed by SDS-PAGE and a 
representative gel is shown in Figure 3.7. At first look, it is obvious that a number 
of endogenous proteins bind to streptavidin (Figure 3.7), which is not surprising 
given that budding yeast has a number of naturally biotinylated proteins 
(Hasslacher et al. 1993; Brewster et al. 1994; Kim et al. 2004; Hoja et al. 2004; 
Werven and Timmers 2006). Even with extensive clearing, there were detectable 
levels of proteins in the bound fraction when no biotinylated cyclic peptides were 
used (Figure 3.7). Unfortunately, we observed very little difference in the bound 
fraction from the pull-down with R6_E04 V4K (CSEKGAGL) or the control 
(CSAKGAGA; last lane). This experiment was repeated many times, while 
empirically changing conditions, yet I was unable to detect any specific proteins 
associated with the experimental R6_E04 V4K peptide. This being said, we did 
submit protein from the pull-downs for mass spectrometry analysis, however the 
results were inconclusive.  
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Figure 3.7: SDS-PAGE analysis of R6_E04 V4K pull-down 
The indicated protein samples from a cyclic peptide pull-down experiment are 
shown after coomassie staining (L, Benchmark Protein Ladder; -, no cyclic 
peptide). For the clearing lanes, one tenth of the 1st and 2nd clearing was run on 
the gel. For the bound, half the material was analyzed by SDS-PAGE and the 
other half was saved for mass spectrometry analysis. The first cyclo-lane is the 
R6_E04 V4K peptide while the second (far right) is the control cyclic peptide. 
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3.3.6 The R6_E04 reporter phenograph mimics a pre-mRNA splicing defect 
 
In conjunction with the biochemical efforts to identify the cellular target of 
R6_E04, I also utilized our existing reporter data to identify possible target 
pathways. Although it was quite obvious that the R6_E04 peptide elicited an 
effect similar to pre-mRNA splicing or nonsense-mediated decay mutants when 
looking at reporter behavior (Figure 2.3B-C), we wanted to compare the data in 
as unbiased a manner as is possible. To do so, I incorporated binned flow 
cytometry data from wild-type cells expressing R6_E04 with the data from the 
yeast deletion collection in Figure 2.14 and hierarchical clustering was used. Not 
surprisingly, all eight biological replicates of R6_E04 clustered within the red-
shifted clade (Figure 3.8A). When focusing on the specific clade into which the 
R6_E04 samples grouped, I also observed the more severe non-essential pre-
mRNA splicing mutants (lea1Δ, ist3Δ, and bud13Δ) in the same group (Figure 
3.8B). When comparing the phenographs of these mutants and R6_E04, there is 
evident similarity (Figure 3.8C). The overall shapes of the phenographs are very 
similar, while R6_E04 cells penetrate the phenograph more. Additionally when 
considering the density of the cells in the pseudocolor plots, there is a noticeable 
increase in mCherry fluorescence. These higher levels of mCherry fluorescence 
are in-between that of the pre-mRNA splicing and nonsense-mediated decay 
mutants (Figure 3.8C). 
 
 130 
 
Figure 3.8: Binning and clustering analysis of reporter expression places 
R6_E04 with pre-mRNA splicing mutants 
Flow cytometry data from wild-type yeast harboring the cyclic peptide R6_E04 
and the gene expression reporter were binned and incorporated into the deletion 
collection dataset from Figure 2.14. The combined dataset was then clustered 
hierarchically (A). The “red-shifted clade” is enlarged to the right and the specific 
clade that contains all R6_E04 biological replicates is further expanded and 
annotated (B). Pre-mRNA splicing mutants and cyclic peptide samples are 
colored green and red respectively. (C) Representative phenographs are shown 
to aid in comparison. Phenographs are as usual with mCherry and GFP 
fluorescence plotted on the y- and x-axis respectively, with the same scales 
applied. The indicated mutant or cyclic peptide is in pseudocolor, overlaid onto 
wild-type cells in grayscale. 
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3.3.7 R6_E04 displays a minor gene-specific pre-mRNA splicing defect  
 
Since yeast expressing R6_E04 clustered with yeast lacking certain pre-
mRNA splicing factors (Figure 3.8), we wanted to determine if splicing of 
endogenous introns was impaired. To assay splicing efficiency, RT-qPCR was 
performed using total RNA isolated from cells expressing the cyclic peptides 
HPQ, R6_E04, R6_E04 ii (intein inactivated), and R6_E04 V4K. For two of the 
introns tested, CYH2 and RPL22B, there was very little difference in splicing 
efficiency for the cyclic peptides tested (Figure 3.9). For the other two genes, 
DBP2 and TEF5, I observed minor yet reproducible splicing defects for R6_E04 
when compared to the ii control, as seen by an increase in the pre-mRNA/total 
ratio. It was concerning that I did not observe a splicing defect for the V4K 
construct, since it still retained its red-shifted reporter phenograph. Although this 
splicing defect of R6_E04 was reproducible, the relative fold increase of 1.5 and 
1.4 is small compared to the 7 to 13 and 3 to 5 fold increases seen in pre-mRNA 
splicing mutants for DBP2 and TEF5 respectively (data not shown). 
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Figure 3.9: RT-qPCR reveals a minor pre-mRNA splicing defect in cells 
expressing R6_E04 
RT-qPCR analysis was performed using total RNA from the indicated strains (ii, 
intein inactivated) for the specified gene. Primers for qPCR are described in 
Table 3.3. The quantities of pre-mRNA and total transcripts were quantified using 
a standard curve and ratios are relative to the HPQ negative control. Error bars 
represent the standard error between biological triplicates. 
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3.3.8 R6_E04 does not appear to inhibit the nonsense-mediated decay 
pathway 
Given the similarity of the reporter phenograph of R6_E04 to mutants of 
the nonsense-mediated decay (NMD) pathway (Figure 3.8C), I tested whether 
cells expressing the R6_E04 cyclic peptide had elevated levels of CYH2 pre-
mRNA, a poorly spliced prototypical endogenous NMD substrate (He et al. 1993; 
He and Jacobson 1995). Included in this experiment were pre-mRNA splicing 
(bud13Δ) and NMD (nmd2Δ) controls. Northern blot analysis of total RNA for 
CYH2 transcripts revealed no CYH2 pre-mRNA accumulation in cells expressing 
R6_E04 or either of the cyclic peptide controls (HPQ and R6_E04; Figure 3.10). 
Since R6_E04 did not appear to have an NMD defect, we were curious if the 
reporter pre-mRNA was specifically stabilized, giving rise to the mCherry 
fluorescence increase. Because our gene expression reporter intron was based 
off CYH2, we were also able to detect reporter pre-mRNA levels with the same 
CYH2 probe. In cells harboring our reporter and the cyclic peptide constructs, I 
did not observe any increase in reporter pre-mRNA levels (Figure 3.10). In all, 
these data do not indicate that the R6_E04 reporter phenotype is not due to 
inhibition of NMD. 
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Figure 3.10: Northern blot analysis reveals no nonsense-mediate decay defect 
in cells expressing R6_E04 
Total RNA was electrophoresed in an agarose gel, visualized for rRNA (ethidium 
bromide; lower panel), transferred to nylon, then probed for reporter pre-mRNA 
and CYH2 transcripts with a body-labeled random-primed CYH2 probe. 
Transcript species are labeled to the right and apply to both blots. Lanes are 
labeled with the cells the RNA was isolated from, make note that the three right-
most samples harbor our gene expression reporter (pRS415 TDH3-Reporter; 
MS169) in addition to the cyclic peptide constructs. The ethidium stained 18S 
and 25S rRNA are used to verify RNA loading levels. 
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3.3.9 Comparison of plate reader analysis with flow cytometry for 
measuring reporter expression 
In almost all the experiments performed with our gene expression 
reporter, flow cytometry analysis was used to measure the expression of GFP 
and mCherry. In preparing for high-throughput drug screen, it would be desirable 
to complete the primary screen using a plate reader since it was possible to 
analyze a 96-well plate in a matter of seconds, compared to 20 minutes with the 
flow cytometer. Instead of analyzing the fluorescence of individual cells, a plate 
reader measures the bulk fluorescence within a given well. Since mutations in 
specific gene expression processes resulted in characteristic flow cytometry 
phenographs, it was critical to determine if I could detect these differences with 
the plate reader. I used a set of prototypical deletion strains with the standard 
TDH3-Reporter. When the cells were ready for analysis, the samples were split 
in half, enabling analysis by both flow cytometry and plate reader (Figure 3.11). 
We were encouraged to see that the pre-mRNA splicing and NMD mutants 
(bud13Δ and lea1Δ, upf1Δ respectively), which have a low GFP/mCh ratio, were 
significantly separated from wild-type. On the other end of the spectrum the 
mRNA export mutant sac3Δ, which results in increased levels of GFP and 
decreased levels of mCherry, was also easily identifiable. With this analysis in 
hand, we were confident that we would be able to detect defects in gene 
expression with our gene expression reporter and a plate reader. 
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Figure 3.11: Reporter expression data generated from flow cytometry and plate 
reader are comparable 
GFP/mCherry ratios were calculated by flow cytometry (single-cell) and plate 
reader (bulk) analysis and plotted. The gene deletions are indicated with labels. 
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3.3.10 Validation and optimization of GM ABC-16 for drug screening with a 
copper inducible reporter 
In preparing our reporter system for high-throughput screening with Ti-3D 
(Texas Institute for Drug & Diagnostic Development, The University of Texas at 
Austin), I first needed to determine if there was appreciable levels of GFP 
fluorescence from the drug-sensitive yeast strain GM ABC-16 since the creators 
of the strain used a doxycycline inducible GFP system in the creation of the 
strain (Suzuki et al. 2011). Since there were 16 copies of an inducible GFP open 
reading frame in this strain, it was possible there would be background GFP 
fluorescence that could interfere with the GFP signal resulting from our reporter. 
In Figure 3.12A I demonstrate that there is negligible GFP fluorescence when 
compared to our standard wild-type yeast strain (BY4742; no GFP), confirming 
that this strain was suitable for our reporter assay. I then assayed reporter 
expression levels from the pRS413 CUP1-Reporter in the same strains to 
confirm that the 16 gene deletions in GM ABC-16 did not affect reporter 
expression. In Figure 3.12B I show that the copper inducible reporter expresses 
at similar levels in the drug-sensitive GM ABC-16 strain than our standard wild-
type strain, further confirming the potential of this strain for our assay. 
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Figure 3.12: The drug-sensitive yeast strain GM ABC-16 is suitable for drug 
screen with inducible reporter 
(A) Yeast strain GM ABC-16 (SS4127) has no appreciable GFP fluorescence 
compared with the standard WT yeast strain BY47472 (SS4050) when 
comparing GFP levels on a histogram. (B) Strain GM ABC-16 expresses 
comparable levels of GFP and mCherry from the pRS413 CUP1-Reporter in the 
presence of 1 mM CuSO4 for 6 hours. 
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Our colleagues at Ti-3D challenged us to determine the conditions in 
which our reporter expressed the highest level of signal in the shortest period of 
time, in order that there was a suitable signal to measure. Early in our validation 
attempts, we determined that standard synthetic dropout media had significant 
autofluorescence, which is a result of riboflavin and folic acid. We began using 
low-fluorescent synthetic dropout media in all drug-screening efforts. We 
empirically determined that our drug screening strain, GM ABC-16 + pRS413 
CUP1-Reporter, was optimally induced when mid/late exponential phase cells 
(OD (A600) of 0.9-1.1) were diluted to early/mid exponential phase (OD (A600) of 
0.25) and treated with 0.5 mM CuSO4 for 4-6 hours. Although we observed an 
increasing level of fluorescence after 6 hours, the cells were reaching the end of 
the exponential growth phase, and we wanted to analyze the cells while they 
were actively growing.  
During the course of assay validation, we desired to use a control 
compound that permitted cells to grow, yet inhibit expression of our reporter, or at 
least shift the phenograph significantly. This compound would be used as a 
plate-to-plate control, as well as to test the robustness or our assay. After 
searching for compounds, we decided to use the absence of CuSO4 as a 
“positive” control, which results in 100% inhibition of GFP and mCherry 
fluorescence. Although we would have liked to use a chemical compound as a 
positive control, we proceeded with these controls in our validation efforts. To 
determine the effect size of our assay, the Z-prime (Z’) score was calculated, 
 140 
which takes into consideration the mean and standard deviation of 48 control 
replicates (half a 96-well plate for each control), and difference between the 
negative and positive control (Figure 3.13, see Materials and Methods 3.2.13 for 
equation, parameter definition, and explanation). The Z’ was calculated based on 
the fluorescence reading divided by the OD (A600), which normalized the wells 
based on cell density. Both the GFP and mCherry Z’ values, 0.82 and 0.85 
respectively, were excellent. This indicated that our assay had great 
reproducibility across the plate and sufficient difference between the negative 
and positive controls. This experiment was repeated two additional times and 
yielded similar values, providing us great confidence in proceeding with our 
screening efforts.  
  
 141 
 
Figure 3.13: The 96-well plate adapted reporter assay is robust and suitable for 
high-throughput screening 
The fluorescence/OD (A600) ratios were calculated for GFP and mCherry for a 96-
well plate containing 48-wells of negative control (blue) and 48-wells of positive 
control cells. GM ABC-16 cells with pRS413 CUP1-Reporter were cultured in 
low-fluorescent synthetic dropout media lacking histidine to late exponential 
phase. Cells were diluted to OD (A600) 0.25 and distributed across the plate and 
0.5 mM CuSO4 was added to negative control wells and the plate was incubated 
for 6 hours (via robotic pipetting). The Z-prime (Z’) was calculated as in the 
Materials and Methods 3.2.13 (σp = standard deviation of positive control, σn = 
standard deviation of negative control, µp = mean of positive control, µn = mean 
of negative control). This experiment was repeated twice, resulting in similar Z’ 
values. 
  
 
 
  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 21354 7028 21412 6937 21115 6836 20733 6542 20367 6547 20398 6405 
B 20922 6603 20715 6820 21782 6797 20480 6623 20766 6348 20576 6333 
C 20866 6913 19976 6908 20651 6685 20321 6572 20122 6397 20101 6441 
D 20749 7063 20401 7194 19759 6733 20274 6667 21555 6431 20018 6349 
E 20852 6883 20282 6860 20314 6719 20377 6679 20118 6351 19882 6511 
F 21278 6952 20637 7002 21210 6826 20612 6562 19499 6491 19906 6496 
G 21260 7019 20918 7104 20767 6768 20705 6775 20487 6628 19811 6606 
H 21302 7235 20731 6864 21106 6814 20691 6781 22621 6648 20163 6585 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 6254 85 6277 58 6102 46 6122 52 5874 51 5956 62 
B 6306 68 5990 46 5992 51 5811 70 5850 46 5710 30 
C 6199 49 5433 56 5983 51 6034 63 5936 67 5752 69 
D 6477 57 5987 15 6178 89 5952 69 6132 59 5655 53 
E 6479 74 6096 64 6195 23 6098 56 6068 57 5646 47 
F 6456 54 6209 63 6307 53 6168 58 6206 40 6000 56 
G 6429 65 6461 50 6237 53 6373 52 6125 60 5884 42 
H 6839 65 6322 70 6566 72 6434 52 6683 56 5876 54 
GFP/OD Values 
mCherry/OD Values 
Negative Control 
(Copper + DMSO) 
Positive Control 
(DMSO) 
σp = 584.27 
σn = 234.04 
µp = 20644.61 
µn = 6715.30 
Z’ = 0.82 
σp = 281.29 
σn = 13.41 
µp = 6127.47 
µn = 56.19 
Z’ = 0.85 
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3.3.11 Initial screens of a diverse set of 3647 small molecules  
Through communication with our Ti-3D collaborators, we decided to begin 
our high-throughput small molecule screening efforts with a diverse set of small 
molecules. The first chemical libraries we screened were the NIH Clinical 
Collections (Molecular Libraries Small Molecule Repository operated by Evotec). 
This library consists of 727 small molecules that have been used in clinical trials, 
resulting in a collection with relatively high bioactivity and therapeutic potential. 
The next library tested was an institutionally derived collection of 600 kinase 
inhibitors. Kinase inhibitors are a very common class of therapeutic and 
biologically useful compounds (Chen 2012; Harrison 2012; Fabbro et al. 2012). 
The last and most diverse set of small molecules screened was The Spectrum 
Collection (MicroSource). This collection contained 2320 compounds and serves 
as a great primary screening tool due to its wide range of biological activity and 
structural diversity. 60% of this library is comprised of existing drugs, 25% are 
natural products, and the remaining 15% are “other bioactive compounds” such 
as non-drug toxins, enzyme inhibitors, membrane active compounds, and 
receptor blockers. Together, these three diverse collections of small molecules 
provided an excellent starting point for our screening efforts. 
Our screening strategy is outlined in Illustration 3.2 and in our primary 
screen we analyzed the aforementioned libraries at 10 µM by plate reader 
analysis with the drug-sensitive yeast strain GM ABC-16. OD (A600), GFP 
fluorescence, and mCherry fluorescence were measured for all wells. OD (A600) 
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normalized fluorescence values were used to calculate % inhibition, relative to 
the negative control samples. Compounds were ranked based on the % inhibition 
of GFP and mCherry separately and compounds with inhibitions of more than 
50% were chosen for a secondary screen. Additionally, cytostatic compounds, as 
seen by no increase in OD (A600), were selected, since they might reveal an 
interesting phenotype at lower concentrations. In all, 354 small molecules were 
selected to be screened in a secondary screen. The secondary screen was 
performed in the same manner as the primary screen, except that three 
concentrations were tested (10 µM, 1 µM, and 100 nM). Additionally, high-
throughput flow cytometry analysis was used to examine reporter fluorescence in 
addition to plate reader analysis. The three concentrations served to determine if 
the compounds resulted in dose-dependent effects, as well as to gauge the effect 
of compounds that were toxic at the primary concentration 10 µM. 
3.3.12 The secondary small molecule screen resulted in 16 high-confidence 
hits  
Of the 354 small molecules that were analyzed in the secondary screen, 
we identified 16 compounds with significant dose-dependent effects on reporter 
expression. In Figure 3.14 I display the phenographs from the secondary screen 
for 10 of the 16 compounds. Across the board, the dose-dependent responses 
are apparent. It was also very encouraging that a number of the compounds still 
have a significant reporter phenotype at the low concentration of 100 nM.  
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Figure 3.14: Dose-dependent reporter effects by high-confidence hits from small 
molecule screen 
Small molecule treated flow cytometry data (pseudocolor) are overlaid onto 
DMSO only data (grayscale) for the three concentrations tested in the secondary 
screen. Phenographs are as usual with GFP and mCherry displayed on the x- 
and y-axis respectively 
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 TI3D_0099_E07 was an interesting hit because there were three structural 
derivatives that resulted in almost identical reporter phenotypes. These three 
analogs of TI3D_0099_E07 only differ by one R group and represent a family of 
inhibitors for a specific kinase. Identifying four very similar small molecules with 
analogous phenotypes was very encouraging and results in higher confidence in 
the validity of this hit. Another interesting group of small molecules were ones 
that result in a phenotype alike TI3D_0104_I03. There were a total of three 
molecules with a more heterogeneous green-shifted phenotype, with the bulk of 
cells separated from the non-fluorescent cells at the origin. When investigating 
the nature of these compounds, all three were nucleoside analogs. 
 Our Ti-3D collaborators then attempted to determine the half maximal 
effective concentration (EC50) for the hit compounds, which essentially is the 
concentration that elicits a response halfway between the negative control and 
the maximal response. EC50 values were calculated for each fluorescent signal 
separately, as well as OD (A600; Figure 3.15). To complete these experiments 
fresh compounds were purchased in order to confirm the validity of the hit, as 
well as make a range of stock concentrations. The concentrations tested varied 
between compounds based on the severity of the reporter phenotype and growth 
inhibition, but all spanned at least a 4-log dilution series. We also determined the 
EC50 for wild-type yeast (BY4742/SS4050). Although a wide range of 
concentrations was used for each compound, some EC50 values were not able to 
be determined. 
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 When studying the EC50 values, we were very encouraged by the results 
of some compounds at very low concentrations, including a number in the low to 
sub-micromolar range. We also observed overall lower EC50 values for the drug-
sensitive strain GM ABC-16 when compared to wild-type yeast, which was 
surprising. Moreover, it was very interesting to observe some compounds with 
significantly different EC50 values for the same compound when comparing the 
effect on GFP and mCherry. For example, the mCherry EC50 for TI3D_0098_014 
is nearly 10-fold lower than that of GFP. On the other hand, the GFP EC50 for 
TI3D_0104_I03 is 20-times lower than the mCherry EC50. These differences 
reveal specific effects on reporter expression instead of an overall decrease in 
expression. 
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Wild-type  GM ABC-16 
 
Abs GFP mCherry  Abs GFP mCherry 
TI3D_0098_O14 - - -  4.35 4.58 0.501 
TI3D_0099_D10 2.58 - 0.54  0.0365 0.843 0.0355 
TI3D_0099_E07 0.126 0.0363 0.0209  0.0268 0.0589 0.0415 
TI3D_0099_I03 12.9 13.3 14.3  12.9 24.0 32.6 
TI3D_0099_M16 0.0538 0.0191 0.0255  0.0467 0.0101 0.0278 
TI3D_0099_O08 - 179 48.9  27.4 6.93 3.57 
TI3D_0100_H19 0.036 0.184 0.0227  0.0144 0.0371 0.0122 
TI3D_0104_A05 25.6 8.3 7.3  17.4 9 9.12 
TI3D_0104_B19 18.1 - -  6.14 - 9.77 
TI3D_0104_I03 40.6 10.7 -  3.42 0.553 12.8 
TI3D_0104_I09 13.7 55 7.15  8.9 5.4 3.70 
TI3D_0105_C07 40.2 2.45 5.56  35 2.68 12.6 
TI3D_0107_B13 4.1 1.35 1.26  0.486 0.372 0.101 
TI3D_0219_C19 9.94 12.5 5.07  1.41 2.23 0.489 
        
Figure 3.15: EC50 values for high-confidence small molecule hits 
The EC50 values for high-confidence small molecule hits are shown. Our 
Ti-3D collaborators determined values by screening compounds across a 
concentration gradient of 6 concentrations covering at least 4-logs. All values are 
in µM and represent the concentration of compounds that elicits 50% of the 
maximal effect. Wild-type cells are strain SS4050 and GM ABC-16 are strain 
SS4127. Abs represents absorbance (OD (A600)) while GFP and mCherry refer to 
fluorescence. The “-“ means the EC50 was unable to be determined. 
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3.3.13 Identification of possible target pathways for small molecule hits 
As with the cyclic peptide hits, we wanted to identify the cellular targets of 
the small molecules that we identified as having potential effects on gene 
expression. The first attempt we made at accomplishing this goal was to use our 
binning and clustering pipeline, CHUBACA, to identify phenographs that are 
similar to deletion mutants. Our prediction was that a small molecule inhibiting a 
specific gene expression process would mimic a genetic perturbation of the same 
process. I binned and clustered the small molecule data from the high confidence 
hits from all three concentrations tested, and then integrated them with several 
dozen gene expression related deletion mutants. The resulting dendrogram is 
shown in Figure 3.16A. Of note, I observed all the small molecules that resulted 
in a green-shift clustering with the deletion mutant rrp6Δ, the 3’ to 5’ exonuclease 
of the nuclear exosome. Although none of the compound-treated phenographs 
are as severely shifted as the rrp6Δ mutant, they are all intermediates between 
the DMSO only control and rrp6Δ (Figure 3.16B). Additionally, one of the red-
shifted hits, TI3D_0104_B19, clustered specifically with the splicing mutant 
bud13Δ (Figure 3.16A top right). 
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Figure 3.16: Preliminary drug target pathways revealed by clustering with 
deletion mutants 
(A) A dendrogram depicting the similarity of flow cytometry phenographs is 
shown. Flow cytometry data from small molecule-treated cells were analyzed 
with a data set of deletion strains corresponding to the gene expression 
machinery. Each node represents a single data set and clades of interest are 
enlarged and annotated to the right. (B) Gene expression reporter phenographs 
representing data in the rrp6Δ green-shifted clade (enlarged in panel A). 
Phenographs are as usual with GFP and mCherry displayed on the x- and y-axis 
respectively, with the drug-treated cells in pseudocolor and negative control cells 
(DMSO only) in grayscale. 
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To go one step further in identifying the potential target pathways for the 
hit compounds, I employed RT-qPCR analysis to look at the level of endogenous 
transcripts. The first transcript analyzed was the RPL18B pre-mRNA, a known in 
vivo substrate of Rrp6p (Sayani and Chanfreau 2012). Since many compounds 
clustered with the rrp6Δ mutant strain, this was an obvious start to determine if 
Rrp6p might be inhibited. In this analysis I also included a control, 5-fluorouracil 
(5-FU), which has been shown to inhibit Rrp6p (Fang et al. 2004; Kammler et al. 
2008), although the mechanism of action is unknown and most likely indirect. 
RPL18B pre-mRNA levels were normalized to both the Pol II transcribed TDH3 
and the Pol III transcribed SCR1. The concentration of compounds was designed 
to reflect the EC50 value. The highest levels of RPL18B pre-mRNA were detected 
in the 5-FU treated cells. Not surprising, some of the hit small molecules had 
elevated levels of RPL18B pre-mRNA, including TI3D_0219_C19, 
TI3D_0104_I03, TI3D_0105_O17, and TI3D_0107_B13. The first three of these 
compounds are green-shifted, similar to 5-FU, and two have been shown to 
inhibit Pol II transcription. I believe that transcription inhibition by these 
compounds leads to increased aberrant transcripts. This would overwhelm Rrp6p 
and lead to decreased processing efficiency, thus elevating the levels of its 
substrate RPL18B pre-mRNA. I will discuss the fourth compound 
TI3D_0107_B13 later, since it has additional phenotypes. 
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Figure 3.17: RT-qPCR analysis of the Rrp6p sensitive RPL18B pre-mRNA in the 
presence of small molecules 
RT-qPCR analysis was performed with total RNA isolated from GM ABC-16 cells 
treated with the indicated concentration of compound for 6 hours. A standard 
curve technique was used to calculate the transcript levels and the RPL18B pre-
mRNA is normalized to two different control transcripts, SCR1 and TDH3. 
Normalized levels are charted relative to DMSO only treated cells. Since this 
experiment served as a quick screen, only one biological replicate was analyzed, 
therefore no error bars are shown. 
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As our reporter is sensitive to pre-mRNA splicing defects and some of the 
hit compounds give rise to a red-shifted/pre-mRNA defect-like phenograph, we 
also wanted to complete RT-qPCR to assay pre-mRNA splicing efficiency of 
endogenous introns. I queried three endogenous introns as well as our synthetic 
reporter intron. In looking at the results, the first finding that stands out is that 
there are obviously gene-specific effects (Figure 3.18). Of note, the efficiency of 
DBP2 splicing has a wide range of defects without consistent patterns with the 
other introns. The two compounds with consistent splicing defects across all four 
introns are TI3D_0104_B19 and TI3D_0105_O17. As stated before, 
TI3D_0105_O17 is a well-characterized transcription inhibitor. Given the 
cotranscriptional nature of pre-mRNA splicing, I was not surprised to see a pre-
mRNA splicing defect, as many transcription mutants display red-shifted reporter 
phenographs (Figure 2.3D). As for TI3D_0104_B19 there are no known links 
between its known mechanism of action and pre-mRNA splicing, making the 
further exploration of this compound a very interesting future research topic.  
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Figure 3.18: RT-qPCR survey for pre-mRNA splicing defects in small molecule 
treated cells 
RT-qPCR analysis was performed with total RNA isolated from GM ABC-16 cells 
treated with the indicated concentration of compound for 6 hours. A standard 
curve technique was used to calculate the transcript levels. The pre-mRNA/total 
ratios are charted relative to DMSO only treated cells. As in Figure 3.17, only one 
biological replicate was analyzed. 
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To confirm the potential pre-mRNA splicing defect observed in 
TI3D_0104_B19 treated cells, I performed a similar RT-qPCR analysis, testing at 
three different concentrations (15, 30, and 60 µM) in biological triplicate (Figure 
3.19A). I was very encouraged to detect dose-dependent pre-mRNA splicing 
defects for all four introns tested, with very strong 4- and 10-fold splicing defects 
for TEF5 and DBP2 introns respectively. Although the degrees of splicing defect 
were less for RPL22B and the reporter intron, the dose dependent response was 
still evident and the fold-changes were similar to splicing mutants. 
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Figure 3.19: Identification of a novel dose-dependent pre-mRNA splicing defect 
in TI3D_0104_B19 treated cells 
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(Figure 3.19 continued) 
 
(A) GM ABC-16 cells with copper inducible reporter were treated with three 
different concentrations of TI3D_0104_B19 and the reporter was induced for 6 
hours. Total RNA was isolated and RT-qPCR was performed using primers in 
Table 3.3. All pre-mRNA/total ratios are taken relative to DMSO only and error 
bars representing one standard error. (B) Same as panel A, except for 3 different 
concentrations of five different compounds were tested. TI3D_0104_B19 was 
tested alongside three structural analogs (SA) and one functional analog (FA). 
The legend on the bottom describes the compounds in terms of structure and 
function relationship to TI3D_0104_B19, and color labels uniform throughout the 
panel. 
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Often, one can determine more about the mechanism of action of a 
compound by surveying compounds with a similar chemical structure or small 
molecules with overlapping activities. One of the four compounds I chose to test 
was the parental compound (SA 1) of TI3D_0104_B19, which shares all three 
known activities. I also chose to examine two additional structural analogs of 
TI3D_0104_B19, SA 2 and SA 3. SA 2 shares all three activities while SA 3 lacks 
activity 3. The last compound I tested, FA 1 (functional analog), does not have a 
similar structure, but displays activities 1 and 3. I treated drug-sensitive yeast 
with these four compounds at the same concentrations and performed RT-qPCR 
analysis for the same four introns as in Figure 3.19A. FA 1 and SA 3 did not have 
an appreciable affect on the splicing efficiency of any of the introns tested. SA 1, 
the parental compound of TI3D_0104_B19, had a very slight splicing defect at 30 
and 60 µM for TEF5 and DBP2 introns, but not for the RPL22B and reporter 
introns. The one other compound that did have an appreciable negative affect on 
the splicing efficiency of all three endogenous introns was SA 2, although the 
overall effects were muted compared to TI3D_0104_B19. Altogether, the general 
splicing inhibition seen with TI3D_0104_B19 treatment is specific to this chemical 
structure and potentially all three known activities. Future efforts to study the 
splicing inhibition activity of this compound can be found in the Discussion 
(Section 3.4). 
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3.4 DISCUSSION  
In this chapter I describe two complementary approaches to discover 
small molecules that modulate yeast gene expression using our versatile gene 
expression reporter. Instead of a standard in vitro high-throughput screen using 
purified target protein, both of our approaches allowed us to survey the effect on 
many different gene expression processes simultaneously in the context of a 
biological system (cell). Both the cyclic peptide and small molecule screens 
yielded putative splicing inhibitors, as well other molecules of interest than can be 
explored further. One general observation in both screens is that cyclic peptides 
and small molecules can elicit more heterogeneous effects (Figures 3.1B and 
3.14). In other words, the reporter phenograph populations are more disperse 
due to increase variability in reporter signal. This potentially shows the result of 
partial inhibition in contrast with a clean deletion of a component of gene 
expression machinery. 
In my cyclic peptide screen I discovered that it is prone to a relatively high 
false-positive rate. One contributing factor to this was a 96-well plate analysis 
artifact, meaning that I observed significant shifts when analyzing potential hits in 
96-well plates (high-throughput mode), but when analyzing carefully from culture 
tubes, this phenotype was absent. Although it is nearly impossible to control for 
96 different growth rates in a single plate, we have overcome this by analyzing 
plates at different time points and measuring the average absorbance of the 
plate. One could also use a plate reader to quickly analyze the growth stage of a 
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given well and select promising wells for flow cytometry analysis at different time 
points, analyzing the wells that are at the ideal optical density (A600). As with any 
yeast genetic screen, false positives are inevitable, but to have a system to either 
eliminate them or quickly rule them out is of great importance. 
In surveying the expression and processing of the SICLOPPS-encoded 
cyclic peptides, we are relying on the chitin-binding-domain (CBD) fused to the 
C-terminal portion of the split intein. Although this is useful, it does not truly 
measure the levels of resulting cyclic peptide, just the precursor and byproduct 
(Illustration 3.1C). Having a way of detecting the cyclic peptide, such as the 
incorporation of an unnatural amino acid, would help determine in vivo levels of 
cyclic peptide. This being said, the SICLOPPS system is a very attractive tool. 
One of the features that set SICLOPPS apart in small molecule screening is the 
ability to rapidly study the structure-activity relationship of the hit cyclic peptides 
by straightforward site-directed mutagenesis, which is much simpler than the 
chemical synthesis of modified compounds. 
We are disappointed that the cellular target for the red-shifted hit R6_E04 
is still unknown. Although we were able to validate a small but reproducible pre-
mRNA splicing defect by RT-qPCR analysis of endogenous introns (Figure 3.9), 
we do not currently have any data that points to a specific target. With the 
attempted pull-down experiments using the biotinylated cyclo-CSEKGAGL 
(R6_E04 V4K), there would need to be a relatively strong interaction between the 
cyclic peptide and its target for us to identify. Further optimization could be useful 
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to further clear the extract as well as adjust the stringency of the washes, etc. It is 
interesting to note that we observed increased activity in the V4K mutant 
compared to the parental R6_E04 (Figure 3.5C), which could indicate that the 
lysine residue plays a role in its activity. Attaching a biotin moiety would most 
likely be detrimental to its activity if this were the case. On the other hand, the 
V4K clone did not have any splicing defect when looking at endogenous introns 
(Figure 3.9), hinting towards a possibility that R6_E04’s activity is specific to our 
reporter.  
As a complementary approach to the biochemical target identification, I 
also performed a FACS screen to identify high copy suppressors using a plasmid 
based genomic tiling library, but my efforts were unsuccessful. An additional fairly 
straightforward experiment would be to repeat the pull-down experiment and 
probe for probable RNAs that the R6_E04 might interact with, such as snRNAs 
or intron-containing pre-mRNAs. Furthermore the biotinylated cyclo-CSEKGAGL 
might be useful to probe for treating extract with the cyclic peptide and 
spliceosome purification. Of course a strong interaction would be required for this 
experiment to work. 
In terms of the high-throughput small molecule screen, I believe the pilot 
efforts made were encouraging, warranting additional screening. The libraries 
that I screened were highly populated with existing and failed drugs. As the 
discovery of novel drugs slows, there is a growing trend of drug repurposing or 
repositioning (Corbett et al. 2012; Gupta et al. 2013; Jin and Wong 2014; Cragg 
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et al. 2014). The idea is to find novel uses for existing drugs that might have 
been overlooked before, or combining drugs for synergistic effects. Our reporter 
assay, with its wide yet specific sensitivity, is ideal for this type of work to identify 
currently unknown activities of existing drugs. 
In moving forward in screening efforts, it would be wise to establish 
additional orthogonal assays to validate and further test potential hit compounds, 
which will also get closer to identifying a cellular target. When using flow 
cytometry, it is also possible to multiplex assays and screen against multiple cell 
types or reporters simultaneously. This can be done by labeling cells with 
different markers or combinations of markers and using them to gate the different 
cells types, in which you can then assay your signal of interest (Chen et al. 
2012). In terms of target identification, I believe our binning and clustering 
analysis with gene expression deletion mutants will continue to work well in 
narrowing down the number of pathways (Figures 3.8 and 3.16). An additional 
tool in yeast drug discovery is the use of chemical genetic interactions (Giaever 
et al. 2004; Parsons et al. 2006; Hillenmeyer et al. 2008), in which one screens 
yeast deletion collections or overexpression libraries for genes that lead to 
differential growth in the presence of a given compound.  
Out of over three thousand small molecules, our screen identified 
TI3D_0104_B19, a novel pre-mRNA splicing inhibitor, as resulting in a red-
shifted phenograph. Not only did the compound treated sample cluster with pre-
mRNA splicing mutants (Figure 3.16A), I also discovered dose-dependent 
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splicing impairment of endogenous introns (Figure 3.19). Given the nature of this 
small molecule and its known functions, it is possible that this molecule acts 
upstream of pre-mRNA splicing and might have indirect effects. There is one 
published work that links TI3D_0104_B19 to alternative splicing in mammalian 
cells, but the molecular details are unclear. Further experimentation is needed to 
determine if this molecule directly inhibits pre-mRNA splicing, and if so, which 
spliceosome component. The availability of a radioisotope-labeled version of this 
compound, as well as its fluorescence properties, can aid in these efforts. It 
would also be interesting to determine the nature behind the gene-specific effects 
of some of the structural derivatives tested. Optimization of this compound in 
terms of pre-mRNA splicing will most likely be needed since most promising 
small molecules have activity in the low- to sub-micromolar range, compared to 
the mid-micromolar range observed in yeast. It would not be surprising though to 
see increased efficacy in mammalian cells if permeability and stability are 
increased. The fact that pre-mRNA splicing is becoming a more sought after 
target for chemotherapeutics is encouraging as well (Dehm 2013; Effenberger et 
al. 2014). 
One gene expression target that our reporter assay is particularly sensitive 
to is the TREX-2 complex, which functions in linking mRNA and export (Fischer 
et al. 2002; Rodriguez-Navarro et al. 2004). As seen in Figure 2.4A, deletion of 
the nonessential components of the TREX-2 complex gives rise to a strong a 
reproducible green-shift. As discussed earlier (Section 3.1.5) the human protein 
 163 
GANP of the TREX-2 complex is strongly implicated in cancer and has been 
shown to be a valuable chemotherapeutic target (Fujimura et al. 2005; Kageshita 
et al. 2006; Wickramasinghe et al. 2010; Phimsen et al. 2012). Very recently 
TREX-2 components have been shown to be involved in DNA damage, genome 
instability and R-loop formation via BRCA2 (Bhatia et al. 2014). The medical 
relevance of the TREX-2 complex and the unique signal in TREX-2 yeast 
mutants further highlight the utility of our reporter as a drug-screening tool. 
I am confident that the cyclic peptide library (including different sizes) is 
still a valuable tool for further exploration, as I have not come close to exploring 
the entire CX7 library. Given the results so far, I believe that these libraries 
contain biological interesting cyclic peptides that can be identified with our 
reporter. In terms of small molecules, our pilot screens of over 3000 compounds 
is barely scratching the surface. With the installation of a truly high-throughput 
flow cytometry system on campus, our optimized reporter system is ready to 
survey tens or hundreds of thousands of molecules. With these two screens, I 
have further demonstrated the broad utility of our reporter in surveying the effect 
of small molecules on a wide range of gene expression process simultaneously.  
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Chapter 4:  Rapid identification of loss-of-function mutants of 
Swm2p 
4.1 BACKGROUND 
In eukaryotic cells, the accurate expression of mRNA requires the 
coordinated efforts of multiple cellular machines to generate, process, and 
translate the desired protein (Komili and Silver 2008). One such machine, the 
spliceosome, is a large and dynamic complex comprised of five small nuclear 
ribonucleoproteins (snRNPs), each consisting of a small nuclear RNA (snRNA) 
and associated proteins. These snRNPs function in pre-mRNA splicing to 
remove noncoding introns to generate translatable mRNAs (Nilsen 2003). 
Although there are differences between the snRNPs that make up the 
spliceosome, their biogenesis is a tightly orchestrated process; most often 
including snRNA processing and modifications, as well as nucleocytoplasmic 
shuttling and packaging (Kiss 2004; Patel and Bellini 2008; Fischer et al. 2011). 
The timely and accurate biogenesis of snRNPs, as well their dynamic 
interactions with the pre-mRNA substrate are essential for an efficient pre-mRNA 
splicing and gene expression program.  
4.1.1 Modifications of snRNAs 
The mechanisms and functions of spliceosomal snRNA modifications 
have been extensively studied and reviewed (Karijolich and Yu 2010), yet there 
is still much to learn about their functions and biological implications. All five 
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snRNAs are modified posttranscriptionally, including 2’-O-methylation, 
pseudouridylation and 5’ cap trimethylation (Reddy and Busch 1988; Grosjean 
and Benne 1998; Massenet et al. 1999; Grosjean 2005). The internal 
modifications to both the backbone (2’-O-methylation) and bases 
(pseudouridylation) are highly conserved and are mainly located in functionally 
important regions (Szkukalek et al. 1995; Gu et al. 1996; Yu et al. 1998; Patton 
and Padgett 2005; Simoes-Barbosa et al. 2008). Although the majority of snRNA 
modifications are catalyzed via RNA-dependent mechanisms (Box H/ACA or Box 
C/D snoRNAs and their associated proteins), some are performed by enzymes in 
a RNA-independent manner. 
4.1.2 Trimethylguanosine synthase 
In terms of 5’ cap trimethylation, U6 is the only snRNA (RNA Pol III 
transcript) that is not trimethylated. After synthesis by RNA polymerase II, the 
m7G cap of the U1, U2, U4, and U5 snRNAs, as well as some small nucleolar 
RNAs (snoRNAs; Mouaikel et al. 2002) and the telomerase RNA (Jády et al. 
2004; Franke et al. 2008), are converted to the 2,2,7-trimethylguanosine (TMG) 
cap structure. This reaction is catalyzed by trimethylguanosine synthase (Tgs1) 
via two successive methylations using the methyl donor S-adenosylmethionine 
(Zhu et al. 2001; Mouaikel et al. 2002; Komonyi et al. 2005; Hausmann and 
Shuman 2005; Hausmann et al. 2007, 2008; Benarroch et al. 2010). Although the 
biogenesis of snRNAs and the localization of specific events have been well 
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characterized in human cells, there is still much that is unknown about snRNA 
biogenesis in the budding yeast. 
Even though Tgs1 is essential in higher eukaryotic organisms (Komonyi et 
al. 2005), Tgs1p is not required for viability in Saccharomyces cerevisiae, yet 
yeast lacking TGS1 exhibit a cold-sensitive growth phenotype (Mouaikel et al. 
2002). The deletion of TGS1 results in splicing and ribosomal RNA (rRNA) 
processing defects, as well as decreased nucleolar organization (Mouaikel et al. 
2002; Colau et al. 2004; Boon and Kos 2010). The nonessential nature of Tgs1p 
in budding yeast argues for functional redundancy or the lack of a strict need for 
the TMG cap in snRNA biogenesis. Recently it has been shown that Tgs1p is 
essential for meiosis in yeast, being responsible for the splicing of the SAE3 and 
PCH2 meiotic transcripts (Qiu et al. 2011).  
In higher eukaryotes, U1, U2, U4, and U5 snRNAs are transported to the 
cytoplasm after acquiring a m7G-cap (Hernandez 2001; Cougot et al. 2004). The 
Sm-proteins then assemble around the Sm-site (Plessel et al. 1994; Kambach et 
al. 1999b, 1999a), and are a requirement for TMG cap formation (Mattaj 1986; 
Plessel et al. 1994). The trimethylated cap and Sm-core then act as import 
signals for the snRNPs to return to the nucleus (Mattaj and De Robertis 1985; 
Hamm et al. 1990; Fischer et al. 1993; Palacios et al. 1997; Huber et al. 1998; 
Narayanan et al. 2002, 2004). In contrast, there is no evidence of a 
nucleocytoplasmic transport cycle for snRNAs in yeast or the export and import 
adaptors required for snRNA/snRNP shuttling. Additionally Tgs1p is localized in 
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the yeast nucleolus (Mouaikel et al. 2002), which is most likely where cap 
trimethylation takes place. 
One open question regarding snRNA trimethylation in yeast concerns 
Tgs1p target specificity. There is some evidence supporting Tgs1p targeting to 
snRNAs via protein-protein interactions with snRNP components (Mattaj 1986; 
Plessel et al. 1994; Mouaikel et al. 2002). More recently, Tgs1p has been found 
to interact physically and genetically with factors involved in splicing and RNA 
processing (Hausmann et al. 2008; Wilmes et al. 2008; Chang et al. 2010; Boon 
and Kos 2010). More specifically, large-scale two-hybrid screens and directed 
studies have identified the interacting partner Swm2p (synthetic with Mud2; Uetz 
et al. 2000; Yu et al. 2008; Chang et al. 2010; Boon and Kos 2010). The 
nonessential SWM2/YNR004W is an interesting gene that codes for a fairly 
poorly characterized small protein (17 kDa; 146 amino acids) that contains no 
recognizable domains (Volckaert et al. 2003) and has only three plausible fungal 
homologs (Wilmes et al. 2008). Of note, the deletion of TGS1 has a similar 
genetic interaction profile to SWM2 null cells (Wilmes et al. 2008), however 
SWM2 and TGS1 do not appear to genetically interact (Chang et al. 2010; Boon 
and Kos 2010). More recently it has been shown that Swmp2 interacts with the 
N-terminus of Tgs1p and that its deletion results in a loss of U3 and snRNA 
trimethylation, with no effect on a number of snoRNAs (Boon and Kos 2010). 
Additionally, those authors discovered that Tgs1p was required for nucleolar 
localization of Swm2p, but not vice versa. These findings lead to a hypothesis 
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that Swm2p may function as a specificity factor for Tgs1p by targeting it to the 
Pol II generated snRNAs. 
4.1.3 Experimental approach and rationale for SWM2 mutagenesis screen 
In our previously published screen of the yeast deletion collection with a 
gene expression reporter, we recognized that the deletion strain lacking SWM2 
had an increase in the pre-mRNA/mRNA ratio, indicating a potential splicing 
defect (Figure 2.3A; Sorenson and Stevens 2014). This sparked our interest 
since the majority of yeast splicing factors have been identified and scrutinized in 
detail. During the course of our initial work, two research articles shed light on the 
potential function of Swm2p (Chang et al. 2010; Boon and Kos 2010), but the 
molecular details behind this potential function were still unclear. With little idea 
of any functional domains or regions of interest within the SWM2 gene, we 
employed a standard mutagenesis approach coupled with our gene expression 
reporter to quickly and efficiently screen tens of thousands of mutants via 
fluorescence-activated cell sorting to identify functionally interesting mutants. Our 
efforts resulted in three swm2 mutants that had reproducible yet gene specific 
effects on pre-mRNA splicing and reduced interaction with Tgs1p. 
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4.2 MATERIALS AND METHODS 
4.2.1 Construction and culturing of yeast strains 
Standard yeast methods were used (Sherman 1991) and yeast were 
grown at 31°C unless otherwise noted. Yeast strains grown in 96-well plates for 
screening purposes were cultured in flat bottom 96-well plates (Corning) with 150 
µL of broth on a microplate shaker (VWR) at 2000 rpm. Yeast strains used in this 
chapter can be found in Table 4.1.  
To generate the genomic SWM2-TAP, strains were generated by 
homologous recombination. First, TRP1 was deleted from the wild-type BY4741 
strain (SS4004) using the MPY-URA3 replacement method (Schneider et al. 
1996) to generate the more versatile wild-type strain SS4019. Briefly, an MPY-
URA3 PCR fragment generated to target TRP1 (Plasmid MS112; Oligos 
MS216/217) was transformed via standard lithium acetate transformation (Geitz 
and Scheistel 1995). Transformants were selected in SD plates lacking uracil. 
Verified strains were then patched on YPD overnight, then streaked onto 
synthetic complete plates with 5-FOA to select for cells in which an MPY 
recombination event occurred, looping out the incorporated URA3 at the TRP1 
locus. The resulting strain SS4019 was transformed with TAP-tagging/truncation 
PCR products using template MS138 and oligos MS164-171 to generate C-
terminal truncation Swm2p-TAP strains SS4038-4044. The Swm2p-TAP clone 
from the TAP-tag collection was used for the full-length strain SS4037 (Howson 
et al. 2005). The mud2∆/swm2∆ strains (SS4147-4150) were obtained from 
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Beate Schwer (Chang et al. 2010). Plasmids and DNA oligonucleotide 
sequences used in strain construction can be found in Tables 4.2 and 4.3 
respectively. The swm2∆ Tgs1p-myc13 strain (SS4153) was made by 
homologous recombination of a PCR product using oligos MS656/657 and 
plasmid MS419. 
Table 4.1 Yeast strains used in Chapter 4 
Strain 
(SS) 
Mating 
type 
Genotype 
 
4004 a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 (BY4741) 
4019 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 (BY4741 trp1Δ) 
4037 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 SWM2-TAP-HIS3MX6 
4038 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 swm2-∆C15-TAP-
TRP1 
4039 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 swm2-∆C30-TAP-
TRP1 
4040 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 swm2-∆C45-TAP-
TRP1 
4041 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 swm2-∆C60-TAP-
TRP1 
4042 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 swm2-∆C75-TAP-
TRP1 
4043 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 swm2-∆C90-TAP-
TRP1 
4044 a his3Δ1 leu2Δ0 met15Δ0 trp1Δ ura3Δ0 swm2-∆C105-TAP-
TRP1 
4052 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2Δ::KanMX 
+ pRS316 TDH3-Reporter (MS127) 
4053 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2Δ::KanMX 
+ pRS316 TDH3-Reporter (MS127) + pRS415 SWM2-TAP 
(MS161) 
4059 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX 
4060 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 tgs1∆::KanMX 
4147 α his3∆1 leu2∆0 met15∆0 ura3∆0 
4148 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 mud2∆::natR 
4149 a his3∆1 leu2∆0 met15∆0 ura3∆0 swm2∆::kanR 
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(Table 4.1 continued) 
 
4150 α his3∆1 leu2∆0 met15∆0 ura3∆0 mud2∆::natR swm2∆::kanR 
4153 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX TGS1-
13myc::HIS3MX6 
4154 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX TGS1-
13myc::HIS3MX6 + pRS415 
4155 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX TGS1-
13myc::HIS3MX6 + pRS415 SWM2-TAP 
4156 α  his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX TGS1-
13myc::HIS3MX6 + pRS415 swm2-P4D9-TAP 
4157 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX TGS1-
13myc::HIS3MX6 + pRS415 swm2-P4E9-TAP 
4158 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX TGS1-
13myc::HIS3MX6 + pRS415 swm2-P4H7-TAP 
4159 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX + pRS415 
4160 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX + pRS415 
SWM2-TAP 
4161 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX + pRS415 
swm2-P4D9-TAP 
4162 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX + pRS415 
swm2-P4E9-TAP 
4163 α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 swm2∆::KanMX + pRS415 
swm2-P4H7-TAP 
4164 α his3∆1 leu2∆0 met15∆0 ura3∆0 mud2∆::natR swm2∆::kanR + 
pRS415 
4165 α his3∆1 leu2∆0 met15∆0 ura3∆0 mud2∆::natR swm2∆::kanR + 
pRS415 SWM2-TAP 
4166 α his3∆1 leu2∆0 met15∆0 ura3∆0 mud2∆::natR swm2∆::kanR + 
pRS415 swm2-P4D9-TAP 
4167 α his3∆1 leu2∆0 met15∆0 ura3∆0 mud2∆::natR swm2∆::kanR + 
pRS415 swm2-P4E9-TAP 
4168 α his3∆1 leu2∆0 met15∆0 ura3∆0 mud2∆::natR swm2∆::kanR + 
pRS415 swm2-P4H7-TAP 
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Table 4.2 Plasmids used in Chapter 4 
MS# 
 
Common Name 
 
Purpose Source 
102 pRS415 Yeast Expression 
Vector 
(Sikorski and 
Hieter 1989) 
112 pMPY-URA3 (pMPY-ZAP) Gene knockout via 
removable URA3 
(Schneider et al. 
1996) 
127 pRS316 TDH3-Reporter TDH3 driven reporter  This work.  
138 pBS1479 (TAP-TRP1) TAP tagging via 
TRP1 
(Puig et al. 
2001) 
159 TA SWM2-TAP Cloning SWM2-TAP This work 
161 pRS415 SWM2-TAP Parental SWM2-TAP 
plasmid 
This work 
395 pRS415 swm2-P4D9-TAP swm2 mutant from 
screen 
This work. 
396 pRS415 swm2-P4E9-TAP swm2 mutant from 
screen 
This work. 
397 pRS415 swm2-P4H7-TAP swm2 mutant from 
screen 
This work. 
419 pFA6a 13myc-His3MX6 C-terminal myc 
tagging vector 
(Longtine et al. 
1998) 
Table 4.3 DNA oligonucleotides used in Chapter 4 
# 
 
Sequence  
(5’ to 3’) 
Purpose 
 
129 CCTGTTATCCCTAGCGGATCTG GFP/TAP-ADH1term PCR3 
154 TAAAACCTATAGAAACTCCTTC SWM2 PCR5 
155 TTAATGATGAACTCGAAAGAGC SWM2 PCR3 
164 GGAATTTGACGAATTTGGTAAACTC
ATAAGTAATCCATTAGAGTCCATGG
AAAAGAGAAG 
SWM2del15 TAPA 
165 TGAGATTGATGTCTCATATGTTAAG
AATTTGAATGTAGTCAGGTCCATG
GAAAAGAGAAG 
SWM2del30 TAPA 
166 TAAAAAGTTGAAGGATCCTCCGCC
TGCTGATAATATCATTAAGTCCATG
GAAAAGAGAAG 
SWM2del45 TAPA 
167 AAGAAGATGCCTTAACCTGTGGTA
TGTTTTGAAGGGCAAGGAATCCAT
GGAAAAGAGAAG 
SWM2del60 TAPA 
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(Table 4.3 continued) 
 
168 TAAATGGAACGAAGAAGGTGCGAA
GACAGTCAATCCGGAAATTTCCAT
GGAAAAGAGAAG 
SWM2del75 TAPA 
169 ACATTTAAAGTCTAGAGCTCTAAAA
ATTTGTCGTTCTAATTTCTCCATGG
AAAAGAGAAG 
SWM2del90 TAPA 
170 CTCCGCAGTATTGGAGCCATATTTT
CAGAATATAGCAAGAAATTCCATG
GAAAAGAGAAG 
SWM2del105 TAPA 
171 AAAGCTAAAAGGTAGGCTCCGTGC
ATATTAGATGAGTGAACACTACGA
CTCACTATAGGG 
SWM2 TAPB 
178 AACTCCTTCATATAAAATGTACTAG SWM2 mut PCR fwd 
179 CCATGGATTAATTAACCCGGGGAT
C 
SWM2 mut PCR rev 
216 TATTGAGCACGTGAGTATACGTGA
TTAAGCACACAAAGGCAGCTTGGA
GTAGGGAACAAAAGCTGG 
TGS1-MPY URA3 UP 
217 TGCAGGCAAGTGCACAAACAATAC
TTAAATAAATACTAC 
TCAGTAATAACCTATAGGGCGAATT
GG 
TGS1-MPY URA3 DOWN 
282 CCATTGTCACTCTAGATGTCAAGC
C 
TEF5 total FWD qPCR 
283 GATACCGAAACCAATTGGGATAAA
T 
TEF5 total REV qPCR 
299 NNNNNNNNG NonamerG for RT 
300 NNNNNNNNA NonamerA for RT 
301 NNNNNNNNT NonamerT for RT 
302 NNNNNNNNC NonamerC for RT 
313 GATAGCACAGAGCAGAGTATCATT
A 
TEF5intFWDjp qPCR 
314 CTGGAGAATTCTGGGTAAGCAGAT
T 
TEF5intREVjp qPCR 
584 ACAGAATAACGAACCAAATTACTAA
CAGT  
DBP2intFWDms qPCR 
585 CCTGGCATATCGTAGTTGATAACG DBP2intREVms qPCR 
586 CTTCACCGAACAAAACAAAGGTT DBP2exonFWDms qPCR 
587 TCGGGAGGAATATTTTGATTAGCT DBP2exonREVms qPCR 
606 GGGAAAATCAGCGTATGTAAAGC SRB2 pre-mRNA FWD qPCR 
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607 GAGTGGCTCTTTCCACGAATATAA SRB2 pre-mRNA REV qPCR 
608 CATCGAAGGACACCTAGCTGAA SRB2 total FWD qPCR 
609 TCCGGCCCCAACGAG SRB2 total REV qPCR 
624 CAAATAGGGTGGGACCAACA RPS21B pre-mRNA FWD qPCR 
625 TCAGGTAACACTTGTGCCAAT RPS21B pre-mRNA REV qPCR 
626 ATCCAGAGGTGAATCCGATG RPS21B total FWD qPCR 
627 AACGACTTCCCCTCTTCTTTTT RPS21B total REV qPCR 
640 GACCCAGGAAAGCATCTTAC snR4 Northern 
645 GATAGTATTAACCACTACTG snR37 Northern 
646 GAATGGAAACGTCAGCAAACA U1 Northern (snR19) 
647 AAAAGAACAGATACTACACTTGA U2 Northern (LSR1) 
648 ACCATGAGGAGACGGTCTGG U4 Northern (snR14) 
649 ACACCCGGAATGGTTCTGGTA U5 Northern (snR7-S/L) 
650 AACGAAATAAATCTCTTTGTAAAAC U6 Northern (snR6) 
656 GACCAAAGATAATACTGTAGACATT
TACGACGTAAATGGTCGGATCCCC
GGGTTAATTAA 
TGS1 F2 
657 CATTGCATTTTCTATCATACGATTC
AACTTGAACAAGTGTGAATTCGAG
CTCGTTTAAAC 
TGS1 R1 
4.2.2 SWM2 cloning and plasmid generation 
The SWM2-TAP open reading frame, along with its native promoter, was 
amplified using genomic DNA from the corresponding tap collection strain 
(Howson et al. 2005) and primers MS129/154, cloned and sequenced verified in 
a cloning vector (pGEM-T Easy; Promega; MS159), then cloned into pRS415 
using NotI, resulting in pRS415 SWM2-TAP (MS161). Site-directed mutagenesis 
was used to introduce individual point mutants. Plasmids and DNA 
oligonucleotide sequences can be found in Tables 4.2 and 4.3 respectively. 
 175 
4.2.3 Generation of swm2 mutant pool 
To generate random swm2 mutants, 1 ng pRS415 SWM2-TAP (MS161) 
was used with 1 µM primers MS178/179 for mutagenic PCR (Beckman et al. 
1985; Cadwell and Joyce 1992) with Taq Polymerase (NEB; 1 unit), 300 µM 
MnCl2, 1 mM dNTPs, and 1X NEB Thermo Pol Buffer. After 18 cycles the PCR 
product was gel purified and transformed into swm2Δ yeast (with pRS316 GPD-
Reporter) alongside restriction enzyme (NdeI and NsiI) treated/gel purified 
MS161 for gap-repair (Gietz and Schiestl 2007; Lundblad and Struhl 2008). 
During optimization, random mutant clones were analyzed to verify a mutation 
rate of about 1.5 nucleotide substitutions per SWM2 open reading frame. Over 
20,000 transformants were obtained on synthetic media lacking leucine and 
uracil, pooled, and then used to inoculate a culture to screen via FACS 
(remaining mutant pool was cryopreserved).  
4.2.4 Mutagenesis screen using reporter and FACS 
 For fluorescence-activated cell sorting, WT cells (swm2Δ + pRS415 
SWM2-TAP and pRS316 GPD-Reporter) were used to determine gating 
boundaries. Immediately before sorting, the mutant pool (grown to OD (A600) 0.5) 
was resuspended in sterile 1X PBS. A FACSAria (Becton Dickinson) was used to 
sort 37K red-shifted cells into synthetic media lacking leucine and uracil. 2000+ 
mutants were plated for individual colonies. Once grown, single clones were 
transferred to 96-well plates for storage and subsequent high-throughput flow 
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cytometry analysis to identify mutant clones that were reproducibly and 
significantly red-shifted. Expression of Swm2p-TAP was verified by western blot 
analysis. SWM2 plasmids from clones of interest were isolated using the 
Zymoprep Yeast Plasmid MiniprepII kit (Zymo) after shuffling out the URA3 
reporter with 5-fluoroorotic acid. Isolated plasmids were transformed into E. coli, 
sequence verified, and retransformed into swm2Δ yeast with the pRS316 GPD-
Reporter to verify effect. 
4.2.5 Western blot analysis 
 Protein samples were separated on PAGE gels and transferred to 
nitrocellulose. Membranes were blocked with BLOTTO (PBST + 5% SDS) and 
probed with 1:5000 peroxidase anti-peroxidase antibody (Rockland) for the TAP 
tag. Probing for the 13myc tag was performed with 1:2500 anti-c-myc purified 
from Myc 1-9E10.2 (ATCC CRL-1729) followed by 1:5000 goat anti-mouse with 
HRP (Rockland 610-1302). Washes were preformed with PBST and visualized 
using X-ray film using chemiluminescence (Perkin Elmer). For the TAP 
coimmunoprecipitations chemifluorescence reagent was used (GE, ECL Plus) 
and signals were detected using a GE Typhoon scanner. Quantification of TAP 
and myc signals was performed using ImageQuant (GE Healthcare) with 
background subtraction. 
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4.2.6 Trimethylguanosine immunoprecipitation 
Immunoprecipitation for 2,2,7-trimethylguanosine (TMG) capped RNA was 
performed using pulverized cell material in 1 mL/g AGK (10 mM HEPES pH 7.9, 
1.5 mM MgCl2, 200 mM KCl, 8% glycerol). About 1 gram of extract was thawed 
on ice (added 1 µM BME, 0.4 mM PMSF, 5 µM leupeptin, and 3 µM pepstatin) 
and cleared by centrifugation (20 minutes, 14,000 x g, 4°C) in a microfuge tube. 
100 µL cleared extract was transferred to a microfuge tube with 5 µL α-TMG 
antibody (K121, Santa Cruz) and rotated for 1 hour at 4°C. The extract/antibody 
mixture was transferred to a tube containing 25 µL pre-washed Protein G 
agarose beads (50 µL slurry, Invitrogen, washed with AGK) and rotated for 2 
hours at 4°C. Samples were centrifuged (3 min., 3000 x g, at 4°C) and the 
supernatant was removed (saving 10 µL). Beads were quickly washed two times 
with 1 mL AGK, and washed a third time for 10 minutes with rotation at 4°C. After 
beads were centrifuged and wash was removed, 100 µL AGK was added to the 
beads (90 µL AGK was added to 10 µL samples of cleared extract and 
supernatant). Two phenol chloroform extractions were preformed and the RNA 
was precipitated overnight at -20°C with sodium acetate and ethanol (glycogen 
added to IP samples). RNA was washed twice with cold 70% ethanol, dried, and 
resuspended in DEPC ddH2O (15 µL for IP and 30 µL for total and supernatant). 
3 µL RNA was used for northern blot analysis. 
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4.2.7 Northern blot analysis  
Equal volumes of RNA and 8M Urea RNA loading buffer (8M urea, 20 mM 
EDTA pH 8.0, 2 mM Tris pH 7.5, 1.68 mg/mL xylene cyanol, 0.56 mg/mL 
bromophenol blue) were heated at 65°C, then electrophoresed in a 7% 19:1 
polyacrylamide gel (8M urea 1X TBE) for 1 hour and 45 minutes at 25 mA. RNA 
was then transferred to a nylon membrane (Whatman) via downward capillary 
transfer (0.01 N NaOH and 3 M NaCl). After crosslinking by UV light (254 nm for 
1 minute) the membrane was probed with 500,000 counts 32P-γ end-labeled DNA 
(boiled immediately prior to addition; see Table 4.3 for DNA oligos) in Church 
Buffer (500 mM Na2HPO4 pH 7.0, 7% SDS, 1 mM ETDA pH 8.0) overnight. The 
blot was then exposed to a phosphorimaging screen and developed in a 
phosphorimager. Quantification of specific signals was performed using 
ImageQuant (GE Healthcare) with background subtraction. IP efficiency was 
calculated by normalizing IP signals to the total signal for each RNA species and 
then calculating efficiency relative to wild-type.  
4.2.8 TAP coimmunoprecipitation  
The procedure for TAP coimmunoprecipitation was based on the original 
work describing the TAP purification method (Puig et al. 2001). Briefly, 500 mL to 
1 L of cells were grown to OD (A600) 0.8 to 1.0 and frozen in 1 mL/g AGK (10 mM 
HEPES pH 7.9, 1.5 mM MgCl2, 200 mM KCl, 8% glycerol). After cryogenically 
pulverizing the material, about 1.25 grams of extract was thawed on ice in a 
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microfuge tube (added to 1 µM DTT, 0.4 mM PMSF, 5 µM leupeptin, and 3 µM 
pepstatin). Proteins were extracted by rotation at 4°C for 30 minutes. The extract 
was then cleared by centrifugation (20 minutes, 14,000 x g, 4°C). 500 µL cleared 
extract (normalized by OD (A595) via Bradford assay) was transferred to a tube 
with 25 µL pre-washed IgG sepharose resin. 50 µL cleared extract was saved for 
“total” sample. The extract and resin were rotated for 1-2 hours at 4°C. 50 µL 
from the supernatant was saved for the “supernatant” sample after centrifuging 
3000 x g for 3 minutes. Resin was then washed four times with 1 mL IPP150 (10 
mM Tris, pH 8.0, 150 mM NaCl, 0.1% NP-40, 1.5 mM MgCl2, 8% glycerol, 1 mM 
DTT) at 3000 x g. The bound proteins were eluted by boiling in 2X LDS + 200 µL 
DTT and saved for western blot analysis. For the total and supernatant samples, 
50 µL of AGK was added and a phenol chloroform extraction was done, 
precipitating the organic phase overnight at -20°C with ice-cold acetone. 
Precipitated proteins were washed twice with 80% ice-cold EtOH, dried on the 
bench, then resuspended in 100 µL 2X LDS + 200 µL DTT. 30 µL of total and 
supernatant, and 1 µL IP (+ 19 µL loading buffer) were used for western blot 
analysis.  
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4.3 RESULTS 
4.3.1 Rapid mutagenic screen of SWM2 using our gene expression reporter 
and FACS 
Our experimentation began by performing a mutagenic screen of SWM2 
utilizing standard error-prone PCR and gap-repair methods within a yeast strain 
lacking SWM2 and harboring our gene expression reporter. Our efforts resulted 
in over 20,000 transformants/clones that were pooled and subsequently 
analyzed. When pre-mRNA splicing is impaired, such as in the case of swm2Δ 
(Figure 4.1A), there is an increase in the mCherry/GFP ratio within cells, shifting 
the population of cells toward the y-axis (mCherry) of our standard flow cytometry 
phenographs (GFP on x-axis). We used the gene expression reporter 
phenographs of wild-type cells and swm2Δ cells to determine the gating 
boundaries for the mutant pool (Figure 4.1A). Our goal was to sort mutant clones 
that were red-shifted, which would indicate impairment of pre-mRNA splicing or a 
related process (Sorenson and Stevens 2014). It was not surprising that very few 
cells within the mutant pool fell within this gate (right panel of Figure 4.1A), since 
most mutations would not likely negatively affect the function of Swm2p. This 
being said, we gated 0.4% of the population that fell into this gate and obtained 
more than 37,000 clones of interest within 15 minutes, most of which were 
cryopreserved for future analysis. In all over 10 million yeast were analyzed 
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which excessively, yet effortlessly, covered our original mutant pool of 20,000 
clones 500 times over. 
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Figure 4.1: Deletion and mutation of SWM2 results in quantifiable reporter 
phenotypes. 
(A) Phenograph overlay is shown with wild-type (red) cells in the background and 
either swm2Δ or pooled mutant cells (blue) in the foreground. All cells are 
expressing the gene expression reporter. The black open triangle in the right 
panel indicates the gate used to sort potential swm2 mutants of interest. 8000 
cells are shown for each dataset. (B) Binning and clustering analysis of reporter 
flow cytometry data from several hundred swm2 mutants and controls (wild-type, 
swm2Δ, xrn1Δ, and prp18Δ). Controls and clones of interest are labeled. 
Numbers in parentheses refers to the class of swm2 mutant and these samples 
are visualized in panel C. (C) Representative sample phenographs from the five 
arbitrary classes of mutants (labeled with blue number), 1 having little to no effect 
and 5 being similar to swm2Δ. 
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4.3.2 Analysis, validation, and characterization of swm2 mutants 
To determine which of the sorted clones had a reproducible and significant 
effect on reporter expression, we isolated individual clones and stored them in 
specific wells within 96-well plates, alongside controls of wild-type SWM2 and 
empty vector (swm2Δ). Several hundred clones were selected and analyzed via 
high-throughput flow cytometry in this secondary screen. We were able to 
classify the mutants into five arbitrary classes; class 1 having no effect, up to 5 
having a phenotype similar to swm2Δ cells. Clones were evenly dispersed 
between these groups and we were encouraged that many had a significant 
effect on reporter expression. To analyze these several hundred clones in a more 
systematic manner, we used our binning and clustering algorithm, CHUBACA, 
resulting in a dendrogram that essentially grouped clones with similar 
phenographs (Figure 2.1B). Representative phenographs from the analysis are 
shown in Figure 2.1C, covering the five previously described arbitrary classes of 
mutants.  
We observed nearly one-third of the mutant clones clustering in a large 
group near the top that contained the wild-type controls (Figure 2.1B). Most 
clones in this clade were classified as 1 and 2, reflecting a minor or insignificant 
effect on reporter expression. The large cluster near the bottom of the 
dendrogram primarily contained class 4 and 5 mutants, along with the swm2Δ 
controls. The relatively smaller clade in the middle consisted of class 2 and 3 
mutants that had an intermediate effect (i.e. P1E11, P4H07, and P1C06). To 
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monitor clustering behavior, we also incorporated data from xrn1Δ and prp18Δ 
cells as green- and red-shifted bootstrap controls respectively (Larimer et al. 
1992; Vijayraghavan et al. 1989). Altogether we trust that our analysis effectively 
grouped mutant clones into groups based on the reporter phenotypes. 
It was very encouraging to have many clones display significant effects on 
our gene expression reporter. With any random mutagenesis approach, there is 
the possibility of generating mutants that result in premature stop codons or 
destabilization of the resulting polypeptide. To quickly identify such mutants, we 
performed numerous western blots, probing for the C-terminal TAP tag on 
Swm2p (Figure 4.2). Approximately 20% of the nearly 80 sampled clones had no 
detectable levels of Swm2p while 30% had reduced levels. Ten non-expressing 
clones were sequenced and 8 contained premature stop codons while 2 were 
expected to produce full-length protein. Not surprisingly, the majority of the 
clones without detectable levels of Swm2p were previously identified as class 4 
or 5 by the reporter phenotype, mimicking a swm2Δ situation.  
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Figure 4.2: Identification of high-confidence swm2 mutants. 
(A) Western blot analysis of Swm2p-TAP expression levels. All clones, including 
controls, were plasmid based and in the swm2Δ strain. Peroxidase anti-
peroxidase antibody was used to probe for the C-terminal TAP tag on Swm2p 
(EV, empty vector; L, Precision Plus Protein Dual Color Standard). Western blots 
were performed for nearly 80 clones.  
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For class 2 to 5 clones expressing wild-type-like levels of Swm2p, I 
isolated the SWM2-TAP plasmid and reintroduced them into the original swm2Δ 
strain with reporter and analyzed reporter expression and Swm2p levels. This 
served to verify that the resulting effect on reporter expression was most likely 
due a mutation of the plasmid borne SWM2 and not a genomic mutation or other 
deleterious occurrence. Out of the 20 clones I attempted to verify, 14 retained a 
reporter phenotype when reintroduced into yeast (Figure 4.3A). Only 4 of the 14 
expressed wild-type-like levels of Swm2p when retransformed (Figure 4.3B), 
which was surprising since they all expressed well in earlier rounds. To rule out 
the possibility that multiple SWM2 plasmids were in these clones, additional 
clones from these were analyzed, but none showed increased expression (data 
not shown). In further analysis of the four highly expressing mutants, I found that 
clone P1A05 had a non-reproducible reporter phenotype and was discarded for 
this reason. The three stared mutants in Figure 4.3B were selected for 
subsequent analysis. 
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Figure 4.3: Characterization of retransformed swm2 mutant clones. 
(A)	   Gene expression reporter phenographs for retransformed swm2 mutant 
clones (blue), overlaid onto data from wild-type cells (red). Yellow starred clones 
were validated in panel B. (B) Western blot analysis of Swm2p-TAP from 
indicated clones. Peroxidase anti-peroxidase antibody was used to probe for the 
TAP tag on Swm2p (EV, empty vector). Clones with yellow stars indicate clones 
that were highly expressed and thus validated as high confidence mutants. 
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In Figure 4.4A, the mutations for the three high-confidence hits are 
mapped to the primary structure of Swm2p for the three verified clones, P4D09, 
P4E09, and P4H07, which had 5, 3, and 6 amino acid substitutions respectively. 
Reporter phenograph overlays for these mutants are shown in Figure 4.4B and 
retain a class 2 or 3 like phenotype. Although there were more mutations than we 
had hoped for, we were encouraged that half of these mutations were in the C-
terminal portion of Swm2p. This agrees with reporter expression data from C-
terminal truncations of Swm2p, in which I noticed increasing mCherry/GFP ratios 
as subsequent 15 amino acid portions are deleted, reaching a similar ratio as 
swm2Δ between truncations of 30 and 45 amino acids (Figure 4.5). Of note, 
truncations of more than 45 amino acids result in drastically reduced or abolished 
signal when soluble proteins are analyzed by western blot (Figure 4.5C; Yaffe 
and Schatz 1984).  
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Figure 4.4: Amino acid substitutions in the three high-confidence swm2 mutants 
cluster towards the C-terminus of Swm2p. 
(A) Mapping point mutations in the three verified clones P4D09, P4E09, and 
P4H07. The three rows contain the mutations specific to the clone labeled to the 
left and color-coded while specific positions are depicted on the top of the 
cartoon and color-coded. (B) Gene expression reporter phenographs for swm2Δ 
and the three verified high-confidence mutants (blue), overlaid onto data from 
wild-type cells (red). 
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Figure 4.5: C-terminal truncations of Swm2p result in an increase of the 
mCherry/GFP reporter signal ratio. 
(A) The cartoon is depicting the truncations made by genomic C-terminal TAP 
tags on Swm2p. The amino acid position/numbers are labeled on the top while 
the C-terminal truncation size is indicated below. (B) Western blot analysis of 
Swm2p C-terminal truncations. Labels continue from panel A (FL, full length 
Swm2p-TAP; -, untagged BY4741). Peroxidase anti-peroxidase antibody was 
used to probe for the TAP tag on Swm2p. Nonspecific background band is 
indicated with the small black arrow. (C) Reporter expression ratios of Swm2p 
truncations and deletions. Reporter expression values (GFP and mCherry) were 
determined by taking the mean values for the 21,000 cells analyzed. The 
mCherry/GFP ratio (pre-mRNA/mRNA) was calculated and made relative to the 
untagged strain. Error bars represent the standard deviation of three biological 
replicates. Dashed lines are used to align the samples with the western blot for 
interpretation. 
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4.3.3 Mutations of Swm2p result in gene-specific pre-mRNA splicing 
defects 
I identified three mutants with a reproducible red-shifted reporter 
phenotype, but wanted to determine if there were splicing defects of endogenous 
introns. To reach this goal, I performed RT-qPCR analysis of the splicing 
efficiency of four endogenous introns using total RNA from wild type, swm2Δ, 
and swm2 mutant strains. When analyzing the data, I observed gene-specific 
effects on pre-mRNA splicing (Figure 4.6). For RPS21B, all three swm2 mutants 
have elevated pre-mRNA/total ratios that are similar to the knockout mutants 
(swm2Δ). In contrast, for SRB2 and TEF5 splicing, the mutants have muted yet 
fairly similar splicing defects to each other when compared to swm2Δ. Standing 
out is DBP2, in which I detect swm2Δ-like splicing defects for swm2-P4D9 and 
swm2-P4H7, yet no measurable splicing defect for swm2-P4E9. It is very 
interesting that we observe such a diverse range of splicing phenotypes for the 
three mutants across each of these introns. I attempted to dissect the three 
mutants in order to find the individual point mutants or groups of mutants that 
contributed to the splicing defects observed, but none presented comparable 
effects (data not shown). We chose to continue characterizing the three parental 
mutants based on these findings. 
 
  
 192 
 
Figure 4.6: swm2 mutants exhibit gene-specific pre-mRNA splicing defects. 
RT-qPCR analysis was performed using total RNA from the indicated strains 
(SS4159-4163) for the specified intron/gene. Primers for qPCR are described in 
Table 4.3. The quantities of pre-mRNA and total transcripts were quantified using 
a standard curve and ratios are relative to the wild-type control (SWM2-TAP). All 
strains are based off the swm2Δ strain with pRS415-derived vectors and grown 
in synthetic medium lacking leucine. Error bars represent the standard error 
between biological triplicates. 
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In identifying gene-specific pre-mRNA splicing defects in the swm2 mutant 
strains, we were interested in knowing if these mutants had any affect on growth 
rate. Although the swm2Δ strain does not have any obvious growth defects, it 
does have a synthetic growth defect with mud2Δ (Chang et al. 2010), which 
codes for a U1 snRNP component (Liao et al. 1993; Abovich et al. 1994; Rutz 
and Séraphin 1999). This synthetic growth phenotype is also seen when Swm2p 
is lacking from strains with mutations of the splicing factors Brr1p, Cwc21p, 
Dbr1p, Mud2p, Prp42p, Snu56p, and Snu66p (Wilmes et al. 2008; Chang et al. 
2010). To test these three mutants for synthetic growth defects, I first verified the 
mud2Δ swm2Δ synthetic growth defect that had been previously reported. As 
seen in Figure 4.7A, the mud2Δ swm2Δ strain has a synthetic growth defect at 
low, permissive and high temperatures when compared to the single-mutant and 
wild-type cells, with the largest difference at the elevated temperature. When 
empty, wild-type, and the mutant swm2 plasmids were introduced into the mud2Δ 
swm2Δ strain and tested on minimal media at the same temperatures, there 
were no discernible growth defects for the double deletion or any of our mutants 
combined with mud2Δ (Figure 4.7B). It does appear that the four strains with a 
version of SWM2 slightly complement growth at 37°C. 
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Figure 4.7: swm2 mutants do not exhibit synthetic growth defects with mud2Δ on 
minimal media. 
Serial dilutions of the indicated strains (labeled to the left) were made and 
spotted onto rich (YPD) or minimal (SD – leu) media and incubated at three 
different temperatures (31°C is permissive). Strains SS4147-4150 were used in A 
and strains SS4164-4168 were used in B. 
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4.3.4 Partially reduced trimethylation of snRNAs in swm2 mutants 
With gene specific pre-mRNA splicing defects in our swm2 mutants and 
previous reports describing reduced snRNA trimethylation in swm2Δ cells (Boon 
and Kos 2010), we wanted to test whether our mutants resulted in reduced 
snRNA trimethylation when compared to wild-type cells. To verify the published 
results and to establish the assay in our laboratory, anti-trimethylguanosine 
antibody was used in immunoprecipitations from extracts derived from wild-type, 
swm2Δ and tgs1Δ cells. As we expected, there is a complete loss of 
trimethylation of the spliceosomal snRNAs and snoRNAs in the cells lacking the 
trimethylguanosine synthase Tgs1p (tgs1Δ; Figure 4.8A; IP lane). Agreeing with 
the previously published results (Boon and Kos 2010), I also observed a specific 
reduction of snRNA trimethylation in swm2Δ cells (Figure 4.8A).  
I then repeated this assay with the three swm2 mutants and observed 
varying degrees of snRNA trimethylation (Figure 4.8B). In calculating IP 
efficiency, there are clear differential effects on snRNA trimethylation. Across the 
board, U5L snRNA trimethylation is reduced by about 20%. Although the mutants 
do not have consistent loss of specific snRNA trimethylation, they each have 2 or 
3 that are significantly reduced. These results describe the steady state of 
snRNA trimethylation, which might hide any slight defects in snRNA maturation 
since spliceosomal snRNAs have a half-life of many hours (Stutz et al. 1993; 
Noble and Guthrie 1996). 
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Figure 4.8: swm2 mutants exhibit intermediate trimethylated-snRNA levels. 
Immunoprecipitations using anti-trimethylguanosine antibody (K121) were 
performed with the strains labeled at the top of the lanes. The resulting RNA 
samples were precipitated and ran on a 7% acrylamide gel. After transfer the 
blots were probed for the indicated RNAs using end-labeled DNA probes (A and 
B; see Table 4.3 for sequences). For panel B, all strains used the swm2Δ 
background with empty vector (-), wild-type (WT) SWM2 or mutant swm2 
(SS4159-4163). (C) IP efficiency was calculated by quantifying the respective IP 
bands, normalizing to the total signal, and made relative to wild-type SWM2. 
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4.3.4 Swm2p mutants have reduced interaction with Tgs1p  
It was previously mentioned that Swm2p interacts with the 
trimethylguanosine synthase Tgs1p in yeast cells (Boon and Kos 2010). If 
Swm2p is acting as a specificity factor for Tgs1p by directing them to snRNAs, it 
is possible that the three mutants we have identified have reduced interaction 
with Tgs1p. To test this possibility I genomically 13myc-tagged Tgs1p in a 
swm2Δ strain. I then introduced empty vector, wild-type and mutant Swm2p-TAP 
vectors and prepared extract. A TAP coimmunoprecipitation was performed and 
western blot analysis was used to identify both the bait (Swm2p-TAP) and 
Tgs1p-13myc (Figure 4.9). It was obvious that the levels of bait differed between 
the samples so I used the bait signal to normalize the bound myc signal. When 
looking at the IP efficiencies, we observed that Tgs1p-myc immunoprecipitated 
with efficiencies of 57-65% with the mutants compared to wild-type Swm2p. 
These results support a model in which Swm2p interaction with Tgs1p could be 
important for efficient pre-mRNA splicing, although further experimentation is 
needed to elucidate the exact mechanism by which this might occur. 
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Figure 4.9: Coimmunoprecipitations reveal decreased affinity of Swm2p mutants 
for Tgs1p. 
TAP coimmunoprecipitations were performed using IgG sepharose and extract 
from a swm2Δ Tgs1p-13myc strain with the indicated vectors (EV, empty vector; 
strains SS4154-4158). Protein samples were separated in a SDS-PAGE gel and 
transferred to nitrocellulose. Western blot analysis was performed with anti-myc 
and anti-TAP antibodies and chemifluorescence reagents. All blots were 
performed on the same membrane, separated to remove control lanes and adjust 
exposure. The levels of bait (Swm2p-TAP) were quantified and normalized (to 
wild-type) levels are reported below the anti-TAP blot. The myc signals for 
Tgs1p-myc were then quantified. Immunoprecipitation efficiency was calculated 
by dividing the myc signal by the bait levels, making the values relative to wild-
type. The normalized IP efficiencies are reported below the anti-myc blot for the 
bound fraction. 
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4.4 DISCUSSION  
When we began our inquiry into YNR004W/SWM2, little was known about 
its function, except that it had a similar genetic interaction profile to TGS1 and 
that its deletion resulted in a similar splicing phenotype to tgs1Δ at decreased 
temperature when using splicing-specific microarrays (Wilmes et al. 2008). 
Additionally, high-throughput protein interactions studies identified Swm2p and 
Tgs1p as interacting partners (Uetz et al. 2000; Yu et al. 2008). With no 
recognizable motifs or domains, we decided to perform a random mutagenesis 
screen to identify mutants that affected its function. By combining the standard 
gap-repair method with our reporter and fluorescence-activated cell sorting, we 
quickly identified three mutants of Swm2p with multiple point mutations that 
elicited gene-specific splicing defects of endogenous introns (Figure 4.6). 
Additionally, these three mutants appear to have significantly reduced interaction 
with Tgs1p (Figure 4.9), and slightly reduced levels of trimethylated snRNAs 
(Figure 4.8). 
As discussed earlier, the relatively small effect on snRNA trimethylation 
might not be an accurate representation of Swm2p’s importance in this role since 
snRNAs are believed to be very stable (Stutz et al. 1993; Noble and Guthrie 
1996). A significant effect on snRNA trimethylation could be masked by 
increased stability of the trimethylated species compared to the unmodified 
species. One way to look at this more closely would be to combine a pulse-chase 
type of approach with the TMG immunoprecipitation experiment to query the 
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mutant’s effect on de novo snRNA trimethylation using labeled S-adenosyl 
methionine. Additionally, the TMG immunopreciipations and Swm2p/Tgs1p 
coimmunoprecipitations are in the process of being repeated multiple times to 
determine the reproduciblilty of these results. 
In the course of characterizing the swm2 mutants from the screen, one 
problem I encountered was a large number of clones that were not expressing 
wild-type levels of Swm2p when using western blot techniques to screen them. 
Although destabilizing and truncation mutants are a common occurrence in 
mutagenesis screens such as ours, it would be advantageous to quickly 
eliminate or flag these mutants. One possible solution would be to replace the 
TAP tagged I used with a fluorescence tag that is distinguishable from GFP and 
mCherry by flow cytometry. The researcher could then gate the cells based on 
this initial fluorescence parameter to identify clones that are adequately 
expressing the protein of interest. This method could radically decrease the 
number of false positive hits produced in this type of screen. In screening over 10 
million cells in the FACS sort, we were not surprised that a handful of clones did 
not result in a reporter phenotype when tested further. With this number of 
clones, we could have inadvertently isolated genomic mutations that resulted in a 
red-shift. 
When dissecting the individual point mutants and groups of point mutants 
from the three isolated mutants, I did not observe phenotypes similar to the 
parental/original mutants. Since I observed both the amino acid substitutions 
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clustering towards the C-terminus of the protein (Figure 4.4A), and the 
detrimental effect of truncating the C-terminus of Swm2p (Figure 4.5C), it would 
be potentially advantageous to start at the C-terminus and combine the individual 
point mutants. I would predict that this combined mutant, which would include 
multiple charge changes, would interfere with protein-protein interactions.  
 One unexpected result was the lack of synthetic growth defects on 
minimal media with the mud2Δ swm2Δ (Figure 4.7B). This was surprising 
because we verified the strong synthetic growth defect on rich media (Figure 
4.7A). Even though the SWM2 and swm2 mutant plasmid appear to slightly 
complement the double deletion at elevated temperatures, I expected to see a 
much larger difference. The strong negative genetic interaction could also be a 
great tool to screen future mutants, if we are able to develop a working situation 
to observe growth phenotypes. Additionally, it would be advantageous to use 
such a situation to also test the swm2 mutants for genetic interactions with 
splicing factor deletions or conditional splicing mutations to further discern the 
function of Swm2p.  
 Since it appears that Swm2p is instrumental in snRNA trimethylation, I 
tested whether Swm2p-TAP can isolate snRNAs. Compared to a positive control 
of the snRNP component Smb1p, Swm2p and mutants purified near background 
levels of snRNAs (data not shown). This would be worth testing again since there 
was excessive background. Moreover, it would be worthwhile to see what 
additional proteins, besides Tgs1p, that Swm2p interacts with using mass 
 202 
spectrometry or a candidate approach with snRNA biogenesis or splicing factors. 
With Swm2p’s function in hypermethylation specificity, it is likely that its 
interaction with Tgs1p is transient and not stable. Additionally, Tgs1p has been 
shown to isolate U4 and U5 snRNAs (Mouaikel et al. 2002, 2003), and it would 
be worthwhile to test this interaction in the context of our mutants to determine if 
Swm2p mediates this interaction. Since the nucleolar localization of Swm2p is 
dependent on Tgs1p, and not vice versa (Boon and Kos 2010), it is expected that 
our mutants might be mislocalized since they have reduced Tgs1p.  
 Altogether our data support a model in which Swm2p interacts with Tgs1p 
and directs hypermethylation of snRNA caps. One outstanding question is how 
Swm2p specifically targets Tgs1p to the snRNAs. Since I did observe above 
background levels of snRNAs immunoprecipitating with Swm2p, it is possible that 
Swm2p directly or indirectly binds to snRNAs or snRNPs. As there are no 
reported physical interaction candidates, we could directly test for physical 
interaction with snRNP components, potentially focusing on splicing factor genes 
with genetic interactions with SWM2 (many negative interactions). It is interesting 
that the limited number of positive genetic interactions are mostly genes coding 
for nucleolar localized components, or genes involved in rRNA biogenesis, 
mRNA export or mRNA degradation. The most striking negative genetic 
interaction that has been reported for SWM2 is MUD2, which codes for a protein 
that directly binds the intron branchpoint and interacts with U1 snRNP early on in 
spliceosome formation (Abovich et al. 1994; Rutz and Séraphin 1999). It is 
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possible that Swm2p has a role with Mud2p or trimethylation of snRNAs is 
particularly important when Mud2p is absent, as a mud2Δ tgs1Δ mutant is 
inviable (Hausmann et al. 2008; Benarroch et al. 2009; Chang et al. 2010). 
Although I did not notice any particular features of the branchpoints that correlate 
with the gene specific splicing defects we observed (Figure 4.6). I am also in the 
process of testing a tgs1Δ mutant with our RT-qPCR assay looking at the splicing 
efficiency of the same introns. 
 I am confident that our reporter will be able to serve yeast molecular 
biologists and geneticists interested in applicable gene expression events. I have 
demonstrated that our fluorescent reporter can be used with FACS to perform 
rapid screens of millions of mutant clones, as compared to conventional 
screening tools such as differential growth on plates. Additionally, our reporter 
can be used as an orthogonal assay to screen previously identified mutants and 
conditions for gene expression effects. As I have stated earlier, it is important to 
test the effects on endogenous substrates and targets, as our reporter is a 
synthetic and unnatural gene. Although I have not described other screening 
efforts I have undertook, it is important to note that our reporter is tunable, as I 
have made it specifically sensitive to the Rnt1p endonuclease by introducing a 
cleavage site within the intron. It will be exciting to see our reporter technology 
aid other researchers in their efforts to more fully understand a diverse range of 
gene expression processes. 
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Chapter 5: Significance and Future Directions 
5.1 SIGNIFICANCE 
When I began my studies in the laboratory of Scott Stevens, I was 
interested in improving upon the pre-mRNA splicing reporter technology that was 
available for the yeast Saccharomyces cerevisiae (Legrain and Rosbash 1989; 
Lesser and Guthrie 1993). Eliminating the constrains of these powerful yet aging 
reporter systems while taking advantages of a sensitive and high throughput 
technique, we successfully developed and validated a flexible single-cell two-
color reporter system (Sorenson and Stevens 2014). Serendipitously our 
carefully designed reporter not only accurately identified cis- and trans-acting 
defects in pre-mRNA splicing, but it also was sensitive and specific to defects in 
other gene expression processes including transcription, chromatin dynamics, 
mRNA export and mRNA degradation/surveillance. 
The high-throughput nature of our reporter system was exemplified in our 
successful screening of the haploid deletion collection, consisting of nearly 5000 
unique deletion mutants. With this screen we were able to identify an 
uncharacterized gene, SWM2/YNR004W, that was partially characterized while 
our efforts were underway (Boon and Kos 2010; Chang et al. 2010). This rich 
dataset, along with our binning and clustering analysis pipeline CHUBACA, 
provide a valuable reference and tool for comparing novel genetic or chemical 
perturbations. Standard genetic screens using budding yeast commonly utilize 
tedious and resource consuming colony-based assays to identify mutants of 
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interest. Utilizing our reporter system a researcher can explore a number of 
different gene expression processes rapidly utilizing fluorescence-activated cell 
sorting to accelerate the identification of interesting mutants from complex 
populations. Furthermore the modification of our assay for small molecule and 
cyclic peptide screening identified two molecules of high-interest. 
5.2 FUTURE DIRECTIONS 
This dissertation is not by any means an exhaustive search of genes and 
compounds, but serves to highlight the development, validation and utilization of 
our reporter system. One significant project that resulted from screening a large 
collection of synthetic histone mutants resulted in the identification a specific 
histone modification that impacts pre-mRNA splicing efficiency of our reporter 
and endogenous introns. In collaborating with two different laboratories, we were 
unable to identify a specific mechanism by which this connection occurs. 
Excitingly, we discovered that deleting the enzyme responsible for this histone 
modification fully suppresses the splicing defect caused by the deletion of a 
specific splicing factor. This specific phenomenon and the general mechanisms 
behind the connections between pre-mRNA splicing and histone modification are 
worth exploring further.  
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5.2.1 Small molecule screening 
I believe that the most fruitful avenue to take with the reporter is to 
continue and expand the small molecule screening efforts. The few thousand 
compounds we tested in our pilot screen are a mere sliver of the number of 
compounds available in large-scale screens. I am confident that we were able to 
successfully adapt our reporter for 96-well plate reader analysis or even 384-well 
plates in a drug-sensitive strain (Suzuki et al. 2011). Additionally, with the newly 
installed high-throughput flow cytometry instrument, screens by flow cytometry 
can be performed an order of magnitude faster that the previous setup (Edwards 
et al. 2001, 2007; Black et al. 2011). If one wanted to perform multiple orthogonal 
assays or screen with our reporter in multiple yeast strains simultaneously, a 
multiplexing approach could be taken (Chen et al. 2012; Kulak and Lum 2013). 
Last, it would be advisable to further study the pre-mRNA splicing defect caused 
by TI3D_0104_B19. 
5.2.2 Swm2p function  
In regards to the mutations we identified of Swm2p that results in gene-
specific pre-mRNA splicing defects and decreased interaction with the 
trimethylguanosine synthase Tgs1p, there are several experiments that should 
be completed. First, repeating the trimethylguanosine immunoprecipations and 
Swm2p coimmunoprecipitations will determine snRNA trimethylation levels and 
Tgs1p interaction with more certainty. Since Tgs1p is required for Swm2p’s 
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nucleolar localization (Boon and Kos 2010), it would be interesting to determine if 
the three mutants described in Chapter 4 have reduced nucleolar residency. 
Last, it would be interesting to combine individual point mutations contained in 
the three isolated mutants, focusing on the C-terminal substitutions that involve a 
change in charge. Given the apparent importance of the C-terminus, this could 
lead to a more complete loss-of-function mutant as compared to the ones already 
isolated. 
5.2.3 Adjusting reporter sensitivity  
Another aspect of our reporter that can be taken advantage of is that one 
can modify the sensitivity of the reporter by addition of cis-acting elements. In 
collaboration with Guillaume Chanfreau at UCLA, I added a Rnt1p cleavage site 
into the intron of our reporter, making the resulting fluorescent signals sensitive 
to this endonuclease. In screening an overexpression library by FACS, we were 
able to identify genes that resulted in altered stability of the reporter pre-mRNA 
when overexpressed, although they did not significantly affect the stability of 
endogenous targets. An alternative Rnt1p cleavage site could be tested in the 
future, as well as testing other RNA elements to affect the stability of the reporter 
pre-mRNA and/or mRNA.  
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5.2.4 Genes and pathways of interest 
One set of genes that would be interesting to explore utilizing our reporter 
to study in more detail are those coding for TREX-2 complex components; SAC3, 
THP1, SEM1, SUS1 and CDC31; functioning to link mRNA transcription and 
export (Fischer et al. 2002; Rodriguez-Navarro et al. 2004). One member of the 
human TREX-2 complex, GANP, is involved in cancer and is an appreciated drug 
target (Fujimura et al. 2005; Kageshita et al. 2006; Wickramasinghe et al. 2010; 
Phimsen et al. 2012). Recently TREX-2 components have been implicated in the 
DNA damage response, genome instability and R-loop formation via the tumor 
suppressor BRCA2 (Bhatia et al. 2014). The unique signal in TREX-2/mRNA 
export mutants, as well as the medical relevance of the human TREX-2 complex, 
make this is an ideal area of future study with our reporter. 
5.3 FINAL CONCLUSION 
Altogether, this work described my efforts in developing a versatile 
reporter system for budding yeast. Not only is our reporter a significant 
improvement to existing pre-mRNA splicing reporters, it enables researchers to 
study many different gene expression processes simultaneously, as well as the 
interconnectedness between these processes. The cyclic peptide, small 
molecule, and SWM2 high-throughput screens are prime examples of the utility 
of our reporter and analysis pipeline. Moreover, the massive dataset that resulted 
from the yeast deletion collection provides our lab and others a prime reference 
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tool for the comparative analysis of additional genetic, chemical, or 
environmental perturbations.  
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APPENDIX I: ANNOTATED SEQUENCE OF GENE EXPRESSION 
REPORTER 
GCGGCCGCGAATTCACTAGTGATTCTCGAGTAACTTTATTTAGTCAAA
AAATTAGCCTTTTAATTCTGCTGTAACCCGTACATGCCCAAAATAGGGGGCG
GGTTACACAGAATATATAACATCGTAGGTGTCTGGGTGAACAGTTTATTCCT
GGCATCCACTAAATATAATGGAGCCCGCTTTTTAAGCTGGCATCCAGAAAAA
AAAAGAATCCCAGCACCAAAATATTGTTTTCTTCACCAACCATCAGTTCATAG
GTCCATTCTCTTAGCGCAACTACAGAGAACAGGGGCACAAACAGGCAAAAA
ACGGGCACAACCTCAATGGAGTGATGCAACCTGCCTGGAGTAAATGATGAC
ACAAGGCAATTGACCCACGCATGTATCTATCTCATTTTCTTACACCTTCTATT
ACCTTCTGCTCTCTCTGATTTGGAAAAAGCTGAAAAAAAAGGTTGAAACCAG
TTCCCTGAAATTATTCCCCTACTTGACTAATAAGTATATAAAGACGGTAGGTA
TTGATTGTAATTCCGTAAATCTATTTCTTAAACTTCTTAAATTCTACTTTTATA
GTTAGTCTTTTTTTTAGTTTTAAAACACCAAGAACTTAGTTTCGAATAAACACA
CATAAACAAACAAAGGATCCATGTCTTCCAGATTCACTAAGACTAGAAAGCA
CAGAGGTCACGTCTCAGGgtATGTAGTTCCATTTGGAAGAGGGAATGAAAGA
ACCAAATATGTCGTGTGTATATCATGGTACAGCATGCTTTCTAAGGGTGAAG
AAGACAACATGGCTATCATCAAGGAATTCATGAGATTCAAGGTTCACATGGA
AGGTTCTGTTAACGGTCACGAATTCGAAATCGAAGGTGAAGGTGAAGGTAG
ACCATACGAAGGTACCCAAACCGCTAAGTTGAAGGTTACCAAGGGTGGTCC
ATTGCCATTCGCTTGGGACATCTTGTCTCCACAATTCATGTACGGTTCTAAG
GCTTACGTTAAGCACCCAGCTGACATCCCAGACTACTTGAAGTTGTCTTTCC
CAGAAGGTTTCAAGTGGGAAAGAGTTATGAACTTCGAAGACGGTGGTGTTG
TTACCGTTACCCAAGACTCTTCTTTGCAAGACGGTGAATTCATCTACAAGGT
TAAGTTGAGAGGTACCAACTTCCCATCTGACGGTCCAGTTATGCAAAAGAAG
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ACTATGGGTTGGGAAGCTTCTTCTGAAAGAATGTACCCAGAAGACGGTGCT
TTGAAGGGTGAAATCAAGCAAAGATTGAAGTTGAAGGACGGTGGTCACTAC
GACGCTGAAGTTAAGACCACCTACAAGGCTAAGAAGCCAGTTCAATTGCCA
GGTGCTTACAACGTTAACATCAAGTTGGACATCACCTCTCACAACGAAGACT
ACACCATCGTTGAACAATACGAAAGAGCTGAAGGTAGACACTCTACCGGTG
GTATGGACGAATTGTACACTTAAGAGTTACCACGTTTCTTTTGTTTCGATAAA
ATGTCCAGTTGAAAACCTGTTTTACTAACGATTTAAAAATTGTATTTCATTACA
ATATTTTTTTTGTACagCCGGTTAAGGTCGTATCGGAGATCCATGGTGAGCA
AGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC
GGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCG
ATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGC
TGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAG
TGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCC
GCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGG
TGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATC
CTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATG
GCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAAC
ATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCC
CATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCC
AGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTG
CTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTA
CAAGAGATCCTAAGCTGGTTCTAACTGGAAATAATTTCCATTAGATTCCTCTT
TTTCTCGTCCATTAACCAAAATATATTATTGAATTCAGCGGTTCCTTTTTTCTC
ATTTTCGCATATAGCTGCACTATTAGAATCAGCCCACTCTAGGTAAACACAG
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TTCCTCGATATACCTCTGTCTTACTATCAGTGGTTAAACCTTATGCAAATATA
ATATATATATATATATATATATATATATCTCATACTTTTGTTGATTCTTGTGTAA
TTATTGGAAAAGACAAAACAAAGCAAGCGTTTCTATTCATATTTACAAGTATT
TTTTATGACAAACTATTTCTTAATTTTCCCACCGGCGGCTTTGAATAAGGCAA
TGTGTCGAC 
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APPENDIX II: TABLE OF RED- AND GREEN-SHIFTED 
DELETION MUTANTS 
Green-shifted Red-shifted Red-shifted Red-shifted 
ACE2 / YLR131C AAT2 / YLR027C MAK32 / YCR019W STE5 / YDR103W 
ARC18 / YLR370C AIM43 / YPL099C MCK1 / YNL307C SWC3 / YAL011W 
ARG82 / YDR173C APM4 / YOL062C MET6 / YER091C SWT21 / YNL187W 
CCR4 / YAL021C ARP6 / YLR085C MGR2 / YPL098C TAF14 / YPL129W 
DEF1 / YKL054C ATG14 / YBR128C MRP51 / YPL118W TAL1 / YLR354C 
DHH1 / YDL160C ATG21 / YPL100W MRPL7 / YDR237W TIS11 / YLR136C 
EFG1 / YGR271C-A BCK1 / YJL095W MTC7 / YEL033W TPO5 / YKL174C 
GBP2 / YCL011C BDF1 / YLR399C MUD2 / YKL074C UBA4 / YHR111W 
GSH1 / YJL101C BEM4 / YPL161C NAM7 / YMR080C UME6 / YDR207C 
LTV1 / YKL143W BUB3 / YOR026W NMD2 / YHR077C UPF3 / YGR072W 
MFT1 / YML062C BUD13 / YGL174W NQM1 / YGR043C VBA3 / YCL069W 
MLP1 / YKR095W BUD16 / YEL029C PAC10 / YGR078C VPS71 / YML041C 
MMP1 / YLL061W BUD32 / YGR262C PCL8 / YPL219W VPS72 / YDR485C 
NEW1 / YPL226W CAF40 / YNL288W POC4 / YPL144W VPS72 / YDR485C 
NUP120 / YKL057C CKI1 / YLR133W POL4 / YCR014C YBR174C / YBR174C 
NUP60 / YAR002W CNB1 / YKL190W PRD1 / YCL057W YCR001W / YCR001W 
PLC1 / YPL268W COX20 / YDR231C QCR8 / YJL166W YDJ1 / YNL064C 
POP2 / YNR052C CRG1 / YHR209W RAV2 / YDR202C YDR133C / YDR133C 
RPS22A / YJL190C CSE2 / YNR010W RER1 / YCL001W YDR239C / YDR239C 
RRP6 / YOR001W DGR2 / YKL121W RIM1 / YCR028C-A YEA4 / YEL004W 
SAC3 / YDR159W DPB4 / YDR121W RPD3 / YNL330C YGR051C / YGR051C 
SEM1 / YDR363W-A DST1 / YGL043W RPL34A / YER056C-A YGR071C / YGR071C 
SUS1 / YBR111W-A EAF1 / YDR359C RPL42B / YHR141C YHI9 / YHR029C 
THP1 / YOL072W EBS1 / YDR206W RPN10 / YHR200W YJL169W / YJL169W 
THP2 / YHR167W EEB1 / YPL095C RPN4 / YDL020C YKL102C / YKL102C 
UBR2 / YLR024C ELP4 / YPL101W RRT2 / YBR246W YKL171W / YKL171W 
XRN1 / YGL173C FAB1 / YFR019W RSN1 / YMR266W YLR358C / YLR358C 
YGR031W / YGR031W FIR1 / YER032W RTF1 / YGL244W YML081W / YML081W 
YNL140C / YNL140C FMP25 / YLR077W RTN1 / YDR233C YMR027W / YMR027W 
 HOS3 / YPL116W RTR1 / YER139C YNL170W / YNL170W 
 HTZ1 / YOL012C SCM4 / YGR049W YNR004W / YNR004W 
 ILV6 / YCL009C SEF1 / YBL066C YOR305W / YOR305W 
 IRC15 / YPL017C SEO1 / YAL067C YOR309C / YOR309C 
 IRC19 / YLL033W SET2 / YJL168C YOR352W / YOR352W 
 IRC25 / YLR021W SGO1 / YOR073W YPL107W / YPL107W 
 IST3 / YIR005W SNU66 / YOR308C YPL150W / YPL150W 
 ISW2 / YOR304W SOH1 / YGL127C YPT7 / YML001W 
 IWR1 / YDL115C SPT8 / YLR055C ZRT2 / YLR130C 
 LEA1 / YPL213W SRB2 / YHR041C  
 LYS4 / YDR234W SRB5 / YGR104C  
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